[{"link": "https://www.wsj.com/articles/thor-industries-shares-rise-on-earnings-beat-11569872327", "title": "Thor Industries Shares Rise on Earnings Beat", "date": "2019-09-30 15:38", "summary": "Recreational vehicle maker reports 23% jump in quarterly revenue. Shares of the recreational-vehicle manufacturer Thor Industries Inc. rose nearly 17% Monday after it reported a better-than-expected fourth-quarter profit as sales grew from a recent European acquisition.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Thor Industries Shares Rise on Earnings Beat. Recreational vehicle maker reports 23% jump in quarterly revenue. Shares of the recreational-vehicle manufacturer Thor Industries Inc. rose nearly 17% Monday after it reported a better-than-expected fourth-quarter profit as sales grew from a recent European acquisition.\"\n\nStock Prediction(s):", "Prediction": "\n- Thor Industries Inc (NYSE: THO) will continue to increase because they are doing well financially and their revenue is growing.", "price_info": {"THO": {"company": "", "ticker": "THO", "move": "up", "prices": [56.6, 56.66]}}}, {"link": "https://www.wsj.com/articles/italian-merger-builds-another-vehicle-for-bigger-payments-deals-11601915647", "title": "Italian Merger Builds Another Vehicle for Bigger Payments Deals", "date": "2020-10-05 12:34", "summary": "Europe now has at least two national pay-tech champions with wider ambitions. Neither Covid-19 nor the Wirecard fiasco have sapped appetite in Europe to create a payments giant to rival U.S. and Asian peers. The latest merger paves the way for more.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Italian Merger Builds Another Vehicle for Bigger Payments Deals. Europe now has at least two national pay-tech champions with wider ambitions. Neither Covid-19 nor the Wirecard fiasco have sapped appetite in Europe to create a payments giant to rival U.S. and Asian peers. The latest merger paves the way for more.\"\n\nStock Prediction(s):", "Prediction": "\n- Visa Inc (NYSE: V) will increase because they are in a good position to capitalize on the merger and the growth of the payments industry.\n- Mastercard Inc (NYSE: MA) will increase because they are in a good position to capitalize on the merger and the growth of the payments industry.\n- American Express Company (NYSE: AXP) will increase because they are in a good position to capitalize on the merger and the growth of the payments industry.", "price_info": {"V": {"company": "", "ticker": "V", "move": "up", "prices": [201.65, 202.22]}, "MA": {"company": "", "ticker": "MA", "move": "up", "prices": [340, 341]}, "AXP": {"company": "", "ticker": "AXP", "move": "up", "prices": [103.317, 103.65]}}}, {"link": "https://www.wsj.com/articles/fast-food-stocks-are-no-value-meal-11563804040", "title": "Fast Food Stocks Are No Value Meal", "date": "2019-07-22 10:00", "summary": "High valuations indicate that expectations are stretched for quick-service restaurants as they start to report earnings. Much like American consumers, investors can't seem to get enough fast food. They will likely require a strong upcoming earnings season to stay satisfied.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fast Food Stocks Are No Value Meal. High valuations indicate that expectations are stretched for quick-service restaurants as they start to report earnings. Much like American consumers, investors can't seem to get enough fast food. They will likely require a strong upcoming earnings season to stay satisfied.\"\n\nStock Prediction(s):", "Prediction": "\n- McDonald's Corporation (NYSE: MCD) will decrease because their stock is overvalued and they are starting to report earnings.\n- Yum! Brands, Inc. (NYSE: YUM) will decrease because their stock is overvalued and they are starting to report earnings.\n- The Wendy's Company (NASDAQ: WEN) will decrease because their stock is overvalued and they are starting to report earnings.\n- Burger King Worldwide, Inc. (", "price_info": {"MCD": {"company": "", "ticker": "MCD", "move": "down", "prices": [214.47, 214.1374]}, "YUM": {"company": "", "ticker": "YUM", "move": "down", "prices": [112.94, 113.05]}, "WEN": {"company": "", "ticker": "WEN", "move": "down", "prices": [18.865, 18.925]}}}, {"link": "https://www.wsj.com/articles/chinese-regulator-flags-a-50-000-fine-against-walmart-11642192977", "title": "Chinese Regulator Flags a $50,000 Fine Against Walmart", "date": "2022-01-14 15:42", "summary": "Local authorities highlight a 2021 infraction by U.S. retailer, latest in a series of criticisms. A local Chinese regulator and state media highlighted this week a roughly $50,000 fine Walmart Inc. paid last year, keeping a spotlight on the U.S. retailer at a time of rising political tensions between Beijing and Washington.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Chinese Regulator Flags a $50,000 Fine Against Walmart. Local authorities highlight a 2021 infraction by U.S. retailer, latest in a series of criticisms. A local Chinese regulator and state media highlighted this week a roughly $50,000 fine Walmart Inc. paid last year, keeping a spotlight on the U.S. retailer at a time of rising political tensions between Beijing and Washington.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will decrease because they are being fined by the Chinese government.\n- JD.com, Inc. (NASDAQ: JD) will increase because they are not being fined by the Chinese government.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [145.12, 145.19]}, "JD": {"company": "", "ticker": "JD", "move": "up", "prices": [73.607, 73.75]}}}, {"link": "https://www.wsj.com/articles/deutsche-banks-bond-with-aston-martin-11569511242", "title": "Deutsche Bank's Bond With Aston Martin", "date": "2019-09-26 11:20", "summary": "German lender's turnaround plan, like that of Aston Martin, its former client, could easily veer off the road. Comparisons with James Bond aren't always stock-market gold.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Deutsche Bank's Bond With Aston Martin. German lender's turnaround plan, like that of Aston Martin, its former client, could easily veer off the road. Comparisons with James Bond aren't always stock-market gold.\"\n\nStock Prediction(s):", "Prediction": "\n- Deutsche Bank AG (NYSE: DB) will decrease because their turnaround plan is not going as well as they had hoped.\n- Aston Martin Lagonda Global Holdings plc (OTC: AZNMF) will increase because they are doing well despite Deutsche Bank's turnaround plan not going as well as they had hoped.", "price_info": {"DB": {"company": "", "ticker": "DB", "move": "up", "prices": [7.43, 7.4]}}}, {"link": "https://www.wsj.com/articles/fed-keeps-options-open-on-yield-caps-but-looks-to-other-tools-first-11593529321", "title": "Fed Keeps Options Open on Yield Caps", "date": "2020-06-30 11:02", "summary": "Officials aren't in a hurry to announce plans on a possible strategy to cap yields with unlimited short-term securities purchases. The Federal Reserve is unlikely to cap short-term Treasury yields as part of its initial package of economic stimulus measures, instead reserving the option to cap yields later.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Keeps Options Open on Yield Caps. Officials aren't in a hurry to announce plans on a possible strategy to cap yields with unlimited short-term securities purchases. The Federal Reserve is unlikely to cap short-term Treasury yields as part of its initial package of economic stimulus measures, instead reserving the option to cap yields later.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve will not announce a yield cap yet, but they will do so in the future. This will not have a major impact on the stock market.\n- The Federal Reserve will announce a yield cap, and this will cause a major sell-off in the stock market.", "price_info": {}}, {"link": "https://www.wsj.com/articles/sap-discloses-investment-by-chairmans-charity-in-joint-venture-11620833711", "title": "SAP Discloses Investment by Chairman's Charity in Joint Venture", "date": "2021-05-12 11:41", "summary": "Software company says the foundation has no active role in planned financial-services venture. BERLIN- SAP SE , the German software company, said Wednesday that a charity set up by Hasso Plattner, SAP's chairman and co-founder, had invested in a financial-services joint venture SAP had created, but it denied any wrongdoing in not disclosing the investment earlier.", "categories": [["Business", "Europe"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/europe-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SAP Discloses Investment by Chairman's Charity in Joint Venture. Software company says the foundation has no active role in planned financial-services venture. BERLIN- SAP SE , the German software company, said Wednesday that a charity set up by Hasso Plattner, SAP's chairman and co-founder, had invested in a financial-services joint venture SAP had created, but it denied any wrongdoing in not disclosing the investment earlier.\"\n\nStock Prediction(s):", "Prediction": "\n- SAP SE (NYSE: SAP) will increase because they have been transparent about the investment and it is not a conflict of interest.\n- The investment by the charity will be a good investment, and SAP SE will increase in value because of it.", "price_info": {"SAP": {"company": "", "ticker": "SAP", "move": "up", "prices": [135.29, 135.94]}}}, {"link": "https://www.wsj.com/articles/oil-price-jumps-above-80-and-natural-gas-races-higher-turbocharged-by-supply-shortages-11633943832", "title": "Oil Jumps Above $80, Turbocharged by Supply Shortages", "date": "2021-10-11 14:51", "summary": "Crude prices are outpacing copper and other commodities by the widest margin in more than a decade. The extended climb in oil prices is leaving some other industrial commodities behind, a divergence that reflects bets that energy supply shortages will offset any slowdown in the global economy.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Jumps Above $80, Turbocharged by Supply Shortages. Crude prices are outpacing copper and other commodities by the widest margin in more than a decade. The extended climb in oil prices is leaving some other industrial commodities behind, a divergence that reflects bets that energy supply shortages will offset any slowdown in the global economy.\"\n\nStock Prediction(s):", "Prediction": "\n- Energy companies will increase because of the supply shortages.\n- Copper companies will decrease because of the competition from oil.", "price_info": {}}, {"link": "https://www.wsj.com/articles/facebook-co-founder-chris-hughes-wants-26-million-for-greenwich-village-townhouse-11566917125", "title": "Facebook Co-Founder Chris Hughes Wants $26 Million for Greenwich Village Townhouse", "date": "2019-08-27 10:45", "summary": "Hughes and his husband Sean Eldridge are selling the 6,000-square-foot property to move into a new home with their expanding family, their agent says. Chris Hughes, a co-founder of Facebook who recently called for the social-media behemoth to be broken up, is listing his downtown New York townhouse for $26 million.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook Co-Founder Chris Hughes Wants $26 Million for Greenwich Village Townhouse. Hughes and his husband Sean Eldridge are selling the 6,000-square-foot property to move into a new home with their expanding family, their agent says. Chris Hughes, a co-founder of Facebook who recently called for the social-media behemoth to be broken up, is listing his downtown New York townhouse for $26 million.\"\n\nStock Prediction(s):", "Prediction": "\n- Hughes will increase the price of his townhouse because he and his husband are expanding their family and need more space.\n- Other townhouses in the area will also increase in price because of the demand from wealthy families who want to be close to downtown.", "price_info": {}}, {"link": "https://www.wsj.com/articles/delta-kb-home-taiwan-semiconductor-what-to-watch-in-the-stock-market-today-11642075136", "title": "Delta, Virgin Galactic, KB Home, Taiwan Semiconductor: What to Watch in the Stock Market Today", "date": "2022-01-13 09:41", "summary": "Earnings season is back. Delta Air Lines shares rose after reporting quarterly results.. U.S. stocks and bond yields crept higher as fresh data on inflation and the labor market provided a mixed picture of the economic recovery. Here's what we're watching in Thursday's trading:", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Delta, Virgin Galactic, KB Home, Taiwan Semiconductor: What to Watch in the Stock Market Today. Earnings season is back. Delta Air Lines shares rose after reporting quarterly results.. U.S. stocks and bond yields crept higher as fresh data on inflation and the labor market provided a mixed picture of the economic recovery. Here's what we're watching in Thursday's trading:\"\n\nStock Prediction(s):", "Prediction": "\n- Delta Air Lines, Inc. (NYSE: DAL) will increase because their earnings report was good.\n- Virgin Galactic Holdings Ltd. (NYSE: SPCE) will increase because their earnings report was good.\n- KB Home (NYSE: KBH) will increase because their earnings report was good.\n- Taiwan Semiconductor Manufacturing Co Ltd. (NYSE: TSM) will increase because their earnings report was good.", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": "up", "prices": [41.03, 41.72]}, "SPCE": {"company": "", "ticker": "SPCE", "move": "up", "prices": [10.525, 10.378]}, "KBH": {"company": "", "ticker": "KBH", "move": "up", "prices": [48.82, 48.04]}, "TSM": {"company": "", "ticker": "TSM", "move": "up", "prices": [143.94, 140.38]}}}, {"link": "https://www.wsj.com/articles/data-privacy-in-the-age-of-online-learning-11607457738", "title": "Data Privacy in the Age of Online Learning", "date": "2020-12-08 15:02", "summary": "Coronavirus forced school districts across the country to move rapidly to online learning. That has some privacy experts concerned.. Schools are relying heavily on technology-from videoconferencing programs to digital-teaching tools and temperature-taking apps-to educate children safely in the age of Covid.", "categories": [["Business", "Journal Reports: Technology"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Data Privacy in the Age of Online Learning. Coronavirus forced school districts across the country to move rapidly to online learning. That has some privacy experts concerned.. Schools are relying heavily on technology-from videoconferencing programs to digital-teaching tools and temperature-taking apps-to educate children safely in the age of Covid.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they make the videoconferencing programs that many school districts are using.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they make the digital-teaching tools that many school districts are using.\n- Google LLC (NASDAQ: GOOGL) will increase because they make the temperature-taking apps that many school districts are using.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [124.93, 124.23]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3173.67, 3174.2]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1807.27, 1811]}}}, {"link": "https://www.wsj.com/articles/feds-mester-says-she-fully-supports-central-banks-patient-stance-11556908592", "title": "Mester Says She Fully Supports Fed's Patient Stance", "date": "2019-05-03 14:36", "summary": "Cleveland Fed leader says risks confronting economy are balanced, inflation weakness likely in part transitory. Federal Reserve Bank of Cleveland President Loretta Mester said April jobs report was evidence of a strong employment sector and central-bank policy is in the right place for now.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Mester Says She Fully Supports Fed's Patient Stance. Cleveland Fed leader says risks confronting economy are balanced, inflation weakness likely in part transitory. Federal Reserve Bank of Cleveland President Loretta Mester said April jobs report was evidence of a strong employment sector and central-bank policy is in the right place for now.\"\n\nStock Prediction(s):", "Prediction": "\n- Cleveland Fed President Loretta Mester will continue to be a strong advocate for the patient stance of the Federal Reserve.\n- The Federal Reserve will continue to be patient as they assess the risks confronting the economy.\n- Inflation weakness is likely in part transitory, and the employment sector is strong.", "price_info": {}}, {"link": "https://www.wsj.com/articles/health-insurance-consumers-to-get-743-million-in-rebates-under-aca-rule-11568131882", "title": "Health-Insurance Consumers to Get $743 Million in Rebates Under ACA Rule", "date": "2019-09-10 13:10", "summary": "Law requires refunds if companies don't spend a big enough share of premium dollars on health care. Health insurers are expected to pay out a record $743 million to consumers this month under an Affordable Care Act rule that requires refunds if the companies don't spend a big enough share of premium dollars on health care.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Health-Insurance Consumers to Get $743 Million in Rebates Under ACA Rule. Law requires refunds if companies don't spend a big enough share of premium dollars on health care. Health insurers are expected to pay out a record $743 million to consumers this month under an Affordable Care Act rule that requires refunds if the companies don't spend a big enough share of premium dollars on health care.\"\n\nStock Prediction(s):", "Prediction": "\n- UnitedHealth Group Inc (NYSE: UNH) will increase because they are one of the largest health-insurance providers in the United States.\n- Anthem, Inc. (NYSE: ANTM) will increase because they are one of the largest health-insurance providers in the United States.\n- Aetna Inc. (NYSE: AET) will increase because they are one of the largest health-insurance providers in the United States.\n-", "price_info": {"UNH": {"company": "", "ticker": "UNH", "move": "up", "prices": [233.5755, 232.41]}, "ANTM": {"company": "", "ticker": "ANTM", "move": "up", "prices": [253.71, 252.9023]}, "AET": {"company": "", "ticker": "AET", "move": "up"}}}, {"link": "https://www.wsj.com/articles/tiktok-tops-1-billion-monthly-users-11632760678", "title": "TikTok Tops 1 Billion Monthly Users", "date": "2021-09-27 15:43", "summary": "Video-sharing app has said it plans to let users create longer-form videos. More than 1 billion people use TikTok every month, according to a statement posted on the video-sharing app's website Monday.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"TikTok Tops 1 Billion Monthly Users. Video-sharing app has said it plans to let users create longer-form videos. More than 1 billion people use TikTok every month, according to a statement posted on the video-sharing app's website Monday.\"\n\nStock Prediction(s):", "Prediction": "\n- ByteDance Ltd. (NYSE: BYT) will increase because they are the company that owns TikTok, and they continue to grow in popularity.\n- Facebook, Inc. (NASDAQ: FB) will decrease because they own Instagram, which is a direct competitor of TikTok.", "price_info": {"BYT": {"company": "", "ticker": "BYT", "move": "up"}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [353.58, 353.315]}}}, {"link": "https://www.wsj.com/articles/apollo-launches-platform-to-make-big-loans-11594031400", "title": "Apollo Launches Platform to Make Big Loans", "date": "2020-07-06 11:59", "summary": "Buyout firm moves deeper into expanding pool of direct lending; Mubadala Investment is lead backer. Apollo Global Management Inc. is launching a big new credit operation as the buyout giant dives deeper into the rapidly expanding pool of direct lending.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apollo Launches Platform to Make Big Loans. Buyout firm moves deeper into expanding pool of direct lending; Mubadala Investment is lead backer. Apollo Global Management Inc. is launching a big new credit operation as the buyout giant dives deeper into the rapidly expanding pool of direct lending.\"\n\nStock Prediction(s):", "Prediction": "\n- Apollo Global Management Inc. (NYSE: APO) will increase because they are expanding their lending business.\n- Credit Suisse Group AG (NYSE: CS) will decrease because they are a direct competitor of Apollo.\n- Deutsche Bank AG (NYSE: DB) will decrease because they are a direct competitor of Apollo.\n- Goldman Sachs Group Inc. (NYSE: GS) will decrease because they are a direct competitor of Apollo.", "price_info": {"APO": {"company": "", "ticker": "APO", "move": "up", "prices": [50.995, 50.46]}, "CS": {"company": "", "ticker": "CS", "move": "down", "prices": [10.625, 10.6596]}, "DB": {"company": "", "ticker": "DB", "move": "down", "prices": [9.9275, 9.94]}, "GS": {"company": "", "ticker": "GS", "move": "down", "prices": [205.8479, 207.15]}}}, {"link": "https://www.wsj.com/articles/new-breed-boomboxes-to-soundtrack-your-summer-11594997066", "title": "New-Breed Boomboxes to Soundtrack Your Summer", "date": "2020-07-17 10:44", "summary": "Classic, on-the-go sound systems may have thumped their last beats, but these updates stream sound from your smartphone as you hoist them by their handles. IN THE '80s, few things were more satisfying than tossing a sound system on your shoulder and blasting some tunes while you walked the block. Now that classic boomboxes have thumped their last mixtape beats, a new breed is streaming sound from your smartphone as you hoist them by their handles. Here, five of our favorites.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"New-Breed Boomboxes to Soundtrack Your Summer. Classic, on-the-go sound systems may have thumped their last beats, but these updates stream sound from your smartphone as you hoist them by their handles. IN THE '80s, few things were more satisfying than tossing a sound system on your shoulder and blasting some tunes while you walked the block. Now that classic boomboxes have thumped their last mixtape beats, a new breed is streaming sound from your smartphone as you hoist them by their handles. Here, five of our favorites.\"\n\nStock Prediction(s):", "Prediction": "\n- Sony Corporation (NYSE: SNE) will increase because they are the company that created the original boombox, and they are releasing a new, updated version.\n- Bose Corporation (NYSE: BOS) will increase because they are releasing a new, updated version of the boombox.\n- JBL, Inc. (NYSE: JBL) will increase because they are releasing a new, updated version of the boombox.\n- Beats", "price_info": {"SNE": {"company": "", "ticker": "SNE", "move": "up", "prices": [75.7773, 76.085]}, "BOS": {"company": "", "ticker": "BOS", "move": "up"}, "JBL": {"company": "", "ticker": "JBL", "move": "up", "prices": [34.0946, 33.99]}}}, {"link": "https://www.wsj.com/articles/liberte-egalite-equity-french-government-holds-key-for-renault-nissan-11570733546", "title": "Libert\u00e9, \u00c9galit\u00e9, Equity: French Government Holds Key for Renault, Nissan", "date": "2019-10-10 14:52", "summary": "Management change at both car makers could pave the road to better relations, but can do little without the support of Emmanuel Macron. The sudden management shakeup that started at Nissan earlier this week has spread to Renault. It is a pity it can't also spread to the management that really matters for the car makers' faltering alliance as well as Renault's merger hopes with Fiat Chrysler: the French government.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Libert\u00e9, \u00c9galit\u00e9, Equity: French Government Holds Key for Renault, Nissan. Management change at both car makers could pave the road to better relations, but can do little without the support of Emmanuel Macron. The sudden management shakeup that started at Nissan earlier this week has spread to Renault. It is a pity it can't also spread to the management that really matters for the car makers' faltering alliance as well as Renault's merger hopes with Fiat Chrysler: the French government.\"\n\nStock Prediction(s):", "Prediction": "\n- Renault SA (EPA: RNO) will increase because the French government is supportive and could help improve relations with Nissan.\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will increase because they are still interested in a merger with Renault, and the French government could help make that happen.\n- Nissan Motor Co Ltd (TSE: 7201) will decrease because of the management shakeup and the uncertain future of the alliance with Renault.", "price_info": {"FCAU": {"company": "", "ticker": "FCAU", "move": "down"}}}, {"link": "https://www.wsj.com/articles/twitter-is-buying-newsletter-provider-revue-11611666920", "title": "Twitter to Buy Newsletter Provider Revue", "date": "2021-01-26 10:52", "summary": "Move reflects interest among social-media companies in providing content creators with tools to make money. Twitter Inc. has reached a deal to buy newsletter platform Revue Holding BV, the companies said Tuesday, reflecting the interest among social-media companies in providing content creators with tools to make money.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Twitter to Buy Newsletter Provider Revue. Move reflects interest among social-media companies in providing content creators with tools to make money. Twitter Inc. has reached a deal to buy newsletter platform Revue Holding BV, the companies said Tuesday, reflecting the interest among social-media companies in providing content creators with tools to make money.\"\n\nStock Prediction(s):", "Prediction": "\n- Twitter, Inc. (NYSE: TWTR) will increase because they are buying Revue, which will give them a foothold in the newsletter market.\n- Salesforce.com, Inc. (NYSE: CRM) will decrease because they are a direct competitor of Twitter.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "up", "prices": [50.64, 50.455]}, "CRM": {"company": "", "ticker": "CRM", "move": "down", "prices": [226.575, 225.08]}}}, {"link": "https://www.wsj.com/articles/shake-shacks-finance-chief-to-depart-11617056258", "title": "Shake Shack's Finance Chief to Depart", "date": "2021-03-30 11:16", "summary": "Current CFO Tara Comonte is set to become CEO of a life-sciences company. Shake Shack Inc. said its finance chief, Tara Comonte, is leaving the burger chain to take the top post at another company.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Shake Shack's Finance Chief to Depart. Current CFO Tara Comonte is set to become CEO of a life-sciences company. Shake Shack Inc. said its finance chief, Tara Comonte, is leaving the burger chain to take the top post at another company.\"\n\nStock Prediction(s):", "Prediction": "\n- Shake Shack Inc. (NYSE: SHAK) will decrease because their CFO is leaving.\n- The life-sciences company that Tara Comonte is going to become CEO of (unnamed) will increase because they are getting a great CEO.", "price_info": {"SHAK": {"company": "", "ticker": "SHAK", "move": "up", "prices": [111.79, 110.56]}}}, {"link": "https://www.wsj.com/articles/the-end-of-exceptionalism-for-bmw-11553096129", "title": "The End of Exceptionalism for BMW", "date": "2019-03-20 11:35", "summary": "The once-reliable Bavarian auto maker's second profit warning in six months is a sign that the car industry really is getting tough. BMW used to be the blue-chip auto maker that didn't give investors nasty surprises. Not any more.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The End of Exceptionalism for BMW. The once-reliable Bavarian auto maker's second profit warning in six months is a sign that the car industry really is getting tough. BMW used to be the blue-chip auto maker that didn't give investors nasty surprises. Not any more.\"\n\nStock Prediction(s):", "Prediction": "\n- BMW AG (ETR: BMW) will decrease because they are not the reliable blue-chip company they used to be.\n- Volkswagen AG (ETR: VOW3) will increase because they are a more reliable company than BMW.", "price_info": {}}, {"link": "https://www.wsj.com/articles/bombardier-shed-snowmobiles-for-jetliners-trains-now-its-giving-up-both-11582055596", "title": "Bombardier Shed Snowmobiles for Jets, Trains. Now, It's Giving Up Both.", "date": "2020-02-18 14:53", "summary": "'Things were piling one on top of the other, it was a very tough situation,' says CEO Alain Bellmare. TORONTO- Bombardier Inc. tried to take on much bigger players in the global market for trains and commercial jetliners. Having shed both those businesses in as many weeks, it now plans to pare the debt that forced those retreats, and navigate a much smaller industry: business jets.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bombardier Shed Snowmobiles for Jets, Trains. Now, It's Giving Up Both.. 'Things were piling one on top of the other, it was a very tough situation,' says CEO Alain Bellmare. TORONTO- Bombardier Inc. tried to take on much bigger players in the global market for trains and commercial jetliners. Having shed both those businesses in as many weeks, it now plans to pare the debt that forced those retreats, and navigate a much smaller industry: business jets.\"\n\nStock Prediction(s):", "Prediction": "\n- Bombardier Inc. (TSE: BBD.B) will decrease because they are selling their business jet division.\n- Textron Inc. (NYSE: TXT) will increase because they are buying Bombardier's business jet division.", "price_info": {"TXT": {"company": "", "ticker": "TXT", "move": "up", "prices": [47.93, 47.64]}}}, {"link": "https://www.wsj.com/articles/target-maintains-its-torrid-pace-11605699302", "title": "Target Maintains Its Torrid Pace", "date": "2020-11-18 11:35", "summary": "Comparable sales jump more than 20% for a second straight quarter as retailer makes broad gains in market share. Target Corp. said sales rose steadily in its most recent quarter, as demand for household goods and home office supplies continued to grow during the pandemic, while shopping shifted online.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Target Maintains Its Torrid Pace. Comparable sales jump more than 20% for a second straight quarter as retailer makes broad gains in market share. Target Corp. said sales rose steadily in its most recent quarter, as demand for household goods and home office supplies continued to grow during the pandemic, while shopping shifted online.\"\n\nStock Prediction(s):", "Prediction": "\n- Target Corporation (NYSE: TGT) will continue to increase because they are seeing success in their online sales and they are making broad gains in market share.", "price_info": {"TGT": {"company": "", "ticker": "TGT", "move": "up", "prices": [169.72, 171.395]}}}, {"link": "https://www.wsj.com/articles/taking-a-page-from-teslas-electric-playbook-11567782259", "title": "Taking a Page From Tesla's Electric Playbook", "date": "2019-09-06 11:04", "summary": "A giant electric vehicle doesn't quite produce something for nothing, but it reminds us of Elon Musk's claims that his company can. Move over Tesla ... way, way over.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Taking a Page From Tesla's Electric Playbook. A giant electric vehicle doesn't quite produce something for nothing, but it reminds us of Elon Musk's claims that his company can. Move over Tesla ... way, way over.\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla, Inc. (TSLA) will continue to increase because they are the only company that is currently producing giant electric vehicles.\n- Ford Motor Company (NYSE: F) will decrease because they are not currently producing giant electric vehicles, and they are a direct competitor of Tesla.", "price_info": {"TSLA": {"company": "Tesla, Inc.", "ticker": "TSLA", "move": "up", "prices": [228.54, 228.6649]}, "F": {"company": "", "ticker": "F", "move": "down", "prices": [9.335, 9.375]}}}, {"link": "https://www.wsj.com/articles/broadcom-in-talks-to-buy-software-firm-sas-11626103731", "title": "Broadcom in Talks to Buy Software Firm SAS", "date": "2021-07-12 15:55", "summary": "A deal by the chip maker would value closely held SAS in the range of $15 billion to $20 billion. Broadcom Inc. is in talks to buy SAS Institute Inc., according to people familiar with the matter, in the latest move by the acquisitive technology giant to beef up in the corporate-software market.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Broadcom in Talks to Buy Software Firm SAS. A deal by the chip maker would value closely held SAS in the range of $15 billion to $20 billion. Broadcom Inc. is in talks to buy SAS Institute Inc., according to people familiar with the matter, in the latest move by the acquisitive technology giant to beef up in the corporate-software market.\"\n\nStock Prediction(s):", "Prediction": "\n- Broadcom Inc. (NASDAQ: AVGO) will increase because they are buying another software company, and they are trying to expand their business.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are also in the software market, and they could benefit from Broadcom's acquisition of SAS.\n- Oracle Corporation (NYSE: ORCL) will decrease because they are also in the software market, and they could lose market share to Broadcom", "price_info": {"ORCL": {"company": "", "ticker": "ORCL", "move": "down", "prices": [87.08, 87.35]}, "AVGO": {"company": "", "ticker": "AVGO", "move": "up", "prices": [485.97, 485.76]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [277.26, 277.235]}}}, {"link": "https://www.wsj.com/articles/covid-wont-steal-christmas-11606329052", "title": "Covid Won't Steal Christmas", "date": "2020-11-25 13:30", "summary": "This holiday shopping season will be different, but there will be shopping. This holiday season will be different from any other, including what people choose to spend money on.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Covid Won't Steal Christmas. This holiday shopping season will be different, but there will be shopping. This holiday season will be different from any other, including what people choose to spend money on.\"\n\nStock Prediction(s):", "Prediction": "\n- Department stores (e.g. Macy's, Sears, J.C. Penney) will increase because people will still need to buy gifts, but they will be looking for discounts.\n- Luxury brands (e.g. Gucci, Prada, Louis Vuitton) will decrease because people will be less likely to spend money on luxury items.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because people will", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3171.7, 3183.53]}}}, {"link": "https://www.wsj.com/articles/j-j-offers-4-billion-opioid-litigation-settlement-11571247596", "title": "J&J Offers $4 Billion Opioid Litigation Settlement", "date": "2019-10-16 13:39", "summary": "The deal, if accepted by states and municipalities, would resolve more than 2,000 lawsuits against the health-products company. Johnson & Johnson has offered to pay about $4 billion to settle all lawsuits in the U.S. accusing the company of contributing to the opioid-addiction epidemic, according to people familiar with the matter.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"J&J Offers $4 Billion Opioid Litigation Settlement. The deal, if accepted by states and municipalities, would resolve more than 2,000 lawsuits against the health-products company. Johnson & Johnson has offered to pay about $4 billion to settle all lawsuits in the U.S. accusing the company of contributing to the opioid-addiction epidemic, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are being sued for their role in the opioid epidemic.\n- Purdue Pharma LP (NYSE: PPHM) will decrease because they are being sued for their role in the opioid epidemic.\n- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will decrease because they are being sued for their role in the opioid epidemic.", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "down", "prices": [135.2001, 135.165]}, "PPHM": {"company": "", "ticker": "PPHM", "move": "down"}, "TEVA": {"company": "", "ticker": "TEVA", "move": "down", "prices": [6.985, 6.95]}}}, {"link": "https://www.wsj.com/articles/samsung-galaxys-foldable-phone-pitch-just-try-them-youll-like-them-11628690400", "title": "Samsung Galaxy's Foldable-Phone Pitch: Just Try Them, You'll Like Them", "date": "2021-08-11 12:24", "summary": "Company banks on more in-store visits and lower prices as it unveils new versions of Galaxy Z Fold, Galaxy Z Flip devices. SEOUL- Samsung Electronics Co. is betting the world is finally ready for its foldable phones.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Samsung Galaxy's Foldable-Phone Pitch: Just Try Them, You'll Like Them. Company banks on more in-store visits and lower prices as it unveils new versions of Galaxy Z Fold, Galaxy Z Flip devices. SEOUL- Samsung Electronics Co. is betting the world is finally ready for its foldable phones.\"\n\nStock Prediction(s):", "Prediction": "\n- Samsung Electronics Co. (OTC: SSNLF) will increase because they are releasing new versions of their foldable phones.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are not releasing a new foldable phone.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [146.3093, 145.835]}}}, {"link": "https://www.wsj.com/articles/cannae-holdings-senator-investment-group-propose-to-acquire-corelogic-11593179188", "title": "Cannae Holdings, Senator Investment Group Propose to Acquire CoreLogic", "date": "2020-06-26 13:42", "summary": "Unsolicited bid represents a 37% premium over CoreLogic's stock price on June 15. Cannae Holdings Inc. and Senator Investment Group LP are proposing to buy CoreLogic Inc. in a deal that would value the financial services intelligence company at $5.16 billion.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Cannae Holdings, Senator Investment Group Propose to Acquire CoreLogic. Unsolicited bid represents a 37% premium over CoreLogic's stock price on June 15. Cannae Holdings Inc. and Senator Investment Group LP are proposing to buy CoreLogic Inc. in a deal that would value the financial services intelligence company at $5.16 billion.\"\n\nStock Prediction(s):", "Prediction": "\n- CoreLogic, Inc. (NYSE: CLGX) will increase because they are being acquired for a 37% premium.\n- Cannae Holdings, Inc. (NYSE: CNNE) will increase because they are proposing to buy CoreLogic.\n- Senator Investment Group LP (NYSE: SNG) will increase because they are proposing to buy CoreLogic.", "price_info": {"CLGX": {"company": "", "ticker": "CLGX", "move": "up", "prices": [68.34, 68.15]}, "CNNE": {"company": "", "ticker": "CNNE", "move": "up", "prices": [39.53, 39.1]}, "SNG": {"company": "", "ticker": "SNG", "move": "up"}}}, {"link": "https://www.wsj.com/articles/coronavirus-exposes-businesses-dependency-on-china-11582035993", "title": "Coronavirus Exposes Businesses' Dependency on China", "date": "2020-02-18 10:57", "summary": "Apple's warning indicates the global impact as companies in China struggle to restart operations and combat worker shortages. Just as the U.S.-China trade war was starting to fade, the coronavirus crisis is exposing how heavily dependent foreign companies are on China for their production and business.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coronavirus Exposes Businesses' Dependency on China. Apple's warning indicates the global impact as companies in China struggle to restart operations and combat worker shortages. Just as the U.S.-China trade war was starting to fade, the coronavirus crisis is exposing how heavily dependent foreign companies are on China for their production and business.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will decrease because their main production line is in China, and they are struggling to restart operations.\n- Boeing Co. (NYSE: BA) will decrease because their main production line is in China, and they are struggling to restart operations.\n- Foxconn Technology Co. Ltd. (TPE: 2354) will decrease because their main production line is in China, and they are struggling to restart operations.\n", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [338.35, 337.21]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [318.14, 315.7]}}}, {"link": "https://www.wsj.com/articles/u-s-diplomats-help-13-north-korean-escapees-held-in-vietnam-reach-safety-11578070481", "title": "U.S. Helps 13 North Korean Escapees Held in Vietnam Reach Safety", "date": "2020-01-03 12:26", "summary": "American officials played a key role when the refugees' fates were in doubt. SEOUL-Caught halfway into a multicountry escape from North Korea, 13 individuals detained in Vietnam reached safety last month due to an unexpected helping hand: the U.S. government.", "categories": [["WSJ News Exclusive", "Asia"]], "category_links": ["https://www.wsj.com/news/types/asia-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Helps 13 North Korean Escapees Held in Vietnam Reach Safety. American officials played a key role when the refugees' fates were in doubt. SEOUL-Caught halfway into a multicountry escape from North Korea, 13 individuals detained in Vietnam reached safety last month due to an unexpected helping hand: the U.S. government.\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. government will be seen as a hero for helping these refugees, and this will increase support for them.\n- The U.S. government will be seen as a hero for helping these refugees, and this will increase support for them.\n- The U.S. government will be seen as a hero for helping these refugees, and this will increase support for them.", "price_info": {}}, {"link": "https://www.wsj.com/articles/one-of-aspens-largest-homes-sells-for-22-million-11583766531", "title": "One of Aspen's Largest Homes Sells for $22 Million", "date": "2020-03-09 11:30", "summary": "The buyer, who purchased the 16,726 square feet property for less than half its original asking price, threw in her Florida home to sweeten the deal. One of the largest homes in the ritzy mountain town of Aspen, Colo., has sold in an unusual transaction for $22 million.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"One of Aspen's Largest Homes Sells for $22 Million. The buyer, who purchased the 16,726 square feet property for less than half its original asking price, threw in her Florida home to sweeten the deal. One of the largest homes in the ritzy mountain town of Aspen, Colo., has sold in an unusual transaction for $22 million.\"\n\nStock Prediction(s):", "Prediction": "\n- Aspen Pharmacare Holdings Ltd. (OTC: APNHY) will increase because one of their largest homes just sold for $22 million.\n- Hilton Worldwide Holdings Inc. (NYSE: HLT) will increase because they own the Waldorf Astoria, which is a popular hotel in Aspen.\n- Marriott International, Inc. (NASDAQ: MAR) will increase because they own the Ritz-Carlton, which is a popular hotel in", "price_info": {"HLT": {"company": "", "ticker": "HLT", "move": "up", "prices": [86.03, 85.51]}, "MAR": {"company": "", "ticker": "MAR", "move": "up", "prices": [106.02, 103.5966]}}}, {"link": "https://www.wsj.com/articles/united-technologies-reports-higher-profit-sales-11580217233", "title": "United Tech's Profit Rises as Break-Up Looms", "date": "2020-01-28 10:59", "summary": "Conglomerate expects Boeing MAX problems to hurt aerospace unit. United Technologies posted higher fourth-quarter profit and sales while warning that Boeing Co.'s problems with its 737 MAX airliner will hurt results in its Collins Aerospace business.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"United Tech's Profit Rises as Break-Up Looms. Conglomerate expects Boeing MAX problems to hurt aerospace unit. United Technologies posted higher fourth-quarter profit and sales while warning that Boeing Co.'s problems with its 737 MAX airliner will hurt results in its Collins Aerospace business.\"\n\nStock Prediction(s):", "Prediction": "\n- United Technologies Corporation (NYSE: UTX) will decrease because their aerospace unit is being hurt by the Boeing MAX problems.", "price_info": {"UTX": {"company": "", "ticker": "UTX", "move": "down", "prices": [153.12, 153.57]}}}, {"link": "https://www.wsj.com/articles/oil-extends-fall-on-coronavirus-related-demand-fears-11582650327", "title": "Oil Extends Fall on Coronavirus Fears", "date": "2020-02-25 15:20", "summary": "Investors still trying to gauge the fallout from virus. Oil prices fell again Tuesday, weighed down by investors' concerns about how the spread of the coronavirus outside China will affect global oil demand.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Extends Fall on Coronavirus Fears. Investors still trying to gauge the fallout from virus. Oil prices fell again Tuesday, weighed down by investors' concerns about how the spread of the coronavirus outside China will affect global oil demand.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will decrease because of the fall in oil prices.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because of the fall in oil prices.\n- Royal Dutch Shell plc (NYSE: RDS.A) will decrease because of the fall in oil prices.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [100.6599, 100.8]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [54.3098, 54.28]}}}, {"link": "https://www.wsj.com/articles/zoom-hires-security-heavyweights-to-fix-flaws-11587061868", "title": "Zoom Hires Security Heavyweights to Fix Flaws", "date": "2020-04-16 14:31", "summary": "Video-conferencing startup models recovery plan on a Microsoft push years ago to boost Windows security. Zoom Video Communications Inc. is calling in the equivalent of the cybersecurity cavalry after security lapses that have drawn attention from U.S. authorities and raised concerns with customers.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Zoom Hires Security Heavyweights to Fix Flaws. Video-conferencing startup models recovery plan on a Microsoft push years ago to boost Windows security. Zoom Video Communications Inc. is calling in the equivalent of the cybersecurity cavalry after security lapses that have drawn attention from U.S. authorities and raised concerns with customers.\"\n\nStock Prediction(s):", "Prediction": "\n- Zoom Video Communications Inc. (NASDAQ: ZM) will increase because they are taking measures to improve their security and have brought in new security experts.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are a competitor of Zoom Video Communications Inc. and they have a history of improving their security.", "price_info": {"ZM": {"company": "", "ticker": "ZM", "move": "up", "prices": [150.2, 150.26]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [175.86, 179.25]}}}, {"link": "https://www.wsj.com/articles/softbank-posts-lower-profit-as-tech-rally-cools-11628579001", "title": "SoftBank to Hold Off on New Investments in China Amid Tech Crackdown", "date": "2021-08-10 13:14", "summary": "World's biggest tech investor posts lower profit as some investments sink in value during April-June quarter. TOKYO- SoftBank Group Corp.s net profit dropped 40% in the latest quarter as the company said it is holding back on new investments in China while it sees how Beijing's move to tame its technology sector plays out.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SoftBank to Hold Off on New Investments in China Amid Tech Crackdown. World's biggest tech investor posts lower profit as some investments sink in value during April-June quarter. TOKYO- SoftBank Group Corp.s net profit dropped 40% in the latest quarter as the company said it is holding back on new investments in China while it sees how Beijing's move to tame its technology sector plays out.\"\n\nStock Prediction(s):", "Prediction": "\n- SoftBank Group Corp. (OTCMKTS: SFTBY) will decrease because they are not making any new investments in China.\n- Alibaba Group Holding Ltd. (NYSE: BABA) will increase because they are still making new investments in China.\n- Baidu Inc. (NASDAQ: BIDU) will increase because they are still making new investments in China.", "price_info": {"BABA": {"company": "", "ticker": "BABA", "move": "up", "prices": [195.89, 196]}, "BIDU": {"company": "", "ticker": "BIDU", "move": "up", "prices": [165.225, 165.54]}}}, {"link": "https://www.wsj.com/articles/europes-biggest-utility-company-to-ramp-up-spending-on-wind-solar-power-11606228607", "title": "Europe's Biggest Utility Company to Ramp Up Spending on Wind, Solar Power", "date": "2020-11-24 09:36", "summary": "Italy's Enel pledges to almost triple renewable capacity by 2030. LONDON- Enel SpA plans to spend \u20ac70 billion, equivalent to $83 billion, expanding its presence in wind and solar power in the coming decade, seeking to cement its position as the world's largest renewable energy producer outside China and to capitalize on the shift to green energy.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Europe's Biggest Utility Company to Ramp Up Spending on Wind, Solar Power. Italy's Enel pledges to almost triple renewable capacity by 2030. LONDON- Enel SpA plans to spend \u20ac70 billion, equivalent to $83 billion, expanding its presence in wind and solar power in the coming decade, seeking to cement its position as the world's largest renewable energy producer outside China and to capitalize on the shift to green energy.\"\n\nStock Prediction(s):", "Prediction": "\n- Enel SpA (BIT: ENEL) will increase because they are expanding their renewable energy production.\n- Siemens AG (NYSE: SIEGY) will increase because they are a competitor of Enel, and they are also expanding their renewable energy production.\n- Vestas Wind Systems A/S (Copenhagen: VWS) will increase because they are a competitor of Enel, and they are also expanding their renewable energy production.", "price_info": {"SIEGY": {"company": "", "ticker": "SIEGY", "move": "up"}}}, {"link": "https://www.wsj.com/articles/papa-johns-taps-target-executive-ann-gugino-as-finance-chief-11601904900", "title": "Papa John's Taps Target Executive Ann Gugino as Finance Chief", "date": "2020-10-05 09:35", "summary": "Papa John's shuffled its management last year after it faced falling sales and controversies. Papa John's International Inc. said it has tapped Ann Gugino, a Target Corp. executive, as its finance chief, effective Monday.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Papa John's Taps Target Executive Ann Gugino as Finance Chief. Papa John's shuffled its management last year after it faced falling sales and controversies. Papa John's International Inc. said it has tapped Ann Gugino, a Target Corp. executive, as its finance chief, effective Monday.\"\n\nStock Prediction(s):", "Prediction": "\n- Papa John's International Inc. (NASDAQ: PZZA) will increase because they have a new finance chief that is experienced in the retail industry.\n- Target Corp. (NYSE: TGT) will decrease because one of their executives is leaving to go to Papa John's.", "price_info": {"TGT": {"company": "", "ticker": "TGT", "move": "down", "prices": [161.6152, 161.69]}, "PZZA": {"company": "", "ticker": "PZZA", "move": "up", "prices": [83.5298, 83.82]}}}, {"link": "https://www.wsj.com/articles/oil-glut-returns-to-near-pre-pandemic-levels-11620809325", "title": "Oil Glut Returns to Near Pre-Pandemic Levels", "date": "2021-05-12 15:37", "summary": "IEA cuts global demand growth forecast as India battles Covid-19 wave. The oil supply glut that built up after the pandemic forced producing countries to slash output has almost returned to normal levels, the International Energy Agency said Wednesday.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Glut Returns to Near Pre-Pandemic Levels. IEA cuts global demand growth forecast as India battles Covid-19 wave. The oil supply glut that built up after the pandemic forced producing countries to slash output has almost returned to normal levels, the International Energy Agency said Wednesday.\"\n\nStock Prediction(s):", "Prediction": "\n- Schlumberger Ltd. (NYSE: SLB) will increase because they are a major oilfield services company and will benefit from the increased production.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because they are a major oil producer and will benefit from the increased production.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because they are a major oil producer and will benefit from the increased production.\n- Chevron Corporation", "price_info": {"SLB": {"company": "", "ticker": "SLB", "move": "up", "prices": [32.03, 32.1]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [59.96, 59.945]}}}, {"link": "https://www.wsj.com/articles/microsofts-shopping-spree-isnt-landing-bargains-11618243997", "title": "Microsoft's Shopping Spree Isn't Landing Bargains", "date": "2021-04-12 12:13", "summary": "Acquisition of Nuance Communications adds to AI capabilities but represents high price for struggling business. Microsoft 's deal makers finally landed on a target they can hit. They sure aren't getting a bargain.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Microsoft's Shopping Spree Isn't Landing Bargains. Acquisition of Nuance Communications adds to AI capabilities but represents high price for struggling business. Microsoft 's deal makers finally landed on a target they can hit. They sure aren't getting a bargain.\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will decrease because they overpaid for Nuance Communications.\n- Nuance Communications (NASDAQ: NUAN) will decrease because they are a struggling business and Microsoft overpaid for them.", "price_info": {"MSFT": {"company": "", "ticker": "MSFT", "move": "down", "prices": [257.29, 256.7463]}, "NUAN": {"company": "", "ticker": "NUAN", "move": "down", "prices": [53.0291, 52.95]}}}, {"link": "https://www.wsj.com/articles/u-s-housing-starts-fall-in-february-11553603643", "title": "Home Building, New-Home Permits Have Softened This Year", "date": "2019-03-26 12:03", "summary": "Single-family home construction drops 17%; residential building permits also fall.. WASHINGTON-A gauge of home construction and queued up projects declined in February and are pulling back this year overall, with a slew of factors, including the government shutdown and housing affordability, potentially impacting the data.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Home Building, New-Home Permits Have Softened This Year. Single-family home construction drops 17%; residential building permits also fall.. WASHINGTON-A gauge of home construction and queued up projects declined in February and are pulling back this year overall, with a slew of factors, including the government shutdown and housing affordability, potentially impacting the data.\"\n\nStock Prediction(s):", "Prediction": "\n- Homebuilders such as Lennar Corporation (NYSE: LEN) and D.R. Horton, Inc. (NYSE: DHI) will decrease because the housing market is slowing down.\n- The Home Depot, Inc. (NYSE: HD) will decrease because people are buying less homes, and they are a big seller of home-related products.", "price_info": {"LEN": {"company": "", "ticker": "LEN", "move": null, "prices": [49.15, 49.13]}, "DHI": {"company": "", "ticker": "DHI", "move": "down", "prices": [41.09, 41]}, "HD": {"company": "", "ticker": "HD", "move": "down", "prices": [189.85, 188.93]}}}, {"link": "https://www.wsj.com/articles/covid-19-relief-funds-drive-up-nurse-pay-hospitals-say-11644316203", "title": "Covid-19 Relief Funds Drive Up Nurse Pay, Hospitals Say", "date": "2022-02-08 12:11", "summary": "Federal funding contributes to huge wage gains amid healthcare labor shortage. Hospitals and lawmakers are pressing the Biden administration to review federal pandemic-relief programs that they say have distorted pay rates for travel nurses.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Covid-19 Relief Funds Drive Up Nurse Pay, Hospitals Say. Federal funding contributes to huge wage gains amid healthcare labor shortage. Hospitals and lawmakers are pressing the Biden administration to review federal pandemic-relief programs that they say have distorted pay rates for travel nurses.\"\n\nStock Prediction(s):", "Prediction": "\n- American Nurses Association (ANA) will increase because Covid-19 relief funds are driving up nurse pay.\n- National Nurses United (NNU) will increase because Covid-19 relief funds are driving up nurse pay.\n- Kaiser Permanente (NYSE: KHC) will increase because Covid-19 relief funds are driving up nurse pay.\n- HCA Healthcare (NYSE: HCA) will increase because Covid-19 relief funds", "price_info": {"ANA": {"company": "Nurses Association", "ticker": "ANA", "move": "up"}, "NNU": {"company": "Nurses United", "ticker": "NNU", "move": "up"}, "KHC": {"company": "", "ticker": "KHC", "move": null, "prices": [35.055, 35.089]}, "HCA": {"company": "", "ticker": "HCA", "move": "up", "prices": [237.795, 239.675]}}}, {"link": "https://www.wsj.com/articles/saudi-arabia-takes-500-million-stake-in-live-nation-11588012121", "title": "Saudi Arabia Takes $500 Million Stake in Live Nation", "date": "2020-04-27 14:28", "summary": "Kingdom's Public Investment Fund said it had bought 5.7% of concert giant. Saudi Arabia's sovereign-wealth fund took a $500 million stake in Live Nation Entertainment Inc. as the world's largest concert promoter faces a year or more without being able to stage any events.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Saudi Arabia Takes $500 Million Stake in Live Nation. Kingdom's Public Investment Fund said it had bought 5.7% of concert giant. Saudi Arabia's sovereign-wealth fund took a $500 million stake in Live Nation Entertainment Inc. as the world's largest concert promoter faces a year or more without being able to stage any events.\"\n\nStock Prediction(s):", "Prediction": "\n- Live Nation Entertainment Inc. (NYSE: LYV) will increase because Saudi Arabia is investing in them.\n- Ticketmaster (NYSE: TKTM) will increase because they are a subsidiary of Live Nation.\n- Anheuser-Busch InBev SA/NV (NYSE: BUD) will decrease because they own a stake in competitor Ticketmaster.", "price_info": {"LYV": {"company": "", "ticker": "LYV", "move": "up", "prices": [42.02, 42.74]}, "TKTM": {"company": "", "ticker": "TKTM", "move": "up"}, "BUD": {"company": "", "ticker": "BUD", "move": "down", "prices": [44.22, 44.25]}}}, {"link": "https://www.wsj.com/articles/home-depots-sales-rise-but-less-than-expected-11551181086", "title": "Home Depot Blames Wet Weather for Soggy Sales", "date": "2019-02-26 15:34", "summary": "Home-improvement retailer forecasts slower growth in 2019, but executives are still upbeat on consumer spending. Home Depot Inc. executives said wet weather around the country hurt quarterly sales at the home-improvement chain and, despite sounding upbeat about consumer spending, tempered growth expectations for 2019.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Home Depot Blames Wet Weather for Soggy Sales. Home-improvement retailer forecasts slower growth in 2019, but executives are still upbeat on consumer spending. Home Depot Inc. executives said wet weather around the country hurt quarterly sales at the home-improvement chain and, despite sounding upbeat about consumer spending, tempered growth expectations for 2019.\"\n\nStock Prediction(s):", "Prediction": "\n- Home Depot Inc. (NYSE: HD) will decrease because of their lower than expected sales.\n- Lowe's Companies, Inc. (NYSE: LOW) will increase because they are not as affected by the weather, and they are a competitor of Home Depot.", "price_info": {"HD": {"company": "", "ticker": "HD", "move": "down", "prices": [187.54, 188.33]}, "LOW": {"company": "", "ticker": "LOW", "move": "up", "prices": [104.95, 104.75]}}}, {"link": "https://www.wsj.com/articles/apple-bets-that-plugging-its-values-can-help-create-value-11553607751", "title": "Apple Makes Values Pitch, but Will People Buy It?", "date": "2019-03-26 09:42", "summary": "How does being a beacon of social responsibility help the iPhone-making paragon of capitalism?. During Apple Inc.'s two-hour presentation Monday, Chief Executive Tim Cook and his throng of executives and celebrities radiated positive social messages like the stage had been hit by a #woke bomb.", "categories": [["Tech", "Keywords"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/keywords?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple Makes Values Pitch, but Will People Buy It?. How does being a beacon of social responsibility help the iPhone-making paragon of capitalism?. During Apple Inc.'s two-hour presentation Monday, Chief Executive Tim Cook and his throng of executives and celebrities radiated positive social messages like the stage had been hit by a #woke bomb.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they are trying to be a beacon of social responsibility.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are trying to be a beacon of social responsibility.\n- Facebook, Inc. (NASDAQ: FB) will increase because they are trying to be a beacon of social responsibility.\n- Google LLC (NASDAQ: GOOGL) will increase", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [191.49, 191.12]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1794, 1793.4875]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [168.45, 168.7801]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1196.065, 1194.2]}}}, {"link": "https://www.wsj.com/articles/juul-halts-online-sales-of-some-flavored-e-cigarettes-11571331640", "title": "Juul Halts Online Sales of Some Flavored E-Cigarettes", "date": "2019-10-17 13:48", "summary": "Move follows similar discontinuation in retail stores last year; online sales account for less than 10% of company's sales. Juul Labs Inc. is halting online sales of its sweet and fruity e-cigarette refill pods as federal regulators prepare to pull most nicotine vaping products off the market in response to a surge in teen vaping.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Juul Halts Online Sales of Some Flavored E-Cigarettes. Move follows similar discontinuation in retail stores last year; online sales account for less than 10% of company's sales. Juul Labs Inc. is halting online sales of its sweet and fruity e-cigarette refill pods as federal regulators prepare to pull most nicotine vaping products off the market in response to a surge in teen vaping.\"\n\nStock Prediction(s):", "Prediction": "\n- Juul Labs Inc. (NASDAQ: JUUL) will decrease because they are no longer selling their flavored e-cigarettes online.\n- Altria Group, Inc. (NYSE: MO) will increase because they are still selling their flavored e-cigarettes online.", "price_info": {"MO": {"company": "", "ticker": "MO", "move": "up", "prices": [44.115, 44.27]}, "JUUL": {"company": "", "ticker": "JUUL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/trump-tariffs-are-short-term-pain-without-long-term-gain-economists-say-11560440436", "title": "Trump Tariffs Are Short-Term Pain Without Long-Term Gain, Economists Say", "date": "2019-06-13 11:40", "summary": "Nearly three-fourths of economists in WSJ survey said they expect short-term trade costs to outweigh any long-term benefits. Most economic forecasters are pessimistic that the Trump administration's trade-tariff policy will reap long-term benefits for the economy, according to The Wall Street Journal's latest monthly survey of economists.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trump Tariffs Are Short-Term Pain Without Long-Term Gain, Economists Say. Nearly three-fourths of economists in WSJ survey said they expect short-term trade costs to outweigh any long-term benefits. Most economic forecasters are pessimistic that the Trump administration's trade-tariff policy will reap long-term benefits for the economy, according to The Wall Street Journal's latest monthly survey of economists.\"\n\nStock Prediction(s):", "Prediction": "\n- The Dow Jones Industrial Average (NYSE: DJIA) will decrease because of the Trump tariffs.\n- The S&P 500 (NYSE: SPX) will decrease because of the Trump tariffs.\n- The Nasdaq Composite (NASDAQ: COMP) will decrease because of the Trump tariffs.", "price_info": {"DJIA": {"company": "", "ticker": "DJIA", "move": "down"}, "SPX": {"company": "", "ticker": "SPX", "move": "down"}, "COMP": {"company": "", "ticker": "COMP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/activist-pressures-at-t-to-deliver-on-time-warner-deal-promises-11568114112", "title": "Activist to AT&T: What's the Plan With WarnerMedia?", "date": "2019-09-10 12:34", "summary": "Elliott says AT&T hasn't articulated strategic rationale for Time Warner acquisition. When AT&T Inc. agreed to buy Time Warner nearly three years ago, it promised to create an entertainment and advertising behemoth that could take on Silicon Valley giants like Alphabet Inc.'s Google and Netflix Inc.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Activist to AT&T: What's the Plan With WarnerMedia?. Elliott says AT&T hasn't articulated strategic rationale for Time Warner acquisition. When AT&T Inc. agreed to buy Time Warner nearly three years ago, it promised to create an entertainment and advertising behemoth that could take on Silicon Valley giants like Alphabet Inc.'s Google and Netflix Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- AT&T Inc. (NYSE: T) will increase because they have been promising a better strategy for their acquisition of WarnerMedia, and this news could be the start of that.\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because they are a direct competitor of AT&T and WarnerMedia.\n- Netflix Inc. (NASDAQ: NFLX) will increase because they are a direct competitor of AT&T and WarnerMedia.", "price_info": {"T": {"company": "", "ticker": "T", "move": "up", "prices": [37.295, 37.365]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1207.325, 1201.77]}, "NFLX": {"company": "", "ticker": "NFLX", "move": "up", "prices": [288.77, 283.88]}}}, {"link": "https://www.wsj.com/articles/at-t-boss-defends-plans-to-stream-warner-bros-films-upon-release-11607449185", "title": "AT&T Boss Defends Plans to Stream Warner Bros. Films Upon Release", "date": "2020-12-08 13:02", "summary": "CEO John Stankey expects coronavirus pandemic to scare many people away from theaters. AT&T Inc. Chief Executive John Stankey defended the decision to release all Warner Bros. movies online the same day they hit theaters next year, arguing that the film producer had to tweak a 2020 playbook that wasn't working during the coronavirus pandemic.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"AT&T Boss Defends Plans to Stream Warner Bros. Films Upon Release. CEO John Stankey expects coronavirus pandemic to scare many people away from theaters. AT&T Inc. Chief Executive John Stankey defended the decision to release all Warner Bros. movies online the same day they hit theaters next year, arguing that the film producer had to tweak a 2020 playbook that wasn't working during the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- AT&T Inc. (NYSE: T) will increase because they are releasing all Warner Bros. movies online the same day they hit theaters next year.\n- AMC Entertainment Holdings Inc (NYSE: AMC) will decrease because they are a direct competitor of AT&T.", "price_info": {"T": {"company": "", "ticker": "T", "move": "up", "prices": [30.5, 30.846]}, "AMC": {"company": "", "ticker": "AMC", "move": "down", "prices": [3.935, 3.88]}}}, {"link": "https://www.wsj.com/articles/hospitals-confront-tensions-over-who-gets-first-covid-19-vaccines-11608645610", "title": "Hospitals Confront Tensions Over Who Gets First Covid-19 Vaccines", "date": "2020-12-22 14:02", "summary": "The vaccine rollout has been bumpy in some hospital systems, where officials changed course after starting worker immunizations. Hospitals pushing ahead with Covid-19 vaccinations are facing calls for more transparency into how they decide who gets the earliest shots, as manufacturers race to distribute limited early supply of vaccine.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hospitals Confront Tensions Over Who Gets First Covid-19 Vaccines. The vaccine rollout has been bumpy in some hospital systems, where officials changed course after starting worker immunizations. Hospitals pushing ahead with Covid-19 vaccinations are facing calls for more transparency into how they decide who gets the earliest shots, as manufacturers race to distribute limited early supply of vaccine.\"\n\nStock Prediction(s):", "Prediction": "\n- Hospital stocks will decrease because of the tension between different hospital systems over who gets the Covid-19 vaccines first.\n- Pharmaceutical stocks will increase because of the increasing demand for Covid-19 vaccines.", "price_info": {}}, {"link": "https://www.wsj.com/articles/oil-little-changed-amid-light-end-of-year-trading-11577727981", "title": "Oil Little Changed Amid Light End-of-Year Trading", "date": "2019-12-30 15:19", "summary": "Traders are waiting on weekly government data on U.S. oil inventories. Crude prices swung between small gains and losses on Monday, with traders looking for a fresh catalyst that could push prices out of their current range.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Little Changed Amid Light End-of-Year Trading. Traders are waiting on weekly government data on U.S. oil inventories. Crude prices swung between small gains and losses on Monday, with traders looking for a fresh catalyst that could push prices out of their current range.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because oil prices are little changed, and they are a big player in the oil industry.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because oil prices are little changed, and they are a big player in the oil industry.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because oil prices are little changed, and they are a big player in the oil industry.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [120.085, 119.85]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [69.605, 69.5]}}}, {"link": "https://www.wsj.com/articles/is-cryptocurrency-ready-for-stephen-moore-11561478622", "title": "Is Cryptocurrency Ready for Stephen Moore?", "date": "2019-06-25 12:03", "summary": "Pundit didn't get onto the Fed board but has joined a 'decentralized central bank' that hopes to tame cryptocurrencies like bitcoin. If you can't beat 'em, join 'em. And if you can't join 'em?", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Is Cryptocurrency Ready for Stephen Moore?. Pundit didn't get onto the Fed board but has joined a 'decentralized central bank' that hopes to tame cryptocurrencies like bitcoin. If you can't beat 'em, join 'em. And if you can't join 'em?\"\n\nStock Prediction(s):", "Prediction": "\n- Bitcoin (BTC) will increase because Stephen Moore is joining a \"decentralized central bank\" that will help to tame it.\n- Ethereum (ETH) will increase because Stephen Moore is joining a \"decentralized central bank\" that will help to tame it.\n- Litecoin (LTC) will increase because Stephen Moore is joining a \"decentralized central bank\" that will help to tame it.", "price_info": {"BTC": {"company": "Bitcoin", "ticker": "BTC", "move": "up"}, "ETH": {"company": "Ethereum", "ticker": "ETH", "move": "up", "prices": [20.29, 20.22]}, "LTC": {"company": "Litecoin", "ticker": "LTC", "move": "up", "prices": [46.31, 46.23]}}}, {"link": "https://www.wsj.com/articles/vegan-restaurant-chain-by-chloe-preps-bankruptcy-sale-11607978756", "title": "Vegan Restaurant Chain By Chloe Preps for Bankruptcy Sale", "date": "2020-12-14 15:45", "summary": "The chain, part-owned by Bain Capital, blames its money problems on the pandemic and says it hopes to sell itself in early 2021. Fast-casual vegan restaurant brand By Chloe has filed for bankruptcy to ease a planned sale after the business suffered a cash crunch brought on by the coronavirus pandemic.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Vegan Restaurant Chain By Chloe Preps for Bankruptcy Sale. The chain, part-owned by Bain Capital, blames its money problems on the pandemic and says it hopes to sell itself in early 2021. Fast-casual vegan restaurant brand By Chloe has filed for bankruptcy to ease a planned sale after the business suffered a cash crunch brought on by the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- By Chloe (private) will increase because they are filing for bankruptcy and hope to sell themselves.\n- Bain Capital (private) will increase because they are part-owners of the vegan restaurant chain.", "price_info": {}}, {"link": "https://www.wsj.com/articles/brushers-arrange-fake-online-sales-to-enhance-sellers-reputations-11596046717", "title": "'Brushers' Are in Focus as Officials Test Packages of Mysterious Seeds", "date": "2020-07-30 11:27", "summary": "E-commerce practice includes faking online sales to enhance vendors' reputations. A e-commerce technique known as brushing is coming into focus this week as federal officials look to whether the practice is behind a phenomenon of seeds appearing in mailboxes across the country.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"'Brushers' Are in Focus as Officials Test Packages of Mysterious Seeds. E-commerce practice includes faking online sales to enhance vendors' reputations. A e-commerce technique known as brushing is coming into focus this week as federal officials look to whether the practice is behind a phenomenon of seeds appearing in mailboxes across the country.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they have been known to use this technique to increase their sales.\n- eBay Inc. (NASDAQ: EBAY) will increase because they have been known to use this technique to increase their sales.\n- Walmart Inc. (NYSE: WMT) will increase because they have been known to use this technique to increase their sales.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [129.85, 129.95]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3066.61, 3072]}, "EBAY": {"company": "", "ticker": "EBAY", "move": "up", "prices": [54.525, 54.72]}}}, {"link": "https://www.wsj.com/articles/huawei-faces-deepening-scrutiny-in-europe-11548930489", "title": "Huawei Faces Deepening Scrutiny in Europe", "date": "2019-01-31 15:22", "summary": "EU is latest authority to consider measures to address concerns about the Chinese telecommunications-equipment maker. The European Union is exploring ways to address security concerns about Huawei Technologies Co. and other Chinese telecommunications-equipment suppliers, EU officials said, a move that could effectively halt sales of Huawei gear in one of the company's most important markets.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Huawei Faces Deepening Scrutiny in Europe. EU is latest authority to consider measures to address concerns about the Chinese telecommunications-equipment maker. The European Union is exploring ways to address security concerns about Huawei Technologies Co. and other Chinese telecommunications-equipment suppliers, EU officials said, a move that could effectively halt sales of Huawei gear in one of the company's most important markets.\"\n\nStock Prediction(s):", "Prediction": "\n- Huawei Technologies Co. (SHE: 002502) will decrease because they are being scrutinized by the EU, and this could halt sales of their gear.\n- Nokia Corporation (NYSE: NOK) will increase because they are not being scrutinized by the EU, and they are a direct competitor of Huawei.\n- Ericsson (NASDAQ: ERIC) will increase because they are not being scrutinized by the EU, and they are a direct", "price_info": {"NOK": {"company": "", "ticker": "NOK", "move": "up", "prices": [6.31, 6.4]}, "ERIC": {"company": "", "ticker": "ERIC", "move": "up", "prices": [8.9, 8.91]}}}, {"link": "https://www.wsj.com/articles/feds-kaplan-fed-likely-on-pause-until-at-least-summer-11549040516", "title": "Fed's Kaplan: Fed Likely On Pause Until At Least Summer", "date": "2019-02-01 12:01", "summary": "'It's very important for the Fed to get out of the way' and let the economy work through some issues, the Dallas Fed president says. Dallas Federal Reserve Bank President Robert Kaplan said he believes the U.S. central bank will hold off on rate increases until at least the summer.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Kaplan: Fed Likely On Pause Until At Least Summer. 'It's very important for the Fed to get out of the way' and let the economy work through some issues, the Dallas Fed president says. Dallas Federal Reserve Bank President Robert Kaplan said he believes the U.S. central bank will hold off on rate increases until at least the summer.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FFR) will decrease because they are likely to hold off on rate increases until the summer.", "price_info": {"FFR": {"company": "", "ticker": "FFR", "move": "up"}}}, {"link": "https://www.wsj.com/articles/fed-minutes-to-show-extent-of-committee-divisions-on-last-months-rate-cut-11566379803", "title": "Fed Minutes to Show Committee Divide on Last Month's Rate Cut", "date": "2019-08-21 09:32", "summary": "They could shed light on what would prompt further reductions from the central bank this year. The Federal Reserve releases the minutes of its July 30-31 meeting on Wednesday at 2 p.m. EDT, shedding more light on its decision to cut interest rates for the first time in more than a decade.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Minutes to Show Committee Divide on Last Month's Rate Cut. They could shed light on what would prompt further reductions from the central bank this year. The Federal Reserve releases the minutes of its July 30-31 meeting on Wednesday at 2 p.m. EDT, shedding more light on its decision to cut interest rates for the first time in more than a decade.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will go up because the minutes will show that the committee is divided on the rate cut, and this could lead to further reductions this year.\n- The market will go down because the minutes will show that the committee is divided on the rate cut, and this could lead to further reductions this year.", "price_info": {}}, {"link": "https://www.wsj.com/articles/medtronic-to-stop-selling-hvad-implantable-heart-pump-over-safety-concerns-11622734967", "title": "Medtronic to Stop Selling Implantable Heart Pump Over Safety Concerns", "date": "2021-06-03 11:42", "summary": "The medical-device company also is starting a support program for patients who have had the device implanted. Medtronic PLC said it is stopping the distribution and sale of its implantable heart pump in light of clinical data suggesting more frequent deaths and neurological events such as stroke compared with other circulatory-support devices.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Medtronic to Stop Selling Implantable Heart Pump Over Safety Concerns. The medical-device company also is starting a support program for patients who have had the device implanted. Medtronic PLC said it is stopping the distribution and sale of its implantable heart pump in light of clinical data suggesting more frequent deaths and neurological events such as stroke compared with other circulatory-support devices.\"\n\nStock Prediction(s):", "Prediction": "\n- Medtronic plc (NYSE: MDT) will decrease because they are stopping the distribution and sale of their implantable heart pump.", "price_info": {"MDT": {"company": "", "ticker": "MDT", "move": "down", "prices": [123.285, 123.45]}}}, {"link": "https://www.wsj.com/articles/why-capex-cant-catch-a-break-11580230652", "title": "Why Capex Can't Catch a Break", "date": "2020-01-28 11:57", "summary": "December's durable goods orders showed that capital spending remains anemic. One-off issues keep getting in the way of a capital spending revival. It is time to ask if those issues aren't the real problem.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why Capex Can't Catch a Break. December's durable goods orders showed that capital spending remains anemic. One-off issues keep getting in the way of a capital spending revival. It is time to ask if those issues aren't the real problem.\"\n\nStock Prediction(s):", "Prediction": "\n- Caterpillar Inc. (NYSE: CAT) will decrease because their main business is construction, and construction is one of the sectors that is most affected by a lack of capital spending.\n- 3M Co. (NYSE: MMM) will decrease because their main business is manufacturing, and manufacturing is one of the sectors that is most affected by a lack of capital spending.\n- Intel Corporation (NASDAQ: INTC) will decrease because their main business is technology", "price_info": {"CAT": {"company": "", "ticker": "CAT", "move": "down", "prices": [136.995, 137.17]}, "MMM": {"company": "", "ticker": "MMM", "move": "down", "prices": [166.0114, 165.9834]}, "INTC": {"company": "", "ticker": "INTC", "move": "down", "prices": [67.44, 67.4419]}}}, {"link": "https://www.wsj.com/articles/judge-dismisses-new-mexico-lawsuit-against-google-over-childrens-data-privacy-11601392392", "title": "Judge Dismisses New Mexico Lawsuit Against Google Over Children's Data Privacy", "date": "2020-09-29 11:13", "summary": "Federal judge rules the internet giant didn't violate prohibition on companies from collecting data on children under 13 without parental consent. A federal court dismissed a New Mexico lawsuit alleging that Alphabet Inc.'s Google knowingly spied on students and their families through its suite of cloud-based products for schools.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Judge Dismisses New Mexico Lawsuit Against Google Over Children's Data Privacy. Federal judge rules the internet giant didn't violate prohibition on companies from collecting data on children under 13 without parental consent. A federal court dismissed a New Mexico lawsuit alleging that Alphabet Inc.'s Google knowingly spied on students and their families through its suite of cloud-based products for schools.\"\n\nStock Prediction(s):", "Prediction": "\n- Google (NASDAQ: GOOGL) will increase because they have been cleared of any wrongdoing in a lawsuit over children's data privacy.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are also expanding into the education market.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they have been lagging behind Google and Amazon in the education market.", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1458.6668, 1458.76]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3161.14, 3163.57]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [113.9254, 113.77]}}}, {"link": "https://www.wsj.com/articles/tesla-countersues-jpmorgan-in-fight-over-warrants-11643035301", "title": "Tesla Countersues JPMorgan in Fight Over Warrants", "date": "2022-01-24 09:41", "summary": "Auto maker alleges the bank's dislike of Elon Musk is behind its $162 million lawsuit in November. Tesla Inc. countersued JPMorgan Chase & Co. on Monday, intensifying a dispute over the payout for a bond sale the bank helped arrange in 2014.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tesla Countersues JPMorgan in Fight Over Warrants. Auto maker alleges the bank's dislike of Elon Musk is behind its $162 million lawsuit in November. Tesla Inc. countersued JPMorgan Chase & Co. on Monday, intensifying a dispute over the payout for a bond sale the bank helped arrange in 2014.\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla Inc. (TSLA) will increase because they are fighting back against JPMorgan and they have a good chance of winning.\n- JPMorgan Chase & Co. (JPM) will decrease because they are being sued by Tesla and they may not win.", "price_info": {"TSLA": {"company": "Tesla Inc.", "ticker": "TSLA", "move": "up", "prices": [896.28, 878.75]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [142.55, 141.11]}}}, {"link": "https://www.wsj.com/articles/fda-narrows-suggested-uses-for-new-alzheimers-drug-11625759738", "title": "FDA Narrows Suggested Uses for New Alzheimer's Drug", "date": "2021-07-08 11:55", "summary": "The agency recommended Aduhelm only for patients in early stages of the disease, which could reduce the cost to Medicare. U.S. health regulators narrowed the prescribing instructions for the first new Alzheimer's drug in nearly two decades, recommending the therapy be given to people with early-stage symptoms of the disease.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"FDA Narrows Suggested Uses for New Alzheimer's Drug. The agency recommended Aduhelm only for patients in early stages of the disease, which could reduce the cost to Medicare. U.S. health regulators narrowed the prescribing instructions for the first new Alzheimer's drug in nearly two decades, recommending the therapy be given to people with early-stage symptoms of the disease.\"\n\nStock Prediction(s):", "Prediction": "\n- Biogen Inc (NASDAQ: BIIB) will increase because their main competitor's drug was only recommended for early-stage patients.\n- Eli Lilly and Co (NYSE: LLY) will decrease because their main competitor's drug was only recommended for early-stage patients.", "price_info": {"LLY": {"company": "", "ticker": "LLY", "move": "down", "prices": [235.68, 235.245]}, "BIIB": {"company": "", "ticker": "BIIB", "move": "up", "prices": [365.95, 368.365]}}}, {"link": "https://www.wsj.com/articles/sofi-loses-three-top-executives-11559675426", "title": "SoFi Loses Three Top Executives", "date": "2019-06-04 15:10", "summary": "Online lenders continue to face tough environment. Three top executives of Social Finance Inc. are leaving the financial-tech startup in the coming weeks, adding to the challenges the company faces as it moves through a tough environment for online lenders.", "categories": [["WSJ News Exclusive", "Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SoFi Loses Three Top Executives. Online lenders continue to face tough environment. Three top executives of Social Finance Inc. are leaving the financial-tech startup in the coming weeks, adding to the challenges the company faces as it moves through a tough environment for online lenders.\"\n\nStock Prediction(s):", "Prediction": "\n- SoFi Inc (NYSE: SOFI) will decrease because they are losing executives.\n- LendingClub Corp (NYSE: LC) will increase because they are a competitor of SoFi and are doing well.\n- Square Inc (NYSE: SQ) will increase because they are a competitor of SoFi and are doing well.", "price_info": {"SOFI": {"company": "", "ticker": "SOFI", "move": "down"}, "LC": {"company": "", "ticker": "LC", "move": "up", "prices": [2.9595, 2.97]}, "SQ": {"company": "", "ticker": "SQ", "move": "up", "prices": [63.4, 63.41]}}}, {"link": "https://www.wsj.com/articles/can-china-really-make-kids-stop-playing-video-games-11631286006", "title": "'Mortal Kombat' Can Teach China a Thing or Two About Videogames", "date": "2021-09-10 11:00", "summary": "From 'penny dreadfuls' to comic books to music, often the best way to make a business boom has been to try limiting it. Back in Business is an occasional column that puts the present day in perspective by looking at business history and those who shaped it. Read previous installments of the column here.", "categories": [["Business", "Back in Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/back-in-business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"'Mortal Kombat' Can Teach China a Thing or Two About Videogames. From 'penny dreadfuls' to comic books to music, often the best way to make a business boom has been to try limiting it. Back in Business is an occasional column that puts the present day in perspective by looking at business history and those who shaped it. Read previous installments of the column here.\"\n\nStock Prediction(s):", "Prediction": "\n- Activision Blizzard, Inc. (NASDAQ: ATVI) will increase because this could lead to China lifting their ban on video games, which would be a major market for the company.\n- Take-Two Interactive Software, Inc. (NASDAQ: TTWO) will increase because this could lead to China lifting their ban on video games, which would be a major market for the company.\n- Nintendo Co., Ltd. (OTCMKTS: NT", "price_info": {"ATVI": {"company": "", "ticker": "ATVI", "move": "up", "prices": [80.035, 80.53]}, "TTWO": {"company": "", "ticker": "TTWO", "move": "up", "prices": [154.49, 155.385]}}}, {"link": "https://www.wsj.com/articles/shell-takes-22-billion-write-down-expecting-lower-oil-and-gas-prices-11593504718", "title": "Shell Takes $22 Billion Write-Down, Expecting Lower Oil and Gas Prices", "date": "2020-06-30 10:27", "summary": "Anglo-Dutch energy giant's action follows a similarly large move by BP. LONDON-Royal Dutch Shell PLC is writing down the value of its assets by up to $22 billion because of lower energy prices following the demand-sapping coronavirus pandemic.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Shell Takes $22 Billion Write-Down, Expecting Lower Oil and Gas Prices. Anglo-Dutch energy giant's action follows a similarly large move by BP. LONDON-Royal Dutch Shell PLC is writing down the value of its assets by up to $22 billion because of lower energy prices following the demand-sapping coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Shell (NYSE: RDS.A) will decrease because they took a $22 billion write-down.\n- BP (NYSE: BP) will decrease because they took a $19 billion write-down.\n- Exxon Mobil (NYSE: XOM) will decrease because they took a $16 billion write-down.\n- Chevron (NYSE: CVX) will decrease because they took a $10 billion write-down.", "price_info": {"BP": {"company": "", "ticker": "BP", "move": "down", "prices": [23.07, 23.075]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [43.73, 43.84]}, "CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [87.9377, 88.13]}}}, {"link": "https://www.wsj.com/articles/apple-tv-on-a-samsung-iphone-giant-makes-risky-jump-to-other-devices-to-sell-services-11553629788", "title": "Apple Makes Friendly With Rivals' Devices", "date": "2019-03-26 15:49", "summary": "As iPhone sales decelerate, company breaks habit of trying to confine users to Apple-only world. When Apple Inc. launched the iPod with iTunes, Steve Jobs fought efforts to make them accessible on rivals' devices. He wanted the newest Apple products to benefit the company's own hardware business", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple Makes Friendly With Rivals' Devices. As iPhone sales decelerate, company breaks habit of trying to confine users to Apple-only world. When Apple Inc. launched the iPod with iTunes, Steve Jobs fought efforts to make them accessible on rivals' devices. He wanted the newest Apple products to benefit the company's own hardware business\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they are breaking their habit of being exclusive and trying to make their products available on other devices.\n- Samsung Electronics Co Ltd (OTC: SSNLF) will decrease because they are a direct competitor of Apple.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [187.06, 187.69]}}}, {"link": "https://www.wsj.com/articles/facebook-wanted-to-create-a-new-currency-it-wasnt-ready-for-the-backlash-11571242795", "title": "Inside Facebook's Botched Attempt to Start a New Cryptocurrency", "date": "2019-10-16 12:19", "summary": "Major partners bolted after Washington challenged the social-media giant's foray into finance. David Marcus gathered a team inside Facebook Inc.'s headquarters in May to toast a skunk works project a year in the making: a bitcoin-like payments system that the social-media giant figured would upend the global flow of money.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Inside Facebook's Botched Attempt to Start a New Cryptocurrency. Major partners bolted after Washington challenged the social-media giant's foray into finance. David Marcus gathered a team inside Facebook Inc.'s headquarters in May to toast a skunk works project a year in the making: a bitcoin-like payments system that the social-media giant figured would upend the global flow of money.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook Inc. (NASDAQ: FB) will decrease because of their botched attempt to start a new cryptocurrency.\n- Bitcoin (BTC) will decrease because of Facebook's botched attempt to start a new cryptocurrency.", "price_info": {"BTC": {"company": "Bitcoin", "ticker": "BTC", "move": "down"}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [188.59, 189]}}}, {"link": "https://www.wsj.com/articles/twitters-snapchat-rival-fleets-feature-comes-to-fleeting-end-11626283397", "title": "Twitter's Snapchat-Rival Fleets Feature Comes to Fleeting End", "date": "2021-07-14 15:51", "summary": "Disappearing posts failed to deliver sought-after increase in user engagement. That was fleeting.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Twitter's Snapchat-Rival Fleets Feature Comes to Fleeting End. Disappearing posts failed to deliver sought-after increase in user engagement. That was fleeting.\"\n\nStock Prediction(s):", "Prediction": "\n- Twitter, Inc. (NYSE: TWTR) will decrease because their Snapchat-rival feature, Fleets, has failed to deliver the increase in user engagement that they were hoping for.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "up", "prices": [70.27, 70.27]}}}, {"link": "https://www.wsj.com/articles/u-s-tariffs-drive-drop-in-chinese-imports-11620811802", "title": "U.S. Tariffs Drive Drop in Chinese Imports", "date": "2021-05-12 14:32", "summary": "Levies now cover about $250 billion a year in goods-down from $370 billion-as U.S. companies shift purchases elsewhere. WASHINGTON-U.S. tariffs have led to a sharp decline in Chinese imports and significant changes in the types of goods Americans buy from China, new data show, with purchases of telecommunications gear, furniture, apparel and other goods shifting to other countries.", "categories": [["WSJ News Exclusive", "Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Tariffs Drive Drop in Chinese Imports. Levies now cover about $250 billion a year in goods-down from $370 billion-as U.S. companies shift purchases elsewhere. WASHINGTON-U.S. tariffs have led to a sharp decline in Chinese imports and significant changes in the types of goods Americans buy from China, new data show, with purchases of telecommunications gear, furniture, apparel and other goods shifting to other countries.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they have shifted their production to Vietnam to avoid the tariffs.\n- Huawei Technologies Co. Ltd. (SHE: 002502) will decrease because they are a Chinese company and will be affected by the tariffs.\n- Dell Technologies Inc. (NYSE: DVMT) will increase because they have shifted their production to Vietnam to avoid the tariffs.\n- HP Inc. (NYSE: HPQ", "price_info": {"DVMT": {"company": "", "ticker": "DVMT", "move": "up"}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [122.555, 122.605]}}}, {"link": "https://www.wsj.com/articles/the-benchmark-set-to-replace-libor-is-acting-weird-11549890002", "title": "The Benchmark Set to Replace Libor Suffers Volatility Spike", "date": "2019-02-11 12:06", "summary": "If SOFR proves unusually volatile or hard to predict, it would diminish the rate's appeal to companies considering tying borrowing costs to it. Recent volatility in the market for overnight cash loans is raising concerns about a new benchmark that could set interest rates for trillions of dollars in mortgages and corporate debt.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Benchmark Set to Replace Libor Suffers Volatility Spike. If SOFR proves unusually volatile or hard to predict, it would diminish the rate's appeal to companies considering tying borrowing costs to it. Recent volatility in the market for overnight cash loans is raising concerns about a new benchmark that could set interest rates for trillions of dollars in mortgages and corporate debt.\"\n\nStock Prediction(s):", "Prediction": "\n- The benchmark set to replace Libor (the London Interbank Offered Rate) will suffer because it is proving to be too volatile. This could diminish its appeal to companies, and could lead to increased borrowing costs.\n- The benchmark set to replace Libor will benefit because it is proving to be more stable and predictable. This could lead to decreased borrowing costs for companies.", "price_info": {}}, {"link": "https://www.wsj.com/articles/spotify-adds-subscribers-as-covid-19-boosts-at-home-streaming-11619604000", "title": "Spotify Adds Subscribers, Says Rogan Drawing More Users Than Expected", "date": "2021-04-28 10:59", "summary": "Audiostreaming platform warns of uncertain growth as newer markets endure a surge in coronavirus cases. Continued at-home listening of music and podcasts helped Spotify Technology SA post another quarter of strong subscription gains, though overall user growth softened as some of the company's newest markets face a fierce resurgence of Covid-19.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Spotify Adds Subscribers, Says Rogan Drawing More Users Than Expected. Audiostreaming platform warns of uncertain growth as newer markets endure a surge in coronavirus cases. Continued at-home listening of music and podcasts helped Spotify Technology SA post another quarter of strong subscription gains, though overall user growth softened as some of the company's newest markets face a fierce resurgence of Covid-19.\"\n\nStock Prediction(s):", "Prediction": "\n- Spotify Technology SA (NYSE: SPOT) will increase because their user base is growing, and they are still seeing strong subscription growth.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are a direct competitor of Spotify.\n- Pandora Media, Inc. (NYSE: P) will decrease because they are a direct competitor of Spotify.", "price_info": {"SPOT": {"company": "", "ticker": "SPOT", "move": "up", "prices": [266.9, 264.12]}, "P": {"company": "", "ticker": "P", "move": "down"}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [133.2587, 133.645]}}}, {"link": "https://www.wsj.com/articles/the-fed-cant-do-it-all-says-alan-blinder-11588357053", "title": "The Fed Can't Do It All, Says Alan Blinder", "date": "2020-05-01 14:17", "summary": "The former Federal Reserve vice chairman says he approves of how the Fed is responding to the economic and financial havoc wrought by the coronavirus. Alan Blinder knows a thing or two about the Federal Reserve, having served as vice chairman from 1994 to 1996 and as a member of President Clinton's Council of Economic Advisers before that.", "categories": [["Markets", "Journal Reports: Funds/ETFs", "Q&A"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-funds-etfs?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Fed Can't Do It All, Says Alan Blinder. The former Federal Reserve vice chairman says he approves of how the Fed is responding to the economic and financial havoc wrought by the coronavirus. Alan Blinder knows a thing or two about the Federal Reserve, having served as vice chairman from 1994 to 1996 and as a member of President Clinton's Council of Economic Advisers before that.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed will continue to increase interest rates because they feel that the economy is strong and they want to prevent inflation.\n- The stock market will continue to increase because the Fed is indicating that they will continue to increase interest rates.", "price_info": {}}, {"link": "https://www.wsj.com/articles/biogens-new-alzheimers-drug-meets-slow-rollout-11634733079", "title": "Biogen's New Alzheimer's Drug Meets Slow Rollout", "date": "2021-10-20 11:52", "summary": "Revenue from the drug, Aduhelm, was $300,000 in the first full quarter of sales. Biogen Inc. reported slow uptake of its new Alzheimer's disease drug Aduhelm in the third-quarter, as some doctors stayed on the fence about whether to prescribe the drug and others struggled to coordinate the complex process of onboarding new patients for treatment.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Biogen's New Alzheimer's Drug Meets Slow Rollout. Revenue from the drug, Aduhelm, was $300,000 in the first full quarter of sales. Biogen Inc. reported slow uptake of its new Alzheimer's disease drug Aduhelm in the third-quarter, as some doctors stayed on the fence about whether to prescribe the drug and others struggled to coordinate the complex process of onboarding new patients for treatment.\"\n\nStock Prediction(s):", "Prediction": "\n- Biogen Inc. (NASDAQ: BIIB) will decrease because their new Alzheimer's drug is not being picked up as quickly as they had hoped.\n- Merck & Co., Inc. (NYSE: MRK) will increase because they do not have a new Alzheimer's drug on the market.", "price_info": {"MRK": {"company": "", "ticker": "MRK", "move": "up", "prices": [81.2, 81.0185]}, "BIIB": {"company": "", "ticker": "BIIB", "move": "up", "prices": [268.4, 266.845]}}}, {"link": "https://www.wsj.com/articles/u-s-retail-sales-fell-in-september-11571229234", "title": "U.S. Retail Sales Fell in September", "date": "2019-10-16 12:44", "summary": "Sales fell 0.3% from August in first monthly decline since February. WASHINGTON-American shoppers pulled back on spending in September, signaling a key support for the U.S. economy this year could be softening amid a broader global economic slowdown.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Retail Sales Fell in September. Sales fell 0.3% from August in first monthly decline since February. WASHINGTON-American shoppers pulled back on spending in September, signaling a key support for the U.S. economy this year could be softening amid a broader global economic slowdown.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will decrease because their main customer base is the middle and lower class, and they are the most sensitive to economic downturns.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are not as sensitive to economic downturns, and they have a wider customer base.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [119.3, 119.44]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1777.11, 1778.8]}}}, {"link": "https://www.wsj.com/articles/employees-pushed-to-keep-learning-new-skills-as-workplace-evolves-11551279600", "title": "'I'm Still Under Construction'; Six Tales of Lifelong Learning", "date": "2019-02-27 15:14", "summary": "Pressure grows in competitive market for workers to figure out future career paths on their own time and dime. Lifelong learning has become a mantra in American corporations as employees face pressure to stay relevant in a rapidly evolving workplace.", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/management-careers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"'I'm Still Under Construction'; Six Tales of Lifelong Learning. Pressure grows in competitive market for workers to figure out future career paths on their own time and dime. Lifelong learning has become a mantra in American corporations as employees face pressure to stay relevant in a rapidly evolving workplace.\"\n\nStock Prediction(s):", "Prediction": "\n- American corporations will increase because they are emphasizing the importance of lifelong learning in order to stay competitive.\n- Other companies that are not mentioned in the article will decrease because they are not emphasizing the importance of lifelong learning in order to stay competitive.", "price_info": {}}, {"link": "https://www.wsj.com/articles/europe-pushes-alternative-to-u-s-backed-covid-19-vaccine-patent-waiver-plan-11622732952", "title": "Europe Pushes Alternative to Vaccine Patent-Waiver Plan", "date": "2021-06-03 13:25", "summary": "EU stance makes a quick deal on the U.S.-backed waiver proposal less likely, and could sink it altogether, experts say. The European Union is pushing back hard against U.S.-backed calls to temporarily waive intellectual property rights for Covid-19 vaccines, preparing a rival plan that officials said would better safeguard drug companies' patents and look for other ways to boost supplies for developing countries.", "categories": [["WSJ News Exclusive", "World"]], "category_links": ["https://www.wsj.com/news/world?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Europe Pushes Alternative to Vaccine Patent-Waiver Plan. EU stance makes a quick deal on the U.S.-backed waiver proposal less likely, and could sink it altogether, experts say. The European Union is pushing back hard against U.S.-backed calls to temporarily waive intellectual property rights for Covid-19 vaccines, preparing a rival plan that officials said would better safeguard drug companies' patents and look for other ways to boost supplies for developing countries.\"\n\nStock Prediction(s):", "Prediction": "\n- The European Union's plan will be successful, and will not require waiving intellectual property rights for Covid-19 vaccines.\n- The United States' plan will be successful, and will require waiving intellectual property rights for Covid-19 vaccines.\n- Neither plan will be successful, and intellectual property rights for Covid-19 vaccines will be waived.", "price_info": {}}, {"link": "https://www.wsj.com/articles/economys-fate-might-hinge-on-question-of-full-employment-11642081833", "title": "As U.S. Approaches 'Full Employment,' New Inflation Risks Emerge", "date": "2022-01-13 15:28", "summary": "Some economists say low unemployment, rising wages and high inflation mean job market is fully healed; others see room to run. For workers, it is great news: the U.S. labor market is nearing, or may already be at, its ideal state of \"full employment.\" But for the economy as a whole, it risks introducing a new source of upward pressure on inflation.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"As U.S. Approaches 'Full Employment,' New Inflation Risks Emerge. Some economists say low unemployment, rising wages and high inflation mean job market is fully healed; others see room to run. For workers, it is great news: the U.S. labor market is nearing, or may already be at, its ideal state of \"full employment.\" But for the economy as a whole, it risks introducing a new source of upward pressure on inflation.\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. economy will slow down because of the new inflation risks that have emerged.\n- The Federal Reserve will increase interest rates to combat the new inflation risks.\n- The stock market will decrease because of the increased interest rates.", "price_info": {}}, {"link": "https://www.wsj.com/articles/twitter-goes-full-marie-kondo-11549557635", "title": "Twitter Goes Full Marie Kondo", "date": "2019-02-07 11:40", "summary": "Cleaning house is costly, but social network is making the right moves. Twitter didn't spark joy for investors.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Twitter Goes Full Marie Kondo. Cleaning house is costly, but social network is making the right moves. Twitter didn't spark joy for investors.\"\n\nStock Prediction(s):", "Prediction": "\n- Twitter, Inc. (NYSE: TWTR) will continue to decrease because they are not making enough money and they are not sparking joy for investors.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "down", "prices": [30.4323, 30.9101]}}}, {"link": "https://www.wsj.com/articles/more-jobs-less-inflation-11615397120", "title": "More Jobs, Less Inflation?", "date": "2021-03-10 12:25", "summary": "A better labor market might actually alleviate some inflationary pressures in the months ahead. Tightening labor markets are supposed to make for higher inflation. But at least in the months ahead, the faster the job market recovers, the less serious some inflationary pressures might be.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"More Jobs, Less Inflation?. A better labor market might actually alleviate some inflationary pressures in the months ahead. Tightening labor markets are supposed to make for higher inflation. But at least in the months ahead, the faster the job market recovers, the less serious some inflationary pressures might be.\"\n\nStock Prediction(s):", "Prediction": "\n- The unemployment rate will continue to decline, which will be good news for the stock market as a whole.\n- The inflation rate will remain low, which will be good news for consumers and for companies that sell goods and services.", "price_info": {}}, {"link": "https://www.wsj.com/articles/boeing-expands-focus-on-air-taxis-11643022001", "title": "Boeing Expands Focus on Air Taxis", "date": "2022-01-24 11:38", "summary": "Wisk joint venture with Google co-founder Larry Page is developing pilotless electric aircraft. Boeing Co. said it is investing a further $450 million in its air-taxi joint venture with Google co-founder Larry Page, developing small, pilotless aircraft for short passenger hops in and around cities.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Boeing Expands Focus on Air Taxis. Wisk joint venture with Google co-founder Larry Page is developing pilotless electric aircraft. Boeing Co. said it is investing a further $450 million in its air-taxi joint venture with Google co-founder Larry Page, developing small, pilotless aircraft for short passenger hops in and around cities.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co. (NYSE: BA) will increase because they are expanding their focus on air taxis.\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because they are a partner in the joint venture.\n- Airbus SE (EPA: AIR) will decrease because they are a direct competitor of Boeing.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [195.85, 196.5]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [2535.84, 2497.93]}}}, {"link": "https://www.wsj.com/articles/saudi-exchange-readies-aramco-ipo-investors-raise-concerns-11571318949", "title": "Saudi Exchange Readies Aramco IPO. Investors Raise Concerns.", "date": "2019-10-17 11:24", "summary": "Five years ago, the Tadawul market didn't allow foreigners to invest. Now it's readying to host one of the world's most anticipated listings.. Saudi Arabia's stock market has-in little less than half a decade-transformed itself by opening to international investors and instituting investor friendly reforms. But as it prepares to host the world's biggest initial public offering, of Aramco, some foreign investors remain concerned about market transparency and how heavily the government intervenes in Saudi shares.", "categories": [["Markets", "Stocks", "IPOs"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/markets/stocks?mod=breadcrumb", "https://www.wsj.com/news/types/ipos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Saudi Exchange Readies Aramco IPO. Investors Raise Concerns.. Five years ago, the Tadawul market didn't allow foreigners to invest. Now it's readying to host one of the world's most anticipated listings.. Saudi Arabia's stock market has-in little less than half a decade-transformed itself by opening to international investors and instituting investor friendly reforms. But as it prepares to host the world's biggest initial public offering, of Aramco, some foreign investors remain concerned about market transparency and how heavily the government intervenes in Saudi shares.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Arabian Oil Co. (NYSE: ARAMCO) will increase because they are getting ready for their IPO and they are a very successful company.\n- The Saudi Exchange (Tadawul) will increase because they are hosting the Aramco IPO and they are a very successful company.\n- Other Saudi Arabian companies will increase because they are associated with the Tadawul and the Aramco IPO.", "price_info": {}}, {"link": "https://www.wsj.com/articles/google-overhauls-cookie-replacement-plan-after-privacy-critiques-11643115603", "title": "Google Overhauls Cookie Replacement Plan After Privacy Critiques", "date": "2022-01-25 12:27", "summary": "New proposal aims to provide less-granular information to advertisers, with implications for rivals and marketers. Google is overhauling its plans for targeted online advertising after pushback from privacy advocates, aiming to give marketers less-granular information about web users than under the tech giant's initial proposal.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Google Overhauls Cookie Replacement Plan After Privacy Critiques. New proposal aims to provide less-granular information to advertisers, with implications for rivals and marketers. Google is overhauling its plans for targeted online advertising after pushback from privacy advocates, aiming to give marketers less-granular information about web users than under the tech giant's initial proposal.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because they are revising their advertising plan to be more privacy-friendly.\n- Facebook, Inc. (NASDAQ: FB) will decrease because they are not as privacy-friendly as Alphabet Inc.", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [2551.83, 2570.19]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [301.8099, 301.71]}}}, {"link": "https://www.wsj.com/articles/westfields-owner-offers-two-unappealing-deals-11602770440", "title": "Westfield's Owner Offers Two Unappealing Deals", "date": "2020-10-15 10:00", "summary": "A small group of shareholders at the owner of Westfield shopping malls have proposed a risky new strategy to replace plans for a rights issue. Shareholders in Europe's largest property company have a choice between two bad options.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Westfield's Owner Offers Two Unappealing Deals. A small group of shareholders at the owner of Westfield shopping malls have proposed a risky new strategy to replace plans for a rights issue. Shareholders in Europe's largest property company have a choice between two bad options.\"\n\nStock Prediction(s):", "Prediction": "\n- Unibail-Rodamco SE (OTC: ULRAF) will decrease because their shareholders are not happy with the new deals.\n- Westfield Corp (OTC: WFGPY) will decrease because their owner is not happy with the new deals.", "price_info": {}}, {"link": "https://www.wsj.com/articles/how-to-build-a-career-path-in-3-steps-11605647450", "title": "How to Build a Career Path in 3 Steps", "date": "2021-07-28 10:54", "summary": "Most Popular News. Whether you are looking for a job for the first time or seeking to make a move in the middle of your career, having a plan is the surest way to find fulfillment and happiness in your professional life. It is better to forge a career path than let yourself get too comfortable and complacent where you are, according to career coach Tracy Timm and recruitment trends expert Tony Lee. That can be a \"recipe for disaster,\" says Miss Timm.", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/management-careers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Build a Career Path in 3 Steps. Most Popular News. Whether you are looking for a job for the first time or seeking to make a move in the middle of your career, having a plan is the surest way to find fulfillment and happiness in your professional life. It is better to forge a career path than let yourself get too comfortable and complacent where you are, according to career coach Tracy Timm and recruitment trends expert Tony Lee. That can be a \"recipe for disaster,\" says Miss Timm.\"\n\nStock Prediction(s):", "Prediction": "\n- People looking for a job will increase demand for the stocks of companies like Indeed (NASDAQ: Indeed) and LinkedIn (NYSE: LNKD).\n- People who are happy with their careers will not be as likely to switch jobs, so the stocks of companies like Indeed (NASDAQ: Indeed) and LinkedIn (NYSE: LNKD) will decrease.", "price_info": {"LNKD": {"company": "", "ticker": "LNKD", "move": "up"}}}, {"link": "https://www.wsj.com/articles/bill-gates-tweets-that-he-and-wife-melinda-are-seeking-a-divorce-11620075934", "title": "Bill and Melinda Gates to Divorce After 27 Years", "date": "2021-05-04 09:48", "summary": "The Microsoft co-founder and his wife, who is co-chair of their philanthropic foundation, say they will continue their work there. Microsoft Corp. co-founder Bill Gates and his wife, Melinda Gates, who is co-chair of their philanthropic foundation, are ending their 27-year marriage, according to a statement posted on both their verified Twitter accounts.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bill and Melinda Gates to Divorce After 27 Years. The Microsoft co-founder and his wife, who is co-chair of their philanthropic foundation, say they will continue their work there. Microsoft Corp. co-founder Bill Gates and his wife, Melinda Gates, who is co-chair of their philanthropic foundation, are ending their 27-year marriage, according to a statement posted on both their verified Twitter accounts.\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will decrease because one of their co-founders is getting a divorce.\n- The Gates Foundation (private) will decrease because one of their co-chairs is getting a divorce.", "price_info": {"MSFT": {"company": "", "ticker": "MSFT", "move": "down", "prices": [248.1, 246.23]}}}, {"link": "https://www.wsj.com/articles/doordash-to-change-pay-model-for-delivery-workers-after-criticism-11563979844", "title": "DoorDash to Change Pay Model for Delivery Workers After Criticism", "date": "2019-07-24 10:50", "summary": "Chief Executive Tony Xu said the new compensation structure would ensure worker pay rises when customers tip on the DoorDash app. DoorDash Inc. plans to change how it pays food-delivery workers after facing criticism for applying customer tips to the minimum payments that workers receive for each drop-off.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"DoorDash to Change Pay Model for Delivery Workers After Criticism. Chief Executive Tony Xu said the new compensation structure would ensure worker pay rises when customers tip on the DoorDash app. DoorDash Inc. plans to change how it pays food-delivery workers after facing criticism for applying customer tips to the minimum payments that workers receive for each drop-off.\"\n\nStock Prediction(s):", "Prediction": "\n- DoorDash Inc. (NYSE: DASH) will increase because they are changing their pay model to ensure that workers are paid more.\n- Grubhub Inc. (NYSE: GRUB) will decrease because they are a direct competitor of DoorDash, and they have been criticized for their pay model in the past.", "price_info": {"DASH": {"company": "", "ticker": "DASH", "move": "up"}, "GRUB": {"company": "", "ticker": "GRUB", "move": "down", "prices": [72.78, 72.945]}}}, {"link": "https://www.wsj.com/articles/u-s-postal-service-plans-peak-surcharges-for-domestic-parcels-11597429510", "title": "U.S. Postal Service Plans 'Peak' Surcharges for Domestic Parcels", "date": "2020-08-14 15:38", "summary": "Agency says proposed fees on commercial shipments during key Christmas shopping season needed to offset higher expenses and volumes. The U.S. Postal Service plans to add new fees onto commercial packages starting in October as it looks to offset the increased expenses from coronavirus and surge in volume expected from online shoppers during the holidays.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Postal Service Plans 'Peak' Surcharges for Domestic Parcels. Agency says proposed fees on commercial shipments during key Christmas shopping season needed to offset higher expenses and volumes. The U.S. Postal Service plans to add new fees onto commercial packages starting in October as it looks to offset the increased expenses from coronavirus and surge in volume expected from online shoppers during the holidays.\"\n\nStock Prediction(s):", "Prediction": "\n- United Parcel Service, Inc. (NYSE: UPS) will increase because they are the only major delivery service that is not implementing surcharges.\n- FedEx Corporation (NYSE: FDX) will increase because they are the only major delivery service that is not implementing surcharges.\n- The United States Postal Service (NYSE: USPS) will decrease because of the proposed surcharges.", "price_info": {"UPS": {"company": "", "ticker": "UPS", "move": null, "prices": [160.25, 160.74]}, "FDX": {"company": "", "ticker": "FDX", "move": "up", "prices": [208.8, 209.18]}, "USPS": {"company": "", "ticker": "USPS", "move": "down"}}}, {"link": "https://www.wsj.com/articles/amid-pandemic-jpmorgan-can-afford-to-think-long-term-11602603330", "title": "Amid Pandemic, JPMorgan Can Afford to Think Long Term", "date": "2020-10-13 11:35", "summary": "JPMorgan Chase posted a stronger-than-expected quarter, but the real upside for the bank will be much further down the road. The biggest bank in the U.S. produced a surprisingly strong quarter. But it isn't a game changer-yet.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Amid Pandemic, JPMorgan Can Afford to Think Long Term. JPMorgan Chase posted a stronger-than-expected quarter, but the real upside for the bank will be much further down the road. The biggest bank in the U.S. produced a surprisingly strong quarter. But it isn't a game changer-yet.\"\n\nStock Prediction(s):", "Prediction": "\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they have a strong quarter and they are looking to the future.\n- Bank of America Corp (NYSE: BAC) will decrease because they are not as strong as JPMorgan Chase and they are looking to the future.\n- Goldman Sachs Group Inc (NYSE: GS) will decrease because they are not as strong as JPMorgan Chase and they are looking to the future.", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [101.03, 100.73]}, "BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [25.12, 25.065]}, "GS": {"company": "", "ticker": "GS", "move": "down", "prices": [210.47, 210.43]}}}, {"link": "https://www.wsj.com/articles/zoom-really-gets-back-to-business-11626711204", "title": "Zoom Really Gets Back to Business", "date": "2021-07-19 12:13", "summary": "First major acquisition by videoconferencing star shows dedication to enterprise market. The pandemic may have made Zoom Video Communications into a household name, but the company clearly prefers life at the office-virtual or otherwise.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Zoom Really Gets Back to Business. First major acquisition by videoconferencing star shows dedication to enterprise market. The pandemic may have made Zoom Video Communications into a household name, but the company clearly prefers life at the office-virtual or otherwise.\"\n\nStock Prediction(s):", "Prediction": "\n- Zoom Video Communications, Inc. (NASDAQ: ZM) will increase because they are making acquisitions to solidify their enterprise market.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are a direct competitor of Zoom, and this acquisition will make Zoom less competitive.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are a direct competitor of Zoom, and this acquisition will make Zoom less competitive.", "price_info": {"ZM": {"company": "", "ticker": "ZM", "move": "up", "prices": [346.41, 351.92]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [276.72, 275.8763]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [142.175, 142.2108]}}}, {"link": "https://www.wsj.com/articles/fed-officials-weighed-money-market-control-strategies-at-october-meeting-11574282609", "title": "Fed Officials Weighed Money-Market Control Strategies at October Meeting", "date": "2019-11-20 15:43", "summary": "Minutes show Fed staff presented central bankers with two approaches to manage short-term rates over the longer run. WASHINGTON-Federal Reserve officials at their October policy meeting weighed but didn't settle on strategies that could provide a more enduring fix to the money-market interest-rate volatility that flared in September.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Officials Weighed Money-Market Control Strategies at October Meeting. Minutes show Fed staff presented central bankers with two approaches to manage short-term rates over the longer run. WASHINGTON-Federal Reserve officials at their October policy meeting weighed but didn't settle on strategies that could provide a more enduring fix to the money-market interest-rate volatility that flared in September.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FFR) will increase because they are looking for a more enduring fix to the money-market interest-rate volatility that flared in September.\n- The Goldman Sachs Group, Inc. (NYSE: GS) will increase because they are a direct competitor of the Federal Reserve.", "price_info": {"FFR": {"company": "", "ticker": "FFR", "move": "up"}, "GS": {"company": "", "ticker": "GS", "move": "up", "prices": [217.44, 218]}}}, {"link": "https://www.wsj.com/articles/feds-rosengren-no-need-to-lower-rates-again-based-on-outlook-11576605600", "title": "Fed's Rosengren: No Need for Rate Change Right Now", "date": "2019-12-17 14:38", "summary": "Boston Fed leader says now is a time for central bankers to take stock of past action. Federal Reserve Bank of Boston leader Eric Rosengren said Tuesday he sees no looming reason right now to either cut or raise short-term interest rates any time soon.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Rosengren: No Need for Rate Change Right Now. Boston Fed leader says now is a time for central bankers to take stock of past action. Federal Reserve Bank of Boston leader Eric Rosengren said Tuesday he sees no looming reason right now to either cut or raise short-term interest rates any time soon.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve Bank of Boston (NYSE: FRB) will stay the same because there is no need for a rate change right now.\n- The Federal Reserve Bank of Dallas (NYSE: FRB) will decrease because they are more hawkish and are more likely to raise rates.\n- The Federal Reserve Bank of New York (NYSE: FRB) will decrease because they are more hawkish and are more likely to raise rates.", "price_info": {"FRB": {"company": "", "ticker": "FRB", "move": "up"}}}, {"link": "https://www.wsj.com/articles/breaking-news-apollo-makes-bid-for-tennecos-powertrain-unit-sources-11575998488", "title": "Apollo Made Bid for Tenneco's Powertrain Unit", "date": "2019-12-10 13:42", "summary": "The private-equity firm's offer is valued at $4.3 billion including adjustments and excluding certain liabilities, but Tenneco is likely to reject it. Apollo Global Management Inc. has made an offer to acquire auto-parts supplier Tenneco Inc.'s powertrain division, according to people familiar with the matter.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apollo Made Bid for Tenneco's Powertrain Unit. The private-equity firm's offer is valued at $4.3 billion including adjustments and excluding certain liabilities, but Tenneco is likely to reject it. Apollo Global Management Inc. has made an offer to acquire auto-parts supplier Tenneco Inc.'s powertrain division, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Apollo Global Management Inc. (NYSE: APO) will increase because they are making offers for other companies.\n- Tenneco Inc. (NYSE: TEN) will decrease because they are likely to reject the offer from Apollo.", "price_info": {"APO": {"company": "", "ticker": "APO", "move": "up", "prices": [44.18, 44.48]}, "TEN": {"company": "", "ticker": "TEN", "move": "down", "prices": [14.2907, 14.3]}}}, {"link": "https://www.wsj.com/articles/hyundais-new-chairman-charts-high-tech-futurewithout-apple-for-now-11613574638", "title": "Hyundai's New Chairman Charts High-Tech Future-Without Apple, for Now", "date": "2021-02-17 10:12", "summary": "Groomed for the job his entire life, the 50-year-old grandson of Hyundai's founder plans for future beyond gas-guzzling cars. When Hyundai Motor Group 's new chairman Chung Eui-sun took over last fall, he outlined a bold road map for a future where flying vehicles and robots make up as much business as typical gas-guzzling cars.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hyundai's New Chairman Charts High-Tech Future-Without Apple, for Now. Groomed for the job his entire life, the 50-year-old grandson of Hyundai's founder plans for future beyond gas-guzzling cars. When Hyundai Motor Group 's new chairman Chung Eui-sun took over last fall, he outlined a bold road map for a future where flying vehicles and robots make up as much business as typical gas-guzzling cars.\"\n\nStock Prediction(s):", "Prediction": "\n- Hyundai Motor Group (KRX: 005380) will increase because they are planning for a future where flying vehicles and robots make up as much business as typical gas-guzzling cars.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are not planning for a future where flying vehicles and robots make up as much business as typical gas-guzzling cars.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [130.94, 129.94]}}}, {"link": "https://www.wsj.com/articles/chinas-economy-is-still-dependent-on-housing-and-exports-11618321051", "title": "China's Economy Is Still Dependent on Housing and Exports", "date": "2021-04-13 10:43", "summary": "Despite Beijing's rhetorical emphasis on new industries and self-reliance, housing and exports continue to drive China's recovery. The world's second-largest economy kept chugging along in early 2021 with the help of some familiar drivers: housing and exports. A dip in the latter last month will probably prove temporary. But increasing regulatory ire could weigh on China's housing market-and industrial metal prices-in the second half. Aside from housing, durable signs of strong domestic demand remain relatively scarce.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"China's Economy Is Still Dependent on Housing and Exports. Despite Beijing's rhetorical emphasis on new industries and self-reliance, housing and exports continue to drive China's recovery. The world's second-largest economy kept chugging along in early 2021 with the help of some familiar drivers: housing and exports. A dip in the latter last month will probably prove temporary. But increasing regulatory ire could weigh on China's housing market-and industrial metal prices-in the second half. Aside from housing, durable signs of strong domestic demand remain relatively scarce.\"\n\nStock Prediction(s):", "Prediction": "\n- China's economy will continue to grow, but at a slower rate because of the regulatory ire mentioned in the article.\n- The housing market in China will also continue to grow, but at a slower rate because of the regulatory ire mentioned in the article.", "price_info": {}}, {"link": "https://www.wsj.com/articles/winter-forecast-is-cold-comfort-for-natural-gas-consumers-11633626848", "title": "Winter Forecast Is Cold Comfort for Natural-Gas Consumers", "date": "2021-10-07 13:14", "summary": "A closely watched forecast shows the coming winter will be manageable for U.S. natural-gas markets. That may not be enough to take the air out of natural-gas prices.. Here's something that might take some pressure out of the fear building in natural-gas markets: A closely watched forecast from the Natural Gas Supply Association says that the U.S. winter will be just slightly colder than last year. That might not be enough to take the edge off of prices, though.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Winter Forecast Is Cold Comfort for Natural-Gas Consumers. A closely watched forecast shows the coming winter will be manageable for U.S. natural-gas markets. That may not be enough to take the air out of natural-gas prices.. Here's something that might take some pressure out of the fear building in natural-gas markets: A closely watched forecast from the Natural Gas Supply Association says that the U.S. winter will be just slightly colder than last year. That might not be enough to take the edge off of prices, though.\"\n\nStock Prediction(s):", "Prediction": "\n- Chesapeake Energy Corporation (NYSE: CHK) will increase because the winter is going to be colder, and natural gas prices will go up.\n- Southwestern Energy Company (NYSE: SWN) will increase because the winter is going to be colder, and natural gas prices will go up.\n- Devon Energy Corporation (NYSE: DVN) will increase because the winter is going to be colder, and natural gas prices will go up.\n- Range Resources", "price_info": {"CHK": {"company": "", "ticker": "CHK", "move": "up", "prices": [65.19, 64.79]}, "SWN": {"company": "", "ticker": "SWN", "move": "up", "prices": [5.205, 5.22]}, "DVN": {"company": "", "ticker": "DVN", "move": "up", "prices": [38.585, 38.4244]}}}, {"link": "https://www.wsj.com/articles/a-new-years-resolution-for-corporations-address-the-trust-crisis-11577473171", "title": "A New Year's Resolution for Corporations: Address the Trust Crisis", "date": "2019-12-27 13:59", "summary": "Companies have plans for our digital lives over the next decade, but they don't have our confidence. \"Every company today is a tech company\" is becoming a cliche. But smartphone apps make it truer everyday, as I learned as workers remodeled our farmhouse over the holidays.", "categories": [["Business", "On Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/on-business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"A New Year's Resolution for Corporations: Address the Trust Crisis. Companies have plans for our digital lives over the next decade, but they don't have our confidence. \"Every company today is a tech company\" is becoming a cliche. But smartphone apps make it truer everyday, as I learned as workers remodeled our farmhouse over the holidays.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they are working on a plan to address the trust crisis.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are working on a plan to address the trust crisis.\n- Facebook, Inc. (NASDAQ: FB) will increase because they are working on a plan to address the trust crisis.\n- Google LLC (NASDAQ: GOOGL", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [289.9, 289.51]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1875.66, 1869.3998]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [207.8973, 208.51]}}}, {"link": "https://www.wsj.com/articles/pandora-could-cut-more-jobs-if-revenue-keeps-falling-cfo-says-11557933567", "title": "Pandora Could Cut More Jobs if Revenue Keeps Falling, CFO Says", "date": "2019-05-15 11:19", "summary": "Copenhagen-based jewelry company aims to turn business around amid a decline in sales. Struggling jewelry chain Pandora A/S plans to make further cuts to head count and other costs as the Danish company advances its turnaround effort, Chief Financial Officer Anders Boyer said.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Pandora Could Cut More Jobs if Revenue Keeps Falling, CFO Says. Copenhagen-based jewelry company aims to turn business around amid a decline in sales. Struggling jewelry chain Pandora A/S plans to make further cuts to head count and other costs as the Danish company advances its turnaround effort, Chief Financial Officer Anders Boyer said.\"\n\nStock Prediction(s):", "Prediction": "\n- Pandora A/S (Copenhagen: PNDORA) will decrease because they are not turning their business around and they are cutting jobs.", "price_info": {}}, {"link": "https://www.wsj.com/articles/companies-ban-work-travel-warn-employees-of-civil-unrest-in-election-week-11604431576", "title": "Companies Ban Travel, Warn Employees of Civil Unrest", "date": "2020-11-03 14:26", "summary": "Employers urge workers to be vigilant while voting and to prepare for possible delays in results, with some discouraging travel to nation's capital. U.S. companies geared up for Election Day with a flurry of memos and emails urging employees to avoid work travel and be on guard against civil unrest and potential disruptions.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Companies Ban Travel, Warn Employees of Civil Unrest. Employers urge workers to be vigilant while voting and to prepare for possible delays in results, with some discouraging travel to nation's capital. U.S. companies geared up for Election Day with a flurry of memos and emails urging employees to avoid work travel and be on guard against civil unrest and potential disruptions.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co (NYSE: BA) will decrease because their employees may not be able to travel to work on Election Day.\n- Ford Motor Co (NYSE: F) will decrease because their employees may not be able to travel to work on Election Day.\n- General Motors Co (NYSE: GM) will decrease because their employees may not be able to travel to work on Election Day.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [153.3, 153.6001]}, "F": {"company": "", "ticker": "F", "move": "down", "prices": [7.8718, 7.86]}, "GM": {"company": "", "ticker": "GM", "move": "down", "prices": [35.405, 35.3]}}}, {"link": "https://www.wsj.com/articles/crude-prices-slip-on-potential-rise-in-libyan-output-11549539850", "title": "Oil Prices Drop on Worries Over Global Demand", "date": "2019-02-07 15:19", "summary": "Crude prices further tumbled amid uncertainty over the fate of the U.S.-China trade talks. \u2022 Oil prices fell to their lowest level in more than a week on Thursday due to renewed worries of a global economic slowdown that could pinch demand for oil.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Prices Drop on Worries Over Global Demand. Crude prices further tumbled amid uncertainty over the fate of the U.S.-China trade talks. \u2022 Oil prices fell to their lowest level in more than a week on Thursday due to renewed worries of a global economic slowdown that could pinch demand for oil.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will decrease because of the fall in oil prices.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because of the fall in oil prices.\n- Royal Dutch Shell plc (NYSE: RDS.A) will decrease because of the fall in oil prices.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [117.93, 118.34]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [74.57, 74.65]}}}, {"link": "https://www.wsj.com/articles/j-c-penney-plots-a-comeback-less-clutter-more-yoga-classes-11572535484", "title": "J.C. Penney Plots a Comeback: Less Clutter, More Yoga Classes", "date": "2019-10-31 11:24", "summary": "CEO tests new services while looking to make Penney stores easier to shop. A glimpse at a future for J.C. Penney Co. can be found in Hurst, Texas, where a remodeled store has a fitness studio, a videogame lounge and style classes.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"J.C. Penney Plots a Comeback: Less Clutter, More Yoga Classes. CEO tests new services while looking to make Penney stores easier to shop. A glimpse at a future for J.C. Penney Co. can be found in Hurst, Texas, where a remodeled store has a fitness studio, a videogame lounge and style classes.\"\n\nStock Prediction(s):", "Prediction": "\n- J.C. Penney Co., Inc. (NYSE: JCP) will increase because they are testing new services and making their stores easier to shop.\n- Nike, Inc. (NYSE: NKE) will increase because they are also testing new services and making their stores easier to shop.", "price_info": {"JCP": {"company": "", "ticker": "JCP", "move": "up", "prices": [0.9939, 0.98875]}, "NKE": {"company": "", "ticker": "NKE", "move": "up"}}}, {"link": "https://www.wsj.com/articles/sanofi-to-work-on-coronavirus-vaccine-11582048364", "title": "Sanofi to Work on Virus Vaccine", "date": "2020-02-18 12:52", "summary": "French drug giant is reviving research prompted by SARS epidemic. Drug giant Sanofi SA has entered the race to develop a vaccine against the new coronavirus, joining a handful of big and small drug makers, and teams of university researchers, looking for a way to prevent its spread.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Sanofi to Work on Virus Vaccine. French drug giant is reviving research prompted by SARS epidemic. Drug giant Sanofi SA has entered the race to develop a vaccine against the new coronavirus, joining a handful of big and small drug makers, and teams of university researchers, looking for a way to prevent its spread.\"\n\nStock Prediction(s):", "Prediction": "\n- Sanofi SA (NYSE: SNY) will increase because they are working on a virus vaccine.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a virus vaccine, but they are a direct competitor of Sanofi.\n- AstraZeneca plc (NYSE: AZN) will decrease because they are also working on a virus vaccine, but they are a direct competitor of Sanofi.\n- Pfizer Inc", "price_info": {"SNY": {"company": "", "ticker": "SNY", "move": "up"}, "JNJ": {"company": "", "ticker": "JNJ", "move": "down"}, "AZN": {"company": "", "ticker": "AZN", "move": "down"}}}, {"link": "https://www.wsj.com/articles/need-financing-here-have-a-blank-check-11597417430", "title": "Need Financing? Here, Have a Blank Check", "date": "2020-08-14 11:03", "summary": "Upstarts are turning to reverse mergers as a way of going public during the economic downturn. These 'blank check' deals offer opportunities-and plenty of risk.. Kim Brady, the chief financial officer of an under-the-radar commercial-truck startup, watched Plan A to raise $1 billion crumble last year after private markets grew wary of pumping money into untested companies.", "categories": [["Business", "On Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/on-business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Need Financing? Here, Have a Blank Check. Upstarts are turning to reverse mergers as a way of going public during the economic downturn. These 'blank check' deals offer opportunities-and plenty of risk.. Kim Brady, the chief financial officer of an under-the-radar commercial-truck startup, watched Plan A to raise $1 billion crumble last year after private markets grew wary of pumping money into untested companies.\"\n\nStock Prediction(s):", "Prediction": "\n- Blank check companies (NASDAQ: BLNK) will increase because they offer a way for startups to go public without having to endure the rigorous process of an IPO.\n- Other tech startups (NASDAQ: TECZ) will decrease because they will have a harder time raising money in the current market conditions.", "price_info": {"BLNK": {"company": "", "ticker": "BLNK", "move": "up"}, "TECZ": {"company": "", "ticker": "TECZ", "move": "down"}}}, {"link": "https://www.wsj.com/articles/altria-cuts-value-of-juul-stake-by-4-5-billion-11572520613", "title": "Altria Slashes Value of Juul Stake Amid Regulatory Pressure", "date": "2019-10-31 15:36", "summary": "Marlboro maker, which paid $12.8 billion for a 35% stake in e-cigarette maker, cites proposed flavor bans for write-down. Altria Group Inc. wrote down its investment in Juul Labs Inc. by more than a third, acknowledging that it hadn't anticipated the regulatory pitfalls confronting the e-cigarette market.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Altria Slashes Value of Juul Stake Amid Regulatory Pressure. Marlboro maker, which paid $12.8 billion for a 35% stake in e-cigarette maker, cites proposed flavor bans for write-down. Altria Group Inc. wrote down its investment in Juul Labs Inc. by more than a third, acknowledging that it hadn't anticipated the regulatory pitfalls confronting the e-cigarette market.\"\n\nStock Prediction(s):", "Prediction": "\n- Altria Group Inc. (NYSE: MO) will decrease because they are losing money on their Juul stake.\n- Juul Labs Inc. (NYSE: JUUL) will increase because they are still a major player in the e-cigarette market.", "price_info": {"MO": {"company": "", "ticker": "MO", "move": "down", "prices": [44.85, 44.79]}, "JUUL": {"company": "", "ticker": "JUUL", "move": "up"}}}, {"link": "https://www.wsj.com/articles/conagra-says-grocery-demand-remains-high-amid-pandemic-11593528462", "title": "Conagra Says Grocery Demand Remains High Amid Pandemic", "date": "2020-06-30 13:22", "summary": "Owner of Birds Eye, Chef Boyardee and other food brands adds manufacturing capacity. Conagra Brands Inc. said it is investing in more manufacturing capacity as demand for its packaged foods remains strong this summer during the continuing coronavirus pandemic.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Conagra Says Grocery Demand Remains High Amid Pandemic. Owner of Birds Eye, Chef Boyardee and other food brands adds manufacturing capacity. Conagra Brands Inc. said it is investing in more manufacturing capacity as demand for its packaged foods remains strong this summer during the continuing coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Conagra Brands, Inc. (NYSE: CAG) will increase because their products are in high demand and they are expanding their manufacturing capacity.\n- The Hershey Company (NYSE: HSY) will decrease because they are also expanding their manufacturing capacity, but they do not have the same breadth of products as Conagra.", "price_info": {"CAG": {"company": "", "ticker": "CAG", "move": "up"}, "HSY": {"company": "", "ticker": "HSY", "move": "down"}}}, {"link": "https://www.wsj.com/articles/walmart-to-scale-back-jetblack-after-investor-talks-fizzle-11581604739", "title": "Walmart to End Jetblack Shopping Service", "date": "2020-02-13 11:45", "summary": "Text-message concierge unit will end deliveries, lay off most of its 350 staffers. Walmart Inc. is shutting down its Jetblack personal-shopping service and laying off most of its roughly 350 staffers after the retailer abandoned plans to find investors for the unprofitable operation.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Walmart to End Jetblack Shopping Service. Text-message concierge unit will end deliveries, lay off most of its 350 staffers. Walmart Inc. is shutting down its Jetblack personal-shopping service and laying off most of its roughly 350 staffers after the retailer abandoned plans to find investors for the unprofitable operation.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will decrease because they are discontinuing their Jetblack shopping service.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [117.2637, 117.03]}}}, {"link": "https://www.wsj.com/articles/apples-gadgets-co-star-in-its-new-tv-drama-11573145328", "title": "Apple's iPhone Is Center Stage in Its New TV Drama", "date": "2019-11-07 11:48", "summary": "iPhones, iPads and Macs share the screen with Jennifer Aniston and Reese Witherspoon in 'The Morning Show'. Apple Inc.'s flagship television series \"The Morning Show\" is a glossy, star-studded program designed to draw subscribers for the company's new streaming service. The show also, it turns out, doubles as an extended commercial for the gadgets that drive Apple's business.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple's iPhone Is Center Stage in Its New TV Drama. iPhones, iPads and Macs share the screen with Jennifer Aniston and Reese Witherspoon in 'The Morning Show'. Apple Inc.'s flagship television series \"The Morning Show\" is a glossy, star-studded program designed to draw subscribers for the company's new streaming service. The show also, it turns out, doubles as an extended commercial for the gadgets that drive Apple's business.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because their iPhone is being used in their new TV drama, and this will create more interest in their products.\n- Samsung Electronics Co Ltd (OTC: SSNLF) will decrease because their main competitor is Apple, and this will create more interest in Apple's products.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/wealth-management-business-helps-ubs-to-better-than-expected-second-quarter-11595313720", "title": "UBS's Focus on Wealthy Clients Cushions Against Losses", "date": "2020-07-21 12:56", "summary": "Majority of the Swiss bank's lending is either to the global rich or to households and companies in Switzerland. UBS Group AG said it could start buying back stock again later this year despite the shadow over markets from the coronavirus pandemic.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"UBS's Focus on Wealthy Clients Cushions Against Losses. Majority of the Swiss bank's lending is either to the global rich or to households and companies in Switzerland. UBS Group AG said it could start buying back stock again later this year despite the shadow over markets from the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- UBS Group AG (NYSE: UBS) will increase because they have a focus on wealthy clients, which cushions them from losses.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are a direct competitor of UBS.\n- Goldman Sachs Group Inc. (NYSE: GS) will decrease because they are a direct competitor of UBS.", "price_info": {"UBS": {"company": "", "ticker": "UBS", "move": "up"}, "JPM": {"company": "", "ticker": "JPM", "move": "down"}, "GS": {"company": "", "ticker": "GS", "move": "down", "prices": [213.1, 213.7]}}}, {"link": "https://www.wsj.com/articles/november-jobs-report-unemployment-rate-2020-11607028480", "title": "U.S. Added 245,000 Jobs Last Month as Hiring Slowed", "date": "2020-12-04 15:53", "summary": "Seventh consecutive month of gains at steadily cooling pace; unemployment rate ticked down to 6.7%. U.S. job growth slowed sharply in November, suggesting the labor-market recovery is losing steam amid a surge in coronavirus cases and new business restrictions.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Added 245,000 Jobs Last Month as Hiring Slowed. Seventh consecutive month of gains at steadily cooling pace; unemployment rate ticked down to 6.7%. U.S. job growth slowed sharply in November, suggesting the labor-market recovery is losing steam amid a surge in coronavirus cases and new business restrictions.\"\n\nStock Prediction(s):", "Prediction": "\n- The unemployment rate will continue to drop as more jobs are created.\n- The stock market will continue to drop as the economy weakens.", "price_info": {}}, {"link": "https://www.wsj.com/articles/cme-group-plans-to-offer-bitcoin-options-in-2020-11568995492", "title": "CME Group Plans to Offer Bitcoin Options", "date": "2019-09-20 12:04", "summary": "Exchange operator offered bitcoin futures in 2017. CME Group Inc. on Friday said it planned to launch options on its bitcoin futures contracts in the first quarter of 2020, the latest move by an established market player to expand into the crypto business.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"CME Group Plans to Offer Bitcoin Options. Exchange operator offered bitcoin futures in 2017. CME Group Inc. on Friday said it planned to launch options on its bitcoin futures contracts in the first quarter of 2020, the latest move by an established market player to expand into the crypto business.\"\n\nStock Prediction(s):", "Prediction": "\n- CME Group Inc. (NASDAQ: CME) will increase because they are expanding their business into the crypto industry.\n- Bitcoin (BTC) will increase because more institutional investors will be looking to invest in it.", "price_info": {"BTC": {"company": "Bitcoin", "ticker": "BTC", "move": "up"}, "CME": {"company": "", "ticker": "CME", "move": "up"}}}, {"link": "https://www.wsj.com/articles/u-s-shuts-down-bagram-air-base-as-afghanistan-pullout-speeds-up-11625221544", "title": "U.S. Steps Up Planning for Emergency Afghan Evacuation", "date": "2021-07-02 15:42", "summary": "American military leaves Bagram air base and officials prepare for possible emergency actions amid concerns over Afghanistan's stability. KABUL-U.S. officials have intensified planning for an emergency evacuation of the American embassy in Kabul amid concern that a worsening security situation in Afghanistan could imperil the remaining military and diplomatic corps, as well as other Americans.", "categories": [["WSJ News Exclusive", "World"]], "category_links": ["https://www.wsj.com/news/world?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Steps Up Planning for Emergency Afghan Evacuation. American military leaves Bagram air base and officials prepare for possible emergency actions amid concerns over Afghanistan's stability. KABUL-U.S. officials have intensified planning for an emergency evacuation of the American embassy in Kabul amid concern that a worsening security situation in Afghanistan could imperil the remaining military and diplomatic corps, as well as other Americans.\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. Department of Defense (DoD) will increase because they are preparing for an emergency evacuation in Afghanistan.\n- The U.S. Department of State (DoS) will decrease because they are also preparing for an emergency evacuation in Afghanistan.", "price_info": {}}, {"link": "https://www.wsj.com/articles/stock-traders-fund-drug-development-11579798645", "title": "Stock Traders Fund Drug Development", "date": "2020-01-23 11:57", "summary": "Shares of Trillium Therapeutics have surged more than 10-fold since December. Never underestimate what a bull market can accomplish.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Stock Traders Fund Drug Development. Shares of Trillium Therapeutics have surged more than 10-fold since December. Never underestimate what a bull market can accomplish.\"\n\nStock Prediction(s):", "Prediction": "\n- Trillium Therapeutics Inc (NASDAQ: TRIL) will continue to surge because they have a promising drug development pipeline.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are a direct competitor of Trillium Therapeutics.\n- Pfizer Inc (NYSE: PFE) will decrease because they are a direct competitor of Trillium Therapeutics.\n- Moderna Inc (NASDAQ: MRNA) will", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "down"}, "PFE": {"company": "", "ticker": "PFE", "move": "down"}, "TRIL": {"company": "", "ticker": "TRIL", "move": null}, "MRNA": {"company": "", "ticker": "MRNA", "move": null}}}, {"link": "https://www.wsj.com/articles/what-the-feds-interest-rate-cut-means-for-you-11583253298", "title": "What the Fed's Interest-Rate Cut Means for You", "date": "2020-03-03 11:34", "summary": "Falling rates can ripple through the cost of mortgages and interest earned on savings accounts. The Federal Reserve cut its short-term benchmark rate by a half percentage point Tuesday morning. The timing of this rate cut, which comes in between the Fed's scheduled policy meeting, hasn't occurred since the 2008 financial crisis.", "categories": [["Markets", "Your Money"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/undefined?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What the Fed's Interest-Rate Cut Means for You. Falling rates can ripple through the cost of mortgages and interest earned on savings accounts. The Federal Reserve cut its short-term benchmark rate by a half percentage point Tuesday morning. The timing of this rate cut, which comes in between the Fed's scheduled policy meeting, hasn't occurred since the 2008 financial crisis.\"\n\nStock Prediction(s):", "Prediction": "\n- The interest rate cut will have a positive effect on the housing market and the stock market.\n- The interest rate cut will have a negative effect on the bond market.", "price_info": {}}, {"link": "https://www.wsj.com/articles/apex-legends-hits-bulls-eye-for-electronic-arts-11557332541", "title": "'Apex Legends' Hits Bull's-Eye for Electronic Arts", "date": "2019-05-08 12:22", "summary": "Surprise 'Fortnite' challenger boosts EA's results and eases pain of other misfires. For Electronic Arts , one out of three has turned out to be...not too bad.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"'Apex Legends' Hits Bull's-Eye for Electronic Arts. Surprise 'Fortnite' challenger boosts EA's results and eases pain of other misfires. For Electronic Arts , one out of three has turned out to be...not too bad.\"\n\nStock Prediction(s):", "Prediction": "\n- Electronic Arts Inc. (NASDAQ: EA) will increase because their game, Apex Legends, is doing well.\n- Activision Blizzard, Inc. (NASDAQ: ATVI) will decrease because their game, Fortnite, is doing better.", "price_info": {"EA": {"company": "", "ticker": "EA", "move": "up", "prices": [93.11, 94.4]}, "ATVI": {"company": "", "ticker": "ATVI", "move": "down"}}}, {"link": "https://www.wsj.com/articles/microsoft-urges-u-s-to-make-tech-giants-pay-for-news-11613066402", "title": "Microsoft Urges U.S. to Make Tech Giants Pay for News", "date": "2021-02-11 13:00", "summary": "Company President Brad Smith says Biden administration should copy Australian proposal opposed by Facebook and Google. SYDNEY- Microsoft Corp. said the U.S. should copy Australia's controversial proposal that tech companies pay newspapers for content-putting it at odds with Alphabet Inc.'s Google and Facebook Inc.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Microsoft Urges U.S. to Make Tech Giants Pay for News. Company President Brad Smith says Biden administration should copy Australian proposal opposed by Facebook and Google. SYDNEY- Microsoft Corp. said the U.S. should copy Australia's controversial proposal that tech companies pay newspapers for content-putting it at odds with Alphabet Inc.'s Google and Facebook Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are advocating for a policy that would make them more money.\n- Alphabet Inc. (NASDAQ: GOOGL) will decrease because they are opposed to the policy, and it would make them less money.\n- Facebook Inc. (NASDAQ: FB) will decrease because they are opposed to the policy, and it would make them less money.", "price_info": {"MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [242.86, 242.79]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "down"}, "FB": {"company": "", "ticker": "FB", "move": "down"}}}, {"link": "https://www.wsj.com/articles/dexamethasone-improves-survival-in-severe-covid-19-patients-study-finds-11592317739", "title": "Steroid Dexamethasone Improves Survival in Severe Covid-19 Patients: Study", "date": "2020-06-16 14:11", "summary": "The steroid cut by a third the number of deaths in Covid-19 patients requiring ventilators, according to University of Oxford study. A generic steroid drug significantly reduced deaths of very sick Covid-19 patients in a large clinical trial, University of Oxford researchers said Tuesday, in surprising results that point to a new treatment for the worst cases.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Steroid Dexamethasone Improves Survival in Severe Covid-19 Patients: Study. The steroid cut by a third the number of deaths in Covid-19 patients requiring ventilators, according to University of Oxford study. A generic steroid drug significantly reduced deaths of very sick Covid-19 patients in a large clinical trial, University of Oxford researchers said Tuesday, in surprising results that point to a new treatment for the worst cases.\"\n\nStock Prediction(s):", "Prediction": "\n- Dexamethasone (NASDAQ: DXM) will increase because it was found to improve survival rates in severe Covid-19 patients.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of Dexamethasone.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "down"}, "PFE": {"company": "", "ticker": "PFE", "move": "down"}, "DXM": {"company": "", "ticker": "DXM", "move": "up"}}}, {"link": "https://www.wsj.com/articles/what-kylie-jenner-can-teach-us-about-m-a-11562942563", "title": "What Kylie Jenner Can Teach Us About M&A", "date": "2019-07-12 10:46", "summary": "Beauty giant Coty could revamp its sagging business by buying youngest Kardashian's e-commerce juggernaut. Coty Inc. intended to \"instantly create\" a beauty superpower with its $12 billion spree on Procter & Gamble Co. 's collection of cosmetic and fragrance brands in 2015. Instead, it created a headache that it may take a Kardashian to cure.", "categories": [["Business", "On Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/on-business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What Kylie Jenner Can Teach Us About M&A. Beauty giant Coty could revamp its sagging business by buying youngest Kardashian's e-commerce juggernaut. Coty Inc. intended to \"instantly create\" a beauty superpower with its $12 billion spree on Procter & Gamble Co. 's collection of cosmetic and fragrance brands in 2015. Instead, it created a headache that it may take a Kardashian to cure.\"\n\nStock Prediction(s):", "Prediction": "\n- Coty Inc. (NYSE: COTY) will increase because they are looking to buy Kylie Jenner's e-commerce company, which is a growing business.\n- Procter & Gamble Co. (NYSE: PG) will decrease because they are selling their beauty brands, which is a core business for Coty.", "price_info": {"COTY": {"company": "", "ticker": "COTY", "move": "up"}, "PG": {"company": "", "ticker": "PG", "move": "down"}}}, {"link": "https://www.wsj.com/articles/fintech-firm-greensky-explores-possible-sale-11565106584", "title": "GreenSky Is Latest Online Lender to Tumble", "date": "2019-08-06 15:31", "summary": "Shares plunge after online lender says it is exploring a potential sale or merger and after missing profit expectations. Investors are falling out of love with online lenders.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GreenSky Is Latest Online Lender to Tumble. Shares plunge after online lender says it is exploring a potential sale or merger and after missing profit expectations. Investors are falling out of love with online lenders.\"\n\nStock Prediction(s):", "Prediction": "\n- GreenSky, Inc. (GSKY) will continue to tumble because they are exploring a potential sale or merger.\n- LendingClub Corporation (NYSE: LC) will increase because they are not exploring a potential sale or merger.", "price_info": {"GSKY": {"company": "GreenSky, Inc.", "ticker": "GSKY", "move": null, "prices": [6.99, 6.98]}, "LC": {"company": "", "ticker": "LC", "move": "up"}}}, {"link": "https://www.wsj.com/articles/companies-include-green-bonds-in-larger-debt-offerings-11635776569", "title": "Companies Include Green Bonds in Larger Debt Offerings", "date": "2021-11-01 10:22", "summary": "Chip maker Micron Technology is the latest big company to issue a green bond alongside a larger debt issuance. Corporate green-bond issuance has reached new highs as U.S. companies including chip maker Micron Technology Inc., retailer Walmart Inc. and data-center company Equinix Inc. add the bonds as part of larger traditional bond offerings.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Companies Include Green Bonds in Larger Debt Offerings. Chip maker Micron Technology is the latest big company to issue a green bond alongside a larger debt issuance. Corporate green-bond issuance has reached new highs as U.S. companies including chip maker Micron Technology Inc., retailer Walmart Inc. and data-center company Equinix Inc. add the bonds as part of larger traditional bond offerings.\"\n\nStock Prediction(s):", "Prediction": "\n- Micron Technology, Inc. (NASDAQ: MU) will increase because they are a green company and they are expanding their debt offerings.\n- Walmart Inc. (NYSE: WMT) will increase because they are a green company and they are expanding their debt offerings.\n- Equinix, Inc. (NASDAQ: EQIX) will increase because they are a green company and they are expanding their debt offerings.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [149.82, 149.86]}, "MU": {"company": "", "ticker": "MU", "move": "up"}, "EQIX": {"company": "", "ticker": "EQIX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/halliburton-takes-u-s-wobbles-in-stride-11571679594", "title": "Halliburton Takes U.S. Wobbles in Stride", "date": "2019-10-21 13:39", "summary": "North American revenue fell by one-fifth but the oil-field services company is prepared, which should continue to lift shares. Halliburton knows the drill.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Halliburton Takes U.S. Wobbles in Stride. North American revenue fell by one-fifth but the oil-field services company is prepared, which should continue to lift shares. Halliburton knows the drill.\"\n\nStock Prediction(s):", "Prediction": "\n- Halliburton Co (NYSE: HAL) will increase because despite a 20% decline in North American revenue, they are still doing well and their stock price has not reflected this yet.\n- Schlumberger Ltd. (NYSE: SLB) will decrease because they are a direct competitor of Halliburton and their stock price has already reflected their poor performance.", "price_info": {"HAL": {"company": "", "ticker": "HAL", "move": "down"}, "SLB": {"company": "", "ticker": "SLB", "move": "down", "prices": [33.61, 33.595]}}}, {"link": "https://www.wsj.com/articles/china-isnt-manipulating-the-yuanits-waiting-out-trump-11565088689", "title": "China Isn't Manipulating the Yuan-It's Waiting Out Trump", "date": "2019-08-06 10:52", "summary": "Beijing seems to have concluded it won't get an acceptable trade deal with the current U.S. president. China's leaders appear to have concluded that they won't secure an acceptable trade deal with President Trump. What they can do is try to weather the next 18 months while inflicting maximum political damage-and hope a weakening U.S. economy delivers a new president.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"China Isn't Manipulating the Yuan-It's Waiting Out Trump. Beijing seems to have concluded it won't get an acceptable trade deal with the current U.S. president. China's leaders appear to have concluded that they won't secure an acceptable trade deal with President Trump. What they can do is try to weather the next 18 months while inflicting maximum political damage-and hope a weakening U.S. economy delivers a new president.\"\n\nStock Prediction(s):", "Prediction": "\n- The Chinese yuan (CNY) will continue to weaken because the Chinese government is not going to make any concessions to the United States.\n- The United States dollar (USD) will strengthen because the Chinese yuan is weakening.", "price_info": {"CNY": {"company": "", "ticker": "CNY", "move": null}, "USD": {"company": "", "ticker": "USD", "move": null}}}, {"link": "https://www.wsj.com/articles/fintech-startup-acorns-hires-twitter-executive-as-cfo-ahead-of-planned-spac-listing-11628692869", "title": "Fintech Startup Acorns Hires Twitter Executive as CFO Ahead of Planned SPAC Listing", "date": "2021-08-11 10:41", "summary": "Rich Sullivan, formerly the vice president of financial planning and analysis at Twitter, joined Acorns on Monday. Digital investing startup Acorns Grow Inc. named Rich Sullivan, a former finance executive at Twitter Inc., as finance chief ahead of its planned public listing.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fintech Startup Acorns Hires Twitter Executive as CFO Ahead of Planned SPAC Listing. Rich Sullivan, formerly the vice president of financial planning and analysis at Twitter, joined Acorns on Monday. Digital investing startup Acorns Grow Inc. named Rich Sullivan, a former finance executive at Twitter Inc., as finance chief ahead of its planned public listing.\"\n\nStock Prediction(s):", "Prediction": "\n- Acorns Grow Inc. (NASDAQ: ACOR) will increase because they have a new CFO, and they are preparing for a public listing.\n- Twitter Inc. (NYSE: TWTR) will decrease because one of their executives left to work at a competitor.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "down"}, "ACOR": {"company": "", "ticker": "ACOR", "move": "up"}}}, {"link": "https://www.wsj.com/articles/women-take-the-helm-on-cruise-ships-11563975210", "title": "Women Take the Helm on Cruise Ships", "date": "2019-07-24 11:57", "summary": "Male-dominated industry seeks more female captains and officers to ease labor crunch, update its image. Capt. Serena Melani -set to become the first woman to helm a new major cruise ship at launch-is used to charting new waters.", "categories": [["Business", "Management", "Management & Careers", "Managing Your Career"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/management-careers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Women Take the Helm on Cruise Ships. Male-dominated industry seeks more female captains and officers to ease labor crunch, update its image. Capt. Serena Melani -set to become the first woman to helm a new major cruise ship at launch-is used to charting new waters.\"\n\nStock Prediction(s):", "Prediction": "\n- Royal Caribbean Cruises Ltd. (NYSE: RCL) will increase because they are seeking to update their image by having more female captains and officers.\n- Carnival Corporation (NYSE: CCL) will decrease because they are a direct competitor of Royal Caribbean Cruises Ltd.", "price_info": {"RCL": {"company": "", "ticker": "RCL", "move": null}, "CCL": {"company": "", "ticker": "CCL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/food-delivery-ipo-puts-profits-back-on-the-menu-11617100519", "title": "Food Delivery IPO Puts Profits Back on the Menu", "date": "2021-03-30 10:11", "summary": "Amazon-backed takeout app has priced its market debut at the bottom of its range. One reason is the threat of higher labor costs.. Shareholders in takeout delivery stocks have a reputation for ignoring losses. That is less true in Europe these days, where there is fresh debate about whether delivery couriers should get a more generous helping.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Food Delivery IPO Puts Profits Back on the Menu. Amazon-backed takeout app has priced its market debut at the bottom of its range. One reason is the threat of higher labor costs.. Shareholders in takeout delivery stocks have a reputation for ignoring losses. That is less true in Europe these days, where there is fresh debate about whether delivery couriers should get a more generous helping.\"\n\nStock Prediction(s):", "Prediction": "\n- Grubhub Inc (NYSE: GRUB) will increase because their IPO is priced lower than expected, and they are still a profitable company.\n- DoorDash Inc (NYSE: DOORD) will increase because their IPO is priced lower than expected, and they are still a profitable company.\n- Uber Technologies Inc (NYSE: UBER) will decrease because their IPO is priced higher than expected, and they are still not profitable.\n- Lyft Inc (NAS", "price_info": {"GRUB": {"company": "", "ticker": "GRUB", "move": "up"}, "DOORD": {"company": "", "ticker": "DOORD", "move": "up"}, "UBER": {"company": "", "ticker": "UBER", "move": "down"}}}, {"link": "https://www.wsj.com/articles/medical-equipment-maker-joerns-seeks-bankruptcy-protection-11561492746", "title": "Medical Equipment Maker Joerns Seeks Bankruptcy Protection", "date": "2019-06-25 15:59", "summary": "Private equity-backed business starts chapter 11 with plan to hand ownership to lenders and bondholders. Joerns Healthcare LLC, a medical equipment maker whose owners include private-equity firms Quad-C Management Inc. and Aurora Capital Partners, sought bankruptcy protection with a reorganization plan that would reduce its debt to $80 million from $400 million.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Medical Equipment Maker Joerns Seeks Bankruptcy Protection. Private equity-backed business starts chapter 11 with plan to hand ownership to lenders and bondholders. Joerns Healthcare LLC, a medical equipment maker whose owners include private-equity firms Quad-C Management Inc. and Aurora Capital Partners, sought bankruptcy protection with a reorganization plan that would reduce its debt to $80 million from $400 million.\"\n\nStock Prediction(s):", "Prediction": "\n- Joerns Healthcare LLC (OTCQB: JOER) will decrease because they are filing for bankruptcy and will have to reduce their debt.\n- Stryker Corporation (NYSE: SYK) will increase because they are not filing for bankruptcy and are a direct competitor of Joerns Healthcare.", "price_info": {"SYK": {"company": "", "ticker": "SYK", "move": "up"}}}, {"link": "https://www.wsj.com/articles/german-manufacturing-slump-piques-fears-over-europes-flagship-economy-11554385603", "title": "German Manufacturing Slump Piques Fears Over Europe's Flagship Economy", "date": "2019-04-04 09:46", "summary": "The slowdown is bad news for the rest of Europe, where a return of economic hardship could prove a boon for populists. FRANKFURT-German manufacturers saw orders drop sharply in February, increasing the likelihood that Europe's flagship economy could contract in the first half of 2019 in a setback for a weakened continent.", "categories": [["Economy", "Europe Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/europe-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"German Manufacturing Slump Piques Fears Over Europe's Flagship Economy. The slowdown is bad news for the rest of Europe, where a return of economic hardship could prove a boon for populists. FRANKFURT-German manufacturers saw orders drop sharply in February, increasing the likelihood that Europe's flagship economy could contract in the first half of 2019 in a setback for a weakened continent.\"\n\nStock Prediction(s):", "Prediction": "\n- Siemens AG (NYSE: SIEGY) will decrease because their main market is in Germany, and the German economy is struggling.\n- Robert Bosch GmbH (OTCMKTS: BOSCHY) will decrease because their main market is in Germany, and the German economy is struggling.\n- Volkswagen AG (OTCMKTS: VOW3) will decrease because their main market is in Germany, and the German economy is struggling.", "price_info": {"SIEGY": {"company": "", "ticker": "SIEGY", "move": "down"}}}, {"link": "https://www.wsj.com/articles/british-pound-falls-to-lowest-level-since-1985-11584537813", "title": "British Pound Falls to Lowest Level Since 1985", "date": "2020-03-18 13:55", "summary": "Decline in sterling comes as investors favor safer assets such as the U.S. dollar. The British pound fell to its lowest level against the dollar in 35 years, a reflection of the U.K. economy's unique exposure to the disruptions ripping through the global economy because of the coronavirus pandemic.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"British Pound Falls to Lowest Level Since 1985. Decline in sterling comes as investors favor safer assets such as the U.S. dollar. The British pound fell to its lowest level against the dollar in 35 years, a reflection of the U.K. economy's unique exposure to the disruptions ripping through the global economy because of the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- The British pound will continue to fall because of the pandemic.\n- The U.S. dollar will continue to rise because of the pandemic.", "price_info": {}}, {"link": "https://www.wsj.com/articles/china-power-outages-pose-new-threat-to-supplies-of-chips-and-other-goods-11632769617", "title": "China Power Outages Pose New Threat to Supply Chains", "date": "2021-09-27 15:06", "summary": "Coal shortages and efforts to control energy consumption are making it harder for Chinese factories to operate. Government efforts to curb energy consumption and reduce carbon emissions, along with surging coal prices, are leading to power outages across many of China's manufacturing hubs, threatening to further disrupt strained global supply chains for semiconductors and other vital goods.", "categories": [["Business", "Asia"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/asia-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"China Power Outages Pose New Threat to Supply Chains. Coal shortages and efforts to control energy consumption are making it harder for Chinese factories to operate. Government efforts to curb energy consumption and reduce carbon emissions, along with surging coal prices, are leading to power outages across many of China's manufacturing hubs, threatening to further disrupt strained global supply chains for semiconductors and other vital goods.\"\n\nStock Prediction(s):", "Prediction": "\n- Semiconductor Manufacturing International Corporation (NYSE: SMI) will decrease because their main market is in China, and the power outages are making it harder for factories to operate.\n- Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) will decrease because their main market is in China, and the power outages are making it harder for factories to operate.\n- Intel Corporation (NASDAQ: INTC) will decrease because their main market is in", "price_info": {"SMI": {"company": "", "ticker": "SMI", "move": null}, "TSM": {"company": "", "ticker": "TSM", "move": "down"}, "INTC": {"company": "", "ticker": "INTC", "move": "down"}}}, {"link": "https://www.wsj.com/articles/russia-opposes-saudi-plan-for-drastic-oil-cuts-11583344913", "title": "Russia Opposes Saudi Plan for Drastic Oil Cuts", "date": "2020-03-04 13:01", "summary": "OPEC and its chief oil market ally remain far apart on a possible response to coronavirus.. Russia on Wednesday opposed a Saudi plan that would ask OPEC and its allies to make drastic crude-production cuts, people familiar with the matter said, as the coronavirus outbreak further erodes demand amid a global oil glut.", "categories": [["WSJ News Exclusive", "World"]], "category_links": ["https://www.wsj.com/news/world?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Russia Opposes Saudi Plan for Drastic Oil Cuts. OPEC and its chief oil market ally remain far apart on a possible response to coronavirus.. Russia on Wednesday opposed a Saudi plan that would ask OPEC and its allies to make drastic crude-production cuts, people familiar with the matter said, as the coronavirus outbreak further erodes demand amid a global oil glut.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Aramco (NYSE: ARAMCO) will decrease because they are a direct competitor of Russia.\n- Russia's Lukoil PJSC (OTCMKTS: LUKOY) will decrease because they are a direct competitor of Saudi Aramco.", "price_info": {}}, {"link": "https://www.wsj.com/articles/airlines-losses-mount-amid-pandemic-but-travel-demand-shows-some-improvement-11603372966", "title": "Airlines' Losses Mount, but Demand Shows Improvement", "date": "2020-10-22 15:34", "summary": "Executives say passengers aren't likely to return in full force until Covid-19 vaccine becomes widely available. Summer was a bust for U.S. airlines. Now they are anxiously watching a fragile uptick in demand to see if it will hold as the number of new coronavirus cases increases.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Airlines' Losses Mount, but Demand Shows Improvement. Executives say passengers aren't likely to return in full force until Covid-19 vaccine becomes widely available. Summer was a bust for U.S. airlines. Now they are anxiously watching a fragile uptick in demand to see if it will hold as the number of new coronavirus cases increases.\"\n\nStock Prediction(s):", "Prediction": "\n- Delta Air Lines, Inc. (NYSE: DAL) will increase because their stock has been dropping and they are seeing an uptick in demand.\n- American Airlines Group, Inc. (NASDAQ: AAL) will increase because their stock has been dropping and they are seeing an uptick in demand.\n- United Airlines Holdings, Inc. (NYSE: UAL) will increase because their stock has been dropping and they are seeing an uptick in demand.\n-", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": null}, "UAL": {"company": "", "ticker": "UAL", "move": null, "prices": [37.2, 37.29]}, "AAL": {"company": "", "ticker": "AAL", "move": "up"}}}, {"link": "https://www.wsj.com/articles/watching-for-a-wage-price-spiral-11642003319", "title": "Watching for a Wage-Price Spiral", "date": "2022-01-12 11:02", "summary": "Rising inflation has had more to do with the pandemic than labor costs. But that could change.. Inflation is high, and the job market is tight. Both of those things have a lot to do with the pandemic, but how much do they have to do with each other?", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Watching for a Wage-Price Spiral. Rising inflation has had more to do with the pandemic than labor costs. But that could change.. Inflation is high, and the job market is tight. Both of those things have a lot to do with the pandemic, but how much do they have to do with each other?\"\n\nStock Prediction(s):", "Prediction": "\n- The overall market will decrease because of the potential wage-price spiral.\n- Companies that are more reliant on labor (such as Walmart Inc. (NYSE: WMT)) will decrease more than companies that are not (such as Amazon.com, Inc. (NASDAQ: AMZN)).", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [143.52, 143.88]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3306.155, 3312.64]}}}, {"link": "https://www.wsj.com/articles/fiat-chrysler-gets-teslas-help-on-emissions-rules-11554752332", "title": "Fiat Chrysler Gets Tesla's Help on Emissions", "date": "2019-04-08 15:38", "summary": "Italian-American auto maker seeks to meet EU carbon-dioxide targets with electric-vehicles deal. Fiat Chrysler Automobiles NV plans to count Tesla Inc . electric cars as part of its fleet to avoid significant fines for violating stricter European Union emissions rules.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fiat Chrysler Gets Tesla's Help on Emissions. Italian-American auto maker seeks to meet EU carbon-dioxide targets with electric-vehicles deal. Fiat Chrysler Automobiles NV plans to count Tesla Inc . electric cars as part of its fleet to avoid significant fines for violating stricter European Union emissions rules.\"\n\nStock Prediction(s):", "Prediction": "\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will increase because they are working with Tesla to produce electric cars and meet emissions targets.\n- Tesla Inc. (NASDAQ: TSLA) will increase because they are working with Fiat Chrysler to produce electric cars and meet emissions targets.", "price_info": {"FCAU": {"company": "", "ticker": "FCAU", "move": "up", "prices": [15.78, 15.79]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [273.22, 273.6]}}}, {"link": "https://www.wsj.com/articles/how-to-estimate-what-youll-spend-on-long-term-care-11572535052", "title": "How to Estimate What You'll Spend on Long-Term Care", "date": "2019-10-31 11:17", "summary": "Retirement columnist Glenn Ruffenach also offers advice about IRA distributions. In your column about unexpected bills in retirement, you didn't address the possibility of long-term care. How can I estimate what those expenses might be in later life? I need this for my parents and me.", "categories": [["Markets", "Journal Reports: Funds/ETFs", "Ask Encore"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-funds-etfs?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Estimate What You'll Spend on Long-Term Care. Retirement columnist Glenn Ruffenach also offers advice about IRA distributions. In your column about unexpected bills in retirement, you didn't address the possibility of long-term care. How can I estimate what those expenses might be in later life? I need this for my parents and me.\"\n\nStock Prediction(s):", "Prediction": "\n- Genworth Financial Inc (NYSE: GNW) will increase because they are a direct competitor of the other long-term care providers and they are the only one with a stock prediction.\n- American International Group Inc (NYSE: AIG) will decrease because they are a direct competitor of the other long-term care providers.\n- Cigna Corporation (NYSE: CI) will decrease because they are a direct competitor of the other long-term care providers.", "price_info": {"GNW": {"company": "", "ticker": "GNW", "move": "up", "prices": [4.28, 4.23]}, "AIG": {"company": "", "ticker": "AIG", "move": "down", "prices": [52.445, 52.5082]}, "CI": {"company": "", "ticker": "CI", "move": "down", "prices": [175.675, 177.285]}}}, {"link": "https://www.wsj.com/articles/european-airlines-fight-against-jet-fuel-taxes-11576612809", "title": "European Airlines Fight Against Jet Fuel Taxes", "date": "2019-12-17 15:00", "summary": "An EU-wide jet fuel tax-excluding the U.K.-could cost airlines around $14.5 billion a year. Airlines including Deutsche Lufthansa AG and Ryanair Holdings PLC are rallying against the threat of jet fuel taxes that could help fund the European Union's environmental ambitions.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"European Airlines Fight Against Jet Fuel Taxes. An EU-wide jet fuel tax-excluding the U.K.-could cost airlines around $14.5 billion a year. Airlines including Deutsche Lufthansa AG and Ryanair Holdings PLC are rallying against the threat of jet fuel taxes that could help fund the European Union's environmental ambitions.\"\n\nStock Prediction(s):", "Prediction": "\n- Airlines will generally increase because of the new tax, with the exception of the U.K. airlines which will decrease because they are not being taxed.\n- Airbus SE (EPA: AIR) will increase because they are a large manufacturer of airplanes.\n- Lufthansa AG (OTCPK: DLAKY) will increase because they are a large European airline.\n- Ryanair Holdings PLC (NASDAQ: RYAAY) will", "price_info": {"RYAAY": {"company": "", "ticker": "RYAAY", "move": "up"}}}, {"link": "https://www.wsj.com/articles/list-of-macys-stores-set-to-close-11580856020", "title": "List of Macy's Stores Set to Close", "date": "2020-02-05 14:38", "summary": "Resume Subscription. Macy's Inc. is accelerating its restructuring efforts after a yearslong slump. Some of the retailer's stores that are set to close this year:", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"List of Macy's Stores Set to Close. Resume Subscription. Macy's Inc. is accelerating its restructuring efforts after a yearslong slump. Some of the retailer's stores that are set to close this year:\"\n\nStock Prediction(s):", "Prediction": "\n- Macy's Inc. (NYSE: M) will decrease because they are closing stores.", "price_info": {"M": {"company": "", "ticker": "M", "move": "down", "prices": [17.165, 17.4375]}}}, {"link": "https://www.wsj.com/articles/justice-department-reaches-settlement-with-fiat-chrysler-over-union-corruption-11611761881", "title": "Fiat Chrysler Reaches DOJ Settlement Over Labor Law Violation", "date": "2021-01-27 14:42", "summary": "Auto maker's U.S. division agrees to plead guilty to a criminal charge and pay $30 million fine for violating labor laws. The Justice Department said it has reached a settlement with Fiat Chrysler's U.S. division in the government's long-running investigation into corruption among top labor leaders in Detroit.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fiat Chrysler Reaches DOJ Settlement Over Labor Law Violation. Auto maker's U.S. division agrees to plead guilty to a criminal charge and pay $30 million fine for violating labor laws. The Justice Department said it has reached a settlement with Fiat Chrysler's U.S. division in the government's long-running investigation into corruption among top labor leaders in Detroit.\"\n\nStock Prediction(s):", "Prediction": "\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will increase because they have resolved a labor law violation.\n- Ford Motor Company (NYSE: F) will decrease because they are a direct competitor of Fiat Chrysler.\n- General Motors Company (NYSE: GM) will decrease because they are a direct competitor of Fiat Chrysler.", "price_info": {"FCAU": {"company": "", "ticker": "FCAU", "move": "up"}, "F": {"company": "", "ticker": "F", "move": "down", "prices": [10.81, 10.72]}, "GM": {"company": "", "ticker": "GM", "move": "down", "prices": [49.41, 48.95]}}}, {"link": "https://www.wsj.com/articles/london-stock-exchanges-future-depends-on-brussels-11582901598", "title": "London Stock Exchange's Future Depends on Brussels", "date": "2020-02-28 09:53", "summary": "Investors may be too relaxed about two European Union decisions that are crucial to the company's growth plans. London Stock Exchange Group's future isn't quite the sure thing investors seem to think.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"London Stock Exchange's Future Depends on Brussels. Investors may be too relaxed about two European Union decisions that are crucial to the company's growth plans. London Stock Exchange Group's future isn't quite the sure thing investors seem to think.\"\n\nStock Prediction(s):", "Prediction": "\n- LSEG plc (LON: LSE) will decrease because the future of their company is uncertain.\n- Deutsche Boerse AG (ETR: DB1) will increase because they are LSEG's main competitor, and they are expecting to benefit from LSEG's uncertainty.", "price_info": {}}, {"link": "https://www.wsj.com/articles/match-keeps-flame-alive-in-lockdown-11588789122", "title": "Match Keeps Flame Alive in Lockdown", "date": "2020-05-06 14:18", "summary": "Match's first-quarter results show singles don't need bars to mingle, after all. If George Costanza taught us anything at all, it's that we want what we can't have. That truth is benefiting Match Group as singles suffer through prolonged isolation.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Match Keeps Flame Alive in Lockdown. Match's first-quarter results show singles don't need bars to mingle, after all. If George Costanza taught us anything at all, it's that we want what we can't have. That truth is benefiting Match Group as singles suffer through prolonged isolation.\"\n\nStock Prediction(s):", "Prediction": "\n- Match Group, Inc. (NASDAQ: MTCH) will increase because their services are still in high demand, even during the pandemic.\n- IAC/InterActiveCorp (NASDAQ: IAC) will decrease because they own a majority stake in Match Group.", "price_info": {"MTCH": {"company": "", "ticker": "MTCH", "move": "up", "prices": [86.6808, 85.5]}, "IAC": {"company": "", "ticker": "IAC", "move": "down"}}}, {"link": "https://www.wsj.com/articles/u-s-winds-down-probe-into-wireless-carriers-over-esim-technology-11574871061", "title": "U.S. Ends Probe Into Wireless Carriers' Influence on Rules for Switching Providers", "date": "2019-11-27 12:42", "summary": "Justice Department says process for setting eSIM standards limited competition, but doesn't file charges. The U.S. ended an antitrust probe, without filing charges, into whether wireless carriers steered technical standards to make it harder for customers to switch providers.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Ends Probe Into Wireless Carriers' Influence on Rules for Switching Providers. Justice Department says process for setting eSIM standards limited competition, but doesn't file charges. The U.S. ended an antitrust probe, without filing charges, into whether wireless carriers steered technical standards to make it harder for customers to switch providers.\"\n\nStock Prediction(s):", "Prediction": "\n- AT&T Inc. (NYSE: T) will increase because the U.S. has ended their probe into their influence on the eSIM standards.\n- Verizon Communications Inc. (NYSE: VZ) will increase because the U.S. has ended their probe into their influence on the eSIM standards.\n- T-Mobile US Inc. (NASDAQ: TMUS) will increase because the U.S. has ended their probe into their influence", "price_info": {"T": {"company": "", "ticker": "T", "move": "up"}, "VZ": {"company": "", "ticker": "VZ", "move": "up", "prices": [60.175, 60.195]}, "TMUS": {"company": "", "ticker": "TMUS", "move": "up"}}}, {"link": "https://www.wsj.com/articles/ges-4q-sales-fell-3-hit-by-supply-chain-woes-11643112508", "title": "GE's Sales Decline 3%, Hit by Supply-Chain Woes", "date": "2022-01-25 11:59", "summary": "Conglomerate projects return to revenue growth this year, fueled by growth in aviation unit. General Electric Co. reported fourth-quarter revenue fell 3%, weighed down by supply-chain difficulties, and projected a return to sales growth this year as its aviation business begins to recover.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GE's Sales Decline 3%, Hit by Supply-Chain Woes. Conglomerate projects return to revenue growth this year, fueled by growth in aviation unit. General Electric Co. reported fourth-quarter revenue fell 3%, weighed down by supply-chain difficulties, and projected a return to sales growth this year as its aviation business begins to recover.\"\n\nStock Prediction(s):", "Prediction": "\n- GE (NYSE: GE) will decrease because their sales are down 3% and they are projecting a return to sales growth this year.\n- Honeywell International Inc. (NYSE: HON) will increase because their sales are up 3% and they are not experiencing the same supply-chain difficulties as GE.\n- United Technologies Corp. (NYSE: UTX) will increase because their sales are up 3% and they are not experiencing the same supply-chain", "price_info": {"GE": {"company": "", "ticker": "GE", "move": "down"}, "HON": {"company": "", "ticker": "HON", "move": "up"}, "UTX": {"company": "", "ticker": "UTX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/this-10-billion-chip-deal-isnt-cheap-11559574016", "title": "This $10 Billion Chip Deal Isn't Cheap", "date": "2019-06-03 11:00", "summary": "German chip giant Infineon is doubling down on the car industry at a precarious time. Companies that announce big deals with limited financial rationale need good strategic reasons. German chip giant Infineon has made an unconvincing start in its acquisition of California-based Cypress Semiconductor .", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"This $10 Billion Chip Deal Isn't Cheap. German chip giant Infineon is doubling down on the car industry at a precarious time. Companies that announce big deals with limited financial rationale need good strategic reasons. German chip giant Infineon has made an unconvincing start in its acquisition of California-based Cypress Semiconductor .\"\n\nStock Prediction(s):", "Prediction": "\n- Cypress Semiconductor Corporation (NASDAQ: CY) will increase because the acquisition by Infineon will help them expand their business.\n- Infineon Technologies AG (OTCMKTS: IFNNY) will increase because the acquisition by Infineon will help them expand their business.\n- Texas Instruments Incorporated (NASDAQ: TXN) will decrease because they are a direct competitor of Cypress Semiconductor.", "price_info": {"CY": {"company": "", "ticker": "CY", "move": "up"}, "TXN": {"company": "", "ticker": "TXN", "move": "down", "prices": [105.64, 105.2636]}}}, {"link": "https://www.wsj.com/articles/avengers-endgame-pulverizes-ticket-presale-records-11554316262", "title": "'Avengers: Endgame' Pulverizes Ticket-Presale Records", "date": "2019-04-03 14:31", "summary": "Movie has biggest single-day ticket sales on Fandago, causes AMC servers to crash. Walt Disney Co. appears to have another hit on its hands with \"Avengers: Endgame.\"", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"'Avengers: Endgame' Pulverizes Ticket-Presale Records. Movie has biggest single-day ticket sales on Fandago, causes AMC servers to crash. Walt Disney Co. appears to have another hit on its hands with \"Avengers: Endgame.\"\"\n\nStock Prediction(s):", "Prediction": "\n- The Walt Disney Company (NYSE: DIS) will increase because \"Avengers: Endgame\" is breaking records.\n- Comcast Corporation (NASDAQ: CMCSA) will increase because they own NBCUniversal, which is the distributor of \"Avengers: Endgame.\"\n- Cinemark Holdings, Inc. (NYSE: CNK) will increase because they are one of the theater chains showing \"Avengers: Endgame.\"", "price_info": {"DIS": {"company": "", "ticker": "DIS", "move": "up", "prices": [112.4323, 112.65]}, "CNK": {"company": "", "ticker": "CNK", "move": "up"}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "up"}}}, {"link": "https://www.wsj.com/articles/facebook-has-made-lots-of-new-rules-this-year-it-doesnt-always-enforce-them-11602775676", "title": "Facebook Has Made Lots of New Rules This Year. It Doesn't Always Enforce Them.", "date": "2020-10-15 11:27", "summary": "A Wall Street Journal test showed content that violated guidelines often remained. Facebook Inc. this year has made a flurry of new rules designed to improve the discourse on its platforms. When users report content that breaks those rules, a test by The Wall Street Journal found, the company often fails to enforce them.", "categories": [["WSJ News Exclusive", "Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook Has Made Lots of New Rules This Year. It Doesn't Always Enforce Them.. A Wall Street Journal test showed content that violated guidelines often remained. Facebook Inc. this year has made a flurry of new rules designed to improve the discourse on its platforms. When users report content that breaks those rules, a test by The Wall Street Journal found, the company often fails to enforce them.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook Inc. (NASDAQ: FB) will decrease because they are not enforcing their own rules.\n- Twitter Inc. (NYSE: TWTR) will decrease because they are not enforcing their own rules.\n- Snap Inc. (NYSE: SNAP) will decrease because they are not enforcing their own rules.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "down"}, "SNAP": {"company": "", "ticker": "SNAP", "move": "down"}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [264.82, 264.19]}}}, {"link": "https://www.wsj.com/articles/hp-rejects-xerox-takeover-offer-11583408223", "title": "HP Rejects Xerox's Raised Takeover Offer", "date": "2020-03-05 11:44", "summary": "Company says a combination would disproportionately benefit Xerox shareholders. HP Inc. rejected Xerox Holdings Corp.'s $35 billion bid to take over the maker of printers, printer supplies and personal computers, again deeming the offer as too low.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"HP Rejects Xerox's Raised Takeover Offer. Company says a combination would disproportionately benefit Xerox shareholders. HP Inc. rejected Xerox Holdings Corp.'s $35 billion bid to take over the maker of printers, printer supplies and personal computers, again deeming the offer as too low.\"\n\nStock Prediction(s):", "Prediction": "\n- HP Inc. (NYSE: HPQ) will stay the same because they have already rejected the offer from Xerox Holdings Corp. (NYSE: XRX).\n- Xerox Holdings Corp. (NYSE: XRX) will increase because they are still trying to takeover HP Inc. (NYSE: HPQ).", "price_info": {"HPQ": {"company": "", "ticker": "HPQ", "move": null}, "XRX": {"company": "", "ticker": "XRX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/natural-gas-crisis-pushes-german-utilities-into-dash-for-cash-11641387867", "title": "Natural-Gas Crisis Pushes German Utilities Into Dash for Cash", "date": "2022-01-05 14:15", "summary": "Energy giant Uniper arranged more than $11 billion in credit lines to weather the biggest surge in gas prices in a generation. European energy companies are racing to secure billions of euros in funds, a sign of the financial strains caused by dramatic moves in natural-gas and power prices this winter.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Natural-Gas Crisis Pushes German Utilities Into Dash for Cash. Energy giant Uniper arranged more than $11 billion in credit lines to weather the biggest surge in gas prices in a generation. European energy companies are racing to secure billions of euros in funds, a sign of the financial strains caused by dramatic moves in natural-gas and power prices this winter.\"\n\nStock Prediction(s):", "Prediction": "\n- Uniper SE (OTC: UNPFY) will increase because they have secured more than $11 billion in credit lines to weather the biggest surge in gas prices in a generation.\n- RWE AG (OTC: RWEOY) will increase because they have secured more than $11 billion in credit lines to weather the biggest surge in gas prices in a generation.\n- Engie SA (OTC: ENGIY) will increase because they have", "price_info": {}}, {"link": "https://www.wsj.com/articles/fed-chairman-powell-to-testify-before-house-committee-on-july-10-11561406091", "title": "Fed Chairman Powell to Testify Before House Committee on July 10", "date": "2019-06-24 15:54", "summary": "He will testify before Senate Banking Committee the following day. Federal Reserve Chairman Jerome Powell will deliver his semiannual monetary policy report to the House Financial Services Committee on July 10, the committee announced Monday.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Chairman Powell to Testify Before House Committee on July 10. He will testify before Senate Banking Committee the following day. Federal Reserve Chairman Jerome Powell will deliver his semiannual monetary policy report to the House Financial Services Committee on July 10, the committee announced Monday.\"\n\nStock Prediction(s):", "Prediction": "\n- The stock prices of banks will increase because Powell is testifying, and this is seen as a positive sign for the economy.\n- The stock prices of technology companies will decrease because Powell is testifying, and this is seen as a negative sign for the economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/best-performance-from-older-iphone-11630774555", "title": "Tips to Get the Best Performance From an Older iPhone", "date": "2021-09-07 12:40", "summary": "To rejuvenate your increasingly vintage model, check its battery health, free up storage and weigh your repair options. New iPhones are just around the corner-we expect them to appear on Sept.14, in Apple's just-announced streamed news event-but before you rush to buy one of the new ones, take a closer look at the one you've got.", "categories": [["Tech", "Personal Tech", "Personal Technology: Nicole Nguyen"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-nicole-nguyen?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tips to Get the Best Performance From an Older iPhone. To rejuvenate your increasingly vintage model, check its battery health, free up storage and weigh your repair options. New iPhones are just around the corner-we expect them to appear on Sept.14, in Apple's just-announced streamed news event-but before you rush to buy one of the new ones, take a closer look at the one you've got.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because people will want to buy a new phone, but they will also want to get the most out of their old phone first.\n- Samsung Electronics Co Ltd (OTC: SSNLF) will decrease because they are a direct competitor of Apple.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [157.0725, 156.97]}}}, {"link": "https://www.wsj.com/articles/ralph-lauren-shares-rise-on-higher-2q-results-same-revenue-outlook-11573139878", "title": "Price Hikes Help Ralph Lauren Boost Profits", "date": "2019-11-07 12:57", "summary": "Fashion brand plans to raise U.S. prices for spring collections. Ralph Lauren Corp. posted higher quarterly profit as the luxury apparel maker pushes through price increases, helping offset some of the rising costs due to tariffs on products imported from China.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Price Hikes Help Ralph Lauren Boost Profits. Fashion brand plans to raise U.S. prices for spring collections. Ralph Lauren Corp. posted higher quarterly profit as the luxury apparel maker pushes through price increases, helping offset some of the rising costs due to tariffs on products imported from China.\"\n\nStock Prediction(s):", "Prediction": "\n- Ralph Lauren Corp. (NYSE: RL) will increase because they are able to raise prices and their profits are up.\n- Nike Inc. (NYSE: NKE) will decrease because they are not able to raise prices as much as Ralph Lauren, and they are also feeling the effects of the tariffs.", "price_info": {"RL": {"company": "", "ticker": "RL", "move": "up"}, "NKE": {"company": "", "ticker": "NKE", "move": "up", "prices": [90.31, 90.4868]}}}, {"link": "https://www.wsj.com/articles/aviation-turbulence-is-another-big-risk-for-ge-11560879651", "title": "Aviation Turbulence Is Another Big Risk for GE", "date": "2019-06-18 13:40", "summary": "Strong orders from the Paris Air Show are undermined by serious headwinds across GE's aviation business. General Electric 's aviation business has some baggage.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Aviation Turbulence Is Another Big Risk for GE. Strong orders from the Paris Air Show are undermined by serious headwinds across GE's aviation business. General Electric 's aviation business has some baggage.\"\n\nStock Prediction(s):", "Prediction": "\n- GE will decrease because their aviation business is in trouble.\n- Honeywell International Inc. (NYSE: HON) will increase because they are a competitor of GE's aviation business.", "price_info": {"HON": {"company": "", "ticker": "HON", "move": "up"}}}, {"link": "https://www.wsj.com/articles/wall-street-bankers-no-longer-fully-vested-11554397745", "title": "Wall Street Bankers No Longer Fully Vested", "date": "2019-04-04 13:09", "summary": "Patagonia is refusing to make fleece vests for greedy bankers, but Wall Street may find a workaround. They have gone from fashion statement to dorky stereotype. Can they become a status symbol?", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Wall Street Bankers No Longer Fully Vested. Patagonia is refusing to make fleece vests for greedy bankers, but Wall Street may find a workaround. They have gone from fashion statement to dorky stereotype. Can they become a status symbol?\"\n\nStock Prediction(s):", "Prediction": "\n- Patagonia, Inc. (NYSE: PAT) will increase because they are refusing to make fleece vests for greedy bankers, and they are a popular outdoor apparel company.\n- Goldman Sachs Group, Inc. (NYSE: GS) will decrease because they are associated with greed, and their fleece vests are becoming dorky.\n- J.P. Morgan Chase & Co. (NYSE: JPM) will decrease because they are associated with greed", "price_info": {"PAT": {"company": "", "ticker": "PAT", "move": "up"}, "GS": {"company": "", "ticker": "GS", "move": "down"}, "JPM": {"company": "", "ticker": "JPM", "move": "down"}}}, {"link": "https://www.wsj.com/articles/profit-climbs-at-canadas-major-banks-11558613195", "title": "Profit Climbs at Canada's Major Banks", "date": "2019-05-23 10:18", "summary": "At Royal Bank of Canada, banking, capital markets, wealth management help drive earnings; TD's revenue rises 7.9%. Royal Bank of Canada and TD Bank Group , two of Canada's largest banking entities, separately reported rises in profit in the latest quarter.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Profit Climbs at Canada's Major Banks. At Royal Bank of Canada, banking, capital markets, wealth management help drive earnings; TD's revenue rises 7.9%. Royal Bank of Canada and TD Bank Group , two of Canada's largest banking entities, separately reported rises in profit in the latest quarter.\"\n\nStock Prediction(s):", "Prediction": "\n- Royal Bank of Canada (NYSE: RY) will increase because their profit rose in the latest quarter.\n- TD Bank Group (NYSE: TD) will increase because their profit rose in the latest quarter.", "price_info": {"RY": {"company": "", "ticker": "RY", "move": "up"}, "TD": {"company": "", "ticker": "TD", "move": "up"}}}, {"link": "https://www.wsj.com/articles/fed-issues-new-bank-guidance-to-improve-main-street-loan-access-11600449797", "title": "Fed Issues New Bank Guidance to Improve Main Street Loan Access", "date": "2020-09-18 13:32", "summary": "The move is a bid to increase loans to small and midsized businesses via the central bank's program. The Federal Reserve issued new guidance to banks Friday in an effort to improve access to new business loans through its $600 billion Main Street Lending Program.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Issues New Bank Guidance to Improve Main Street Loan Access. The move is a bid to increase loans to small and midsized businesses via the central bank's program. The Federal Reserve issued new guidance to banks Friday in an effort to improve access to new business loans through its $600 billion Main Street Lending Program.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed's new guidance will increase the amount of loans available to small and midsized businesses, which will benefit banks such as JPMorgan Chase & Co. (NYSE: JPM), Wells Fargo & Co. (NYSE: WFC), and Bank of America Corp. (NYSE: BAC).\n- The Fed's new guidance will not have a significant impact on banks such as Citigroup Inc. (NYSE: C), Goldman Sachs Group Inc. (NYSE: GS),", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [98.4889, 98.3465]}, "WFC": {"company": "", "ticker": "WFC", "move": "up"}, "BAC": {"company": "", "ticker": "BAC", "move": "up"}, "C": {"company": "", "ticker": "C", "move": "up"}, "GS": {"company": "", "ticker": "GS", "move": "up"}}}, {"link": "https://www.wsj.com/articles/whats-not-to-like-about-strategy-shares-nasdaq-7handl-index-etf-11639757973", "title": "What's Not to Like About a Fund With a 7% Yield", "date": "2021-12-17 11:23", "summary": "A booming stock market isn't what most conservative investors think of as a source of income. But that, and leverage, are the magic behind the juicy payouts in a popular ETF.. The Federal Reserve indicated this week that it might raise interest rates at least three times next year to stifle inflation. Until then, in a world of paltry interest rates, investors should be wary of investments that sound magical because they provide more than a pittance of income.", "categories": [["Markets", "The Intelligent Investor"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/the-intelligent-investor?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What's Not to Like About a Fund With a 7% Yield. A booming stock market isn't what most conservative investors think of as a source of income. But that, and leverage, are the magic behind the juicy payouts in a popular ETF.. The Federal Reserve indicated this week that it might raise interest rates at least three times next year to stifle inflation. Until then, in a world of paltry interest rates, investors should be wary of investments that sound magical because they provide more than a pittance of income.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve will continue to raise interest rates, which will cause the prices of the stocks in the ETF to decrease, and the yield to increase.\n- The yield on the ETF will continue to be attractive to investors, which will cause the price of the ETF to increase.", "price_info": {}}, {"link": "https://www.wsj.com/articles/who-us-a-cartel-says-head-of-oil-cartel-11549906663", "title": "'Who, Us, a Cartel?' Says Head of Oil Cartel", "date": "2019-02-11 12:37", "summary": "OPEC is getting more sensitive to the notion that it tries to control oil prices. Did you say \"cartel?\" Go wash your mouth out with soap-preferably an oil-based one.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"'Who, Us, a Cartel?' Says Head of Oil Cartel. OPEC is getting more sensitive to the notion that it tries to control oil prices. Did you say \"cartel?\" Go wash your mouth out with soap-preferably an oil-based one.\"\n\nStock Prediction(s):", "Prediction": "\n- OPEC will decrease because they are getting more sensitive to the notion that they are a cartel.\n- Non-OPEC countries will increase because they are not part of the cartel, and they will be able to produce more oil.", "price_info": {}}, {"link": "https://www.wsj.com/articles/germanys-merck-to-acquire-versum-in-6-56-billion-cash-deal-11555078607", "title": "Germany's Merck to Buy Versum for $6.56 Billion", "date": "2019-04-12 12:54", "summary": "The $53-a-share deal for the semiconductor materials company scuttles a merger agreement with Entegris. Merck KGaA said Friday it reached a deal to buy Versum Materials Inc. for $53 a share in cash, scuttling a merger with Entegris Inc.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Germany's Merck to Buy Versum for $6.56 Billion. The $53-a-share deal for the semiconductor materials company scuttles a merger agreement with Entegris. Merck KGaA said Friday it reached a deal to buy Versum Materials Inc. for $53 a share in cash, scuttling a merger with Entegris Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- Merck KGaA (FRA: MKK) will increase because they are buying a competitor for $6.56 billion.\n- Entegris Inc (NASDAQ: ENTG) will decrease because they are being bought out by Merck for $6.56 billion.", "price_info": {"ENTG": {"company": "", "ticker": "ENTG", "move": "down"}}}, {"link": "https://www.wsj.com/articles/an-aspen-mansion-built-for-high-altitude-living-asks-49-million-11594134079", "title": "An Aspen Mansion Built for High Altitude Living Asks $49 Million", "date": "2020-07-07 11:01", "summary": "The 15,000-square-foot home pumps extra oxygen into the master bedroom to lessen the effects of altitude sickness. A custom-built Aspen, Colo., mansion with high-tech features is going on the market for $49 million. If it sells for that price, the property would be among the most expensive ever to trade in the area, according to the listing agent.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"An Aspen Mansion Built for High Altitude Living Asks $49 Million. The 15,000-square-foot home pumps extra oxygen into the master bedroom to lessen the effects of altitude sickness. A custom-built Aspen, Colo., mansion with high-tech features is going on the market for $49 million. If it sells for that price, the property would be among the most expensive ever to trade in the area, according to the listing agent.\"\n\nStock Prediction(s):", "Prediction": "\n- The high-tech features in this Aspen mansion will lead to an increase in the price of the property, as people are willing to pay more for luxury homes that offer unique amenities.\n- Other luxury home builders, such as Toll Brothers Inc. (NYSE: TOL) and NVR Inc. (NYSE: NVR), will also see an increase in their stock prices as people become more interested in purchasing luxury homes.", "price_info": {"TOL": {"company": "", "ticker": "TOL", "move": "up"}, "NVR": {"company": "", "ticker": "NVR", "move": "up"}}}, {"link": "https://www.wsj.com/articles/yums-3q-profit-pressured-by-investment-in-grubhub-11572434934", "title": "Yum's Profit Pressured by Stake in Grubhub", "date": "2019-10-30 11:44", "summary": "Owner of chain restaurants also said general and administrative expenses increased 2%, while costs covering franchise advertising and services jumped 13%. Yum Brands Inc. marked down the value of its investment in Grubhub Inc., a move that hurt the restaurant chain's third-quarter profit but doesn't reflect the recent major selloff in shares of the delivery service.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Yum's Profit Pressured by Stake in Grubhub. Owner of chain restaurants also said general and administrative expenses increased 2%, while costs covering franchise advertising and services jumped 13%. Yum Brands Inc. marked down the value of its investment in Grubhub Inc., a move that hurt the restaurant chain's third-quarter profit but doesn't reflect the recent major selloff in shares of the delivery service.\"\n\nStock Prediction(s):", "Prediction": "\n- Yum Brands Inc. (NYSE: YUM) will decrease because their investment in Grubhub is hurting their profit.\n- Grubhub Inc. (NYSE: GRUB) will increase because their stock has been dropping recently, and this news will cause people to invest in them again.", "price_info": {"YUM": {"company": "", "ticker": "YUM", "move": "down", "prices": [100.35, 101.005]}, "GRUB": {"company": "", "ticker": "GRUB", "move": "up"}}}, {"link": "https://www.wsj.com/articles/delta-reports-loss-amid-omicron-surge-but-expects-to-make-recovery-11642073701", "title": "Delta Reports Loss but Expects to Make Recovery", "date": "2022-01-13 12:57", "summary": "Airline expects variant to delay demand recovery by 60 days but said its effects will soon begin to dissipate. Delta Air Lines Inc. said Thursday it expects to shake off the impact of Omicron, the fast-spreading Covid-19 variant that knocked the airline's operation off course and damped revenue at the end of the year.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Delta Reports Loss but Expects to Make Recovery. Airline expects variant to delay demand recovery by 60 days but said its effects will soon begin to dissipate. Delta Air Lines Inc. said Thursday it expects to shake off the impact of Omicron, the fast-spreading Covid-19 variant that knocked the airline's operation off course and damped revenue at the end of the year.\"\n\nStock Prediction(s):", "Prediction": "\n- Delta Air Lines Inc. (NYSE: DAL) will increase because they have already stated that their effects from the virus will soon dissipate.\n- American Airlines Group Inc. (NASDAQ: AAL) will decrease because they are a direct competitor of Delta.", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": null}, "AAL": {"company": "", "ticker": "AAL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/numbers-aint-what-they-used-to-be-in-turbulent-u-s-economy-11624557962", "title": "Numbers Ain't What They Used to Be in Turbulent Economy", "date": "2021-06-24 14:06", "summary": "Durable goods, jobs and home sales have all wrong-footed economists who didn't count on big revisions lately. There is a rule of thumb in data watching that, if you want to understand which way things are trending, you need to watch the revisions. What is happening with capital spending might be a case in point.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Numbers Ain't What They Used to Be in Turbulent Economy. Durable goods, jobs and home sales have all wrong-footed economists who didn't count on big revisions lately. There is a rule of thumb in data watching that, if you want to understand which way things are trending, you need to watch the revisions. What is happening with capital spending might be a case in point.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will be volatile because the data keeps getting revised and it is hard to tell what is really happening.\n- The market will rebound because the revisions show that the economy is not as bad as people thought.", "price_info": {}}, {"link": "https://www.wsj.com/articles/david-farrs-covid-lessons-11607093722", "title": "David Farr's Covid Lessons", "date": "2020-12-04 09:55", "summary": "The CEO of Emerson Electric applied lessons learned over two decades at the head of the industrial giant-adapted for the pandemic-to lead the 90,000 person company through the crisis. Here are his best tips.. David Farr has seen his share of crises over two decades atop Emerson Electric Co. , but no CEO could have been prepared for the pandemic that has swept the globe. The Wall Street Journal interviewed Mr. Farr dozens of times throughout the course of the year about how he managed amid the coronavirus threat. Here are a few of the leadership principles that he believes have helped Emerson succeed and not just survive. (Read the full story.)", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"David Farr's Covid Lessons. The CEO of Emerson Electric applied lessons learned over two decades at the head of the industrial giant-adapted for the pandemic-to lead the 90,000 person company through the crisis. Here are his best tips.. David Farr has seen his share of crises over two decades atop Emerson Electric Co. , but no CEO could have been prepared for the pandemic that has swept the globe. The Wall Street Journal interviewed Mr. Farr dozens of times throughout the course of the year about how he managed amid the coronavirus threat. Here are a few of the leadership principles that he believes have helped Emerson succeed and not just survive. (Read the full story.)\"\n\nStock Prediction(s):", "Prediction": "\n- Emerson Electric Co. (NYSE: EMR) will increase because their CEO has a lot of experience with managing crises and they have been successful in adapting to the Covid-19 pandemic.\n- Honeywell International Inc. (NYSE: HON) will increase because their CEO has a lot of experience with managing crises and they have been successful in adapting to the Covid-19 pandemic.\n- 3M Co. (NYSE: MMM) will", "price_info": {"EMR": {"company": "", "ticker": "EMR", "move": "up", "prices": [76.96, 78.985]}, "HON": {"company": "", "ticker": "HON", "move": "up"}, "MMM": {"company": "", "ticker": "MMM", "move": null}}}, {"link": "https://www.wsj.com/articles/fidelity-taps-bmos-joanna-rotenberg-to-head-4-trillion-personal-investing-business-11632146409", "title": "Fidelity Taps Joanna Rotenberg to Head $4 Trillion Personal-Investing Business", "date": "2021-09-20 10:00", "summary": "The appointment comes amid Americans' renewed interest in stock trading. Fidelity Investments appointed Joanna Rotenberg to head its personal-investing business, picking an outsider to spearhead the division amid unprecedented demand from individual investors.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fidelity Taps Joanna Rotenberg to Head $4 Trillion Personal-Investing Business. The appointment comes amid Americans' renewed interest in stock trading. Fidelity Investments appointed Joanna Rotenberg to head its personal-investing business, picking an outsider to spearhead the division amid unprecedented demand from individual investors.\"\n\nStock Prediction(s):", "Prediction": "\n- Fidelity Investments (NYSE: FIS) will increase because they have a new head of their personal-investing business, and this is a good sign for their company.\n- Charles Schwab Corp (NYSE: SCHW) will increase because they are also a competitor of Fidelity Investments, and they are seeing an increase in demand from individual investors.", "price_info": {"FIS": {"company": "", "ticker": "FIS", "move": "up", "prices": [122.7538, 122.0496]}, "SCHW": {"company": "", "ticker": "SCHW", "move": "up"}}}, {"link": "https://www.wsj.com/articles/ann-taylor-parent-gets-35-million-offer-for-tween-brand-justice-11602695325", "title": "Ann Taylor Parent Gets $35 Million Offer for Tween Brand Justice", "date": "2020-10-14 13:08", "summary": "IHL Group proposes to acquire the brand out of bankruptcy from Ascena Retail. Ascena Retail Group Inc., the parent company of Ann Taylor and Lane Bryant, got a $35 million offer to buy tween chain Justice out of bankruptcy and turn it into a primarily online brand.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ann Taylor Parent Gets $35 Million Offer for Tween Brand Justice. IHL Group proposes to acquire the brand out of bankruptcy from Ascena Retail. Ascena Retail Group Inc., the parent company of Ann Taylor and Lane Bryant, got a $35 million offer to buy tween chain Justice out of bankruptcy and turn it into a primarily online brand.\"\n\nStock Prediction(s):", "Prediction": "\n- Ascena Retail Group Inc. (NASDAQ: ASNA) will increase because they are getting a $35 million offer to sell Justice.\n- IHL Group (private) will increase because they are the ones making the offer to buy Justice.", "price_info": {"ASNA": {"company": "", "ticker": "ASNA", "move": "up"}}}, {"link": "https://www.wsj.com/articles/study-of-hiv-related-mutation-adds-to-worries-about-first-gene-edited-babies-11559646973", "title": "Study of HIV-Related Mutation Adds to Worries About First Gene-Edited Babies", "date": "2019-06-05 12:03", "summary": "Scientist tried to mimic mutation thought to generate resistance to virus that causes AIDS, but study says that mutation could also shorten lives. A genetic mutation thought to make people resistant to the virus that causes AIDS could also shorten their lives, according to a new study that has renewed concern over a Chinese experiment that created the world's first gene-edited babies.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Study of HIV-Related Mutation Adds to Worries About First Gene-Edited Babies. Scientist tried to mimic mutation thought to generate resistance to virus that causes AIDS, but study says that mutation could also shorten lives. A genetic mutation thought to make people resistant to the virus that causes AIDS could also shorten their lives, according to a new study that has renewed concern over a Chinese experiment that created the world's first gene-edited babies.\"\n\nStock Prediction(s):", "Prediction": "\n- CRISPR Therapeutics AG (NASDAQ: CRSP) will decrease because of the news about the HIV-related mutation.\n- Editas Medicine, Inc. (NASDAQ: EDIT) will decrease because of the news about the HIV-related mutation.\n- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) will decrease because of the news about the HIV-related mutation.", "price_info": {"CRSP": {"company": "", "ticker": "CRSP", "move": "down", "prices": [37.335, 37.81]}, "EDIT": {"company": "", "ticker": "EDIT", "move": "down"}, "SGMO": {"company": "", "ticker": "SGMO", "move": "down"}}}, {"link": "https://www.wsj.com/articles/chips-are-running-hot-11577990924", "title": "Chips Are Running Hot", "date": "2020-01-02 13:48", "summary": "Semiconductor stocks boomed in 2019 despite weakening sales, leaving valuations risky. Semiconductor companies had a rough year in 2019. Their investors did much, much better.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Chips Are Running Hot. Semiconductor stocks boomed in 2019 despite weakening sales, leaving valuations risky. Semiconductor companies had a rough year in 2019. Their investors did much, much better.\"\n\nStock Prediction(s):", "Prediction": "\n- Advanced Micro Devices, Inc. (NASDAQ: AMD) will continue to increase because their chips are in high demand.\n- Intel Corporation (NASDAQ: INTC) will continue to decrease because their chips are in high demand.\n- Nvidia Corporation (NASDAQ: NVDA) will continue to increase because their chips are in high demand.", "price_info": {"AMD": {"company": "", "ticker": "AMD", "move": "up"}, "INTC": {"company": "", "ticker": "INTC", "move": "down"}, "NVDA": {"company": "", "ticker": "NVDA", "move": "up"}}}, {"link": "https://www.wsj.com/articles/im-scared-thats-a-reason-to-buy-11584984021", "title": "I'm Scared. That's a Reason to Buy.", "date": "2020-03-23 13:20", "summary": "The true contrarian only buys when it makes him feel physically sick to press the buy key. The true contrarian only buys when it makes him feel physically sick to press the buy key. At the moment I not only feel sick at the idea but want to disinfect the keyboard before using it. Does that mean it's time to buy?", "categories": [["Markets", "Streetwise"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/streetwise?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"I'm Scared. That's a Reason to Buy.. The true contrarian only buys when it makes him feel physically sick to press the buy key. The true contrarian only buys when it makes him feel physically sick to press the buy key. At the moment I not only feel sick at the idea but want to disinfect the keyboard before using it. Does that mean it's time to buy?\"\n\nStock Prediction(s):", "Prediction": "\n- The author is recommending to buy stocks in the midst of a pandemic, which is inherently risky.\n- The author does not specify any particular stocks to buy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/washington-wants-to-know-why-timothy-sloan-hasnt-fixed-wells-fargo-11552316533", "title": "Wells Fargo Regulators Weigh Executive Shakeup as CEO Heads to Washington", "date": "2019-03-11 11:02", "summary": "At a House hearing, CEO is likely to be asked about bank's ongoing problems and whether he can finally repair its image. More than two years after a scandal erupted over fake customer accounts, Wells Fargo & Co. remains at sharp odds with its government overseers. How sharp should come into focus Tuesday, when Chief Executive Timothy Sloan appears before a House Financial Services Committee newly dominated by Democrats with a decidedly populist tilt.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Wells Fargo Regulators Weigh Executive Shakeup as CEO Heads to Washington. At a House hearing, CEO is likely to be asked about bank's ongoing problems and whether he can finally repair its image. More than two years after a scandal erupted over fake customer accounts, Wells Fargo & Co. remains at sharp odds with its government overseers. How sharp should come into focus Tuesday, when Chief Executive Timothy Sloan appears before a House Financial Services Committee newly dominated by Democrats with a decidedly populist tilt.\"\n\nStock Prediction(s):", "Prediction": "\n- Wells Fargo & Co. (NYSE: WFC) will decrease because of the ongoing problems with the company and the negative image it has.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because it is seen as a more stable and reliable company.\n- Bank of America Corp (NYSE: BAC) will increase because it is seen as a more stable and reliable company.", "price_info": {"WFC": {"company": "", "ticker": "WFC", "move": "down", "prices": [49.985, 50.01]}, "JPM": {"company": "", "ticker": "JPM", "move": "up"}, "BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [29.025, 29.025]}}}, {"link": "https://www.wsj.com/articles/big-winners-from-natural-gas-crunch-coal-power-plants-in-europe-11637150981", "title": "Big Winners From Natural-Gas Crunch: Coal Power Plants in Europe", "date": "2021-11-17 13:27", "summary": "Profit margins are far and away the highest they have been in years. Under Europe's climate policies, this shouldn't be happening.. Coal power plants are running at full tilt in parts of Europe and enjoying a rare bout of massive profitability, a setback to efforts to cut carbon emissions.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Big Winners From Natural-Gas Crunch: Coal Power Plants in Europe. Profit margins are far and away the highest they have been in years. Under Europe's climate policies, this shouldn't be happening.. Coal power plants are running at full tilt in parts of Europe and enjoying a rare bout of massive profitability, a setback to efforts to cut carbon emissions.\"\n\nStock Prediction(s):", "Prediction": "\n- Coal stocks will increase because of the increase in demand for coal-fired power plants.\n- Renewable energy stocks will decrease because of the increase in demand for coal-fired power plants.", "price_info": {}}, {"link": "https://www.wsj.com/articles/nissan-to-cut-12-500-jobs-world-wide-over-more-than-three-years-11564040409", "title": "Nissan to Cut 12,500 Jobs as Profit Sinks", "date": "2019-07-25 10:07", "summary": "Eight months after Ghosn's arrest, company struggles to turn corner as festering problems in the U.S. worsen. YOKOHAMA, Japan- Nissan Motor Co. said it would cut 12,500 jobs, or 9% of its global workforce, after reporting an implosion in profit in the latest quarter that stemmed in large part from the U.S.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Nissan to Cut 12,500 Jobs as Profit Sinks. Eight months after Ghosn's arrest, company struggles to turn corner as festering problems in the U.S. worsen. YOKOHAMA, Japan- Nissan Motor Co. said it would cut 12,500 jobs, or 9% of its global workforce, after reporting an implosion in profit in the latest quarter that stemmed in large part from the U.S.\"\n\nStock Prediction(s):", "Prediction": "\n- Nissan Motor Co. (OTCPK: NSANY) will decrease because they are cutting 12,500 jobs.\n- Honda Motor Co. (NYSE: HMC) will increase because they are not cutting jobs.\n- Toyota Motor Corp. (NYSE: TM) will increase because they are not cutting jobs.", "price_info": {"HMC": {"company": "", "ticker": "HMC", "move": "up"}, "TM": {"company": "", "ticker": "TM", "move": "up"}}}, {"link": "https://www.wsj.com/articles/jpmorgans-30-billion-racial-equity-pledge-one-year-later-11635267290", "title": "JPMorgan's $30 Billion Racial Equity Pledge, One Year Later", "date": "2021-10-26 12:54", "summary": "The bank says it has committed $13 billion in loans and spending, with the bulk going to affordable housing. JPMorgan Chase & Co. said it has already committed $13 billion of the $30 billion in lending and spending it pledged last year for improving racial equity.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"JPMorgan's $30 Billion Racial Equity Pledge, One Year Later. The bank says it has committed $13 billion in loans and spending, with the bulk going to affordable housing. JPMorgan Chase & Co. said it has already committed $13 billion of the $30 billion in lending and spending it pledged last year for improving racial equity.\"\n\nStock Prediction(s):", "Prediction": "\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they have made good on their pledge to invest $30 billion in racial equity.\n- Bank of America Corp (NYSE: BAC) will decrease because they have not made a similar pledge, and they are a direct competitor of JPMorgan Chase.\n- Citigroup Inc. (NYSE: C) will decrease because they have not made a similar pledge, and they are a direct competitor of JPMorgan Chase.", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "up"}, "BAC": {"company": "", "ticker": "BAC", "move": "down"}, "C": {"company": "", "ticker": "C", "move": "down"}}}, {"link": "https://www.wsj.com/articles/europes-lenders-want-to-grow-their-investment-banks-again-11627483745", "title": "Europe's Lenders Want to Grow Their Investment Banks Again", "date": "2021-07-28 10:49", "summary": "Keeping busy in capital markets has helped Barclays and Deutsche Bank deliver steady performances but plans to expand their investment banks still seem risky.. Barclays and Deutsche Bank are on form right now, but investors need to be cautious of their growing ambitions for the volatile investment-banking business.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Europe's Lenders Want to Grow Their Investment Banks Again. Keeping busy in capital markets has helped Barclays and Deutsche Bank deliver steady performances but plans to expand their investment banks still seem risky.. Barclays and Deutsche Bank are on form right now, but investors need to be cautious of their growing ambitions for the volatile investment-banking business.\"\n\nStock Prediction(s):", "Prediction": "\n- Barclays plc (NYSE: BCS) will increase because they are doing well in their investment-banking business.\n- Deutsche Bank AG (NYSE: DB) will increase because they are doing well in their investment-banking business.\n- Royal Bank of Scotland Group plc (NYSE: RBS) will decrease because they are not doing as well as Barclays and Deutsche Bank in their investment-banking business.", "price_info": {"BCS": {"company": "", "ticker": "BCS", "move": null}, "DB": {"company": "", "ticker": "DB", "move": "up", "prices": [12.47, 12.485]}, "RBS": {"company": "", "ticker": "RBS", "move": "down"}}}, {"link": "https://www.wsj.com/articles/economic-hopes-worries-swing-treasury-yields-11592323243", "title": "Economic Hopes, Worries Swing Treasury Yields", "date": "2020-06-16 15:43", "summary": "Fed chairman warns of significant long-term damage from higher unemployment, wave of small-business failures. U.S. government-bond yields swung wildly Tuesday amid conflicting signs about the pace of the global economic recovery from the pandemic.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Economic Hopes, Worries Swing Treasury Yields. Fed chairman warns of significant long-term damage from higher unemployment, wave of small-business failures. U.S. government-bond yields swung wildly Tuesday amid conflicting signs about the pace of the global economic recovery from the pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- The yield on the 10-year Treasury note will decrease because the market is worried about the global economy.\n- The yield on the 2-year Treasury note will increase because the market is expecting the Federal Reserve to cut interest rates.", "price_info": {}}, {"link": "https://www.wsj.com/articles/qualcomm-lg-reach-new-chip-licensing-deal-11566307760", "title": "Qualcomm, LG Reach New Patent-Licensing Deal", "date": "2019-08-20 13:37", "summary": "The agreement allows South Korean company to sell smartphones containing the semiconductor maker's technology. Qualcomm Inc. reached a new patent-licensing deal with LG Electronics Inc., securing its technology in a suite of wireless devices while federal regulators continue to scrutinize its business practices on antitrust grounds.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Qualcomm, LG Reach New Patent-Licensing Deal. The agreement allows South Korean company to sell smartphones containing the semiconductor maker's technology. Qualcomm Inc. reached a new patent-licensing deal with LG Electronics Inc., securing its technology in a suite of wireless devices while federal regulators continue to scrutinize its business practices on antitrust grounds.\"\n\nStock Prediction(s):", "Prediction": "\n- Qualcomm Inc. (NASDAQ: QCOM) will increase because they have secured a new patent-licensing deal with LG Electronics Inc.\n- LG Electronics Inc. (KRX: 066570) will increase because they will be able to sell smartphones containing Qualcomm's technology.", "price_info": {"QCOM": {"company": "", "ticker": "QCOM", "move": "up"}}}, {"link": "https://www.wsj.com/articles/twitter-ceo-announcement-spotlights-rare-executive-move-11638381022", "title": "Twitter CEO Announcement Spotlights Rare Executive Move", "date": "2021-12-01 12:50", "summary": "Moving directly from tech chief to chief executive is uncommon, even among tech companies. Twitter Inc. promoted its chief technology officer to chief executive earlier this week. Experts say such a move is rare, although technology skills increasingly are valued in the corner office.", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/cio-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Twitter CEO Announcement Spotlights Rare Executive Move. Moving directly from tech chief to chief executive is uncommon, even among tech companies. Twitter Inc. promoted its chief technology officer to chief executive earlier this week. Experts say such a move is rare, although technology skills increasingly are valued in the corner office.\"\n\nStock Prediction(s):", "Prediction": "\n- Twitter Inc. (NYSE: TWTR) will increase because their new CEO has a technology background and is more likely to be able to lead the company in the right direction.\n- Facebook Inc. (NASDAQ: FB) will decrease because their new CEO does not have a technology background and is more likely to make mistakes.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "up"}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [319.2425, 316.1971]}}}, {"link": "https://www.wsj.com/articles/fed-to-review-financial-trading-rules-for-officials-11631803236", "title": "Fed to Review Financial Trading Rules for Officials", "date": "2021-09-16 10:40", "summary": "Action follows news of stock trading by Dallas, Boston Fed leaders. The Federal Reserve is launching a review of its internal rules governing the financial activities of its officials in the wake of news last week that the leaders of the Dallas and Boston regional Fed banks actively traded in financial markets.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed to Review Financial Trading Rules for Officials. Action follows news of stock trading by Dallas, Boston Fed leaders. The Federal Reserve is launching a review of its internal rules governing the financial activities of its officials in the wake of news last week that the leaders of the Dallas and Boston regional Fed banks actively traded in financial markets.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve will tighten their rules on financial trading by their officials, which will have a negative impact on the stock prices of banks and other financial institutions.\n- The Federal Reserve will loosen their rules on financial trading by their officials, which will have a positive impact on the stock prices of banks and other financial institutions.", "price_info": {}}, {"link": "https://www.wsj.com/articles/fed-hires-blackrock-to-help-calm-markets-its-etf-business-wins-big-11600450267", "title": "Fed Hires BlackRock to Help Calm Markets. Its ETF Business Wins Big.", "date": "2020-09-18 13:31", "summary": "The central bank's market intervention helped the largest U.S. provider of corporate bond exchange-traded funds get larger. The Federal Reserve's March commitment to deploy billions of dollars to prop up the economy was a boon for the company the Fed hired to help execute its plan: BlackRock Inc., the world's largest asset manager.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Hires BlackRock to Help Calm Markets. Its ETF Business Wins Big.. The central bank's market intervention helped the largest U.S. provider of corporate bond exchange-traded funds get larger. The Federal Reserve's March commitment to deploy billions of dollars to prop up the economy was a boon for the company the Fed hired to help execute its plan: BlackRock Inc., the world's largest asset manager.\"\n\nStock Prediction(s):", "Prediction": "\n- BlackRock, Inc. (NYSE: BLK) will increase because they are the largest asset manager, and they have a good relationship with the Federal Reserve.\n- Vanguard Group (NYSE: VGR) will decrease because they are the second largest asset manager, and they do not have a good relationship with the Federal Reserve.", "price_info": {"BLK": {"company": "", "ticker": "BLK", "move": "up"}, "VGR": {"company": "", "ticker": "VGR", "move": "down"}}}, {"link": "https://www.wsj.com/articles/chinas-latest-crackdown-on-bitcoin-other-cryptocurrencies-shakes-market-11621853002", "title": "Beijing's Renewed Crackdown Shakes Crypto Markets", "date": "2021-05-24 11:36", "summary": "Major digital-currency exchanges suspend some activities that targeted users in China. China's efforts to restrain cryptocurrency trading and mining are adding to the wild moves in bitcoin and other markets.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Beijing's Renewed Crackdown Shakes Crypto Markets. Major digital-currency exchanges suspend some activities that targeted users in China. China's efforts to restrain cryptocurrency trading and mining are adding to the wild moves in bitcoin and other markets.\"\n\nStock Prediction(s):", "Prediction": "\n- Bitcoin (BTC) will decrease because Beijing is cracking down on the market.\n- Ethereum (ETH) will decrease because Beijing is cracking down on the market.\n- Litecoin (LTC) will decrease because Beijing is cracking down on the market.\n- Ripple (XRP) will decrease because Beijing is cracking down on the market.", "price_info": {"BTC": {"company": "Bitcoin", "ticker": "BTC", "move": "down"}, "ETH": {"company": "Ethereum", "ticker": "ETH", "move": "down"}, "LTC": {"company": "Litecoin", "ticker": "LTC", "move": "down"}, "XRP": {"company": "Ripple", "ticker": "XRP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/archegos-gives-investors-warning-signs-11617123833", "title": "Archegos Gives Investors Warning Signs", "date": "2021-03-30 13:03", "summary": "Question is whether Archegos is just an accident on a lonely road or a pileup waiting to happen. On the highway, the most dangerous moment is when everything is calm and the outlook is great, because that's when you put on the cruise control, turn up the music and miss the lumbering RV pulling out of a rest stop.", "categories": [["Markets", "Streetwise"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/streetwise?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Archegos Gives Investors Warning Signs. Question is whether Archegos is just an accident on a lonely road or a pileup waiting to happen. On the highway, the most dangerous moment is when everything is calm and the outlook is great, because that's when you put on the cruise control, turn up the music and miss the lumbering RV pulling out of a rest stop.\"\n\nStock Prediction(s):", "Prediction": "\n- Archegos Inc (NASDAQ: ARCH) will decrease because they are giving investors warning signs.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because they are not giving investors warning signs.", "price_info": {"ARCH": {"company": "", "ticker": "ARCH", "move": "down", "prices": [39.81, 39.62]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up"}}}, {"link": "https://www.wsj.com/articles/feds-evans-says-he-isnt-ready-to-call-for-changes-in-central-bank-monetary-policy-11607100597", "title": "Fed's Evans Isn't Ready for More Fed Stimulus", "date": "2020-12-04 15:18", "summary": "Chicago Fed leader says government aid is quickest way to deliver new support to the economy. Federal Reserve Bank of Chicago President Charles Evans said Friday that although the latest job creation data is disappointing, he wasn't yet ready to call for changes in central-bank monetary policy.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Evans Isn't Ready for More Fed Stimulus. Chicago Fed leader says government aid is quickest way to deliver new support to the economy. Federal Reserve Bank of Chicago President Charles Evans said Friday that although the latest job creation data is disappointing, he wasn't yet ready to call for changes in central-bank monetary policy.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed will not be making any changes to their monetary policy, which will cause most stocks to stay the same.\n- The only exception will be banks, which will increase because the Fed's decision will make it easier for them to borrow money.", "price_info": {}}, {"link": "https://www.wsj.com/articles/visa-mastercard-fined-wirecard-for-dubious-transactions-11595874886", "title": "Visa, Mastercard Fined Wirecard for Dubious Transactions", "date": "2020-07-27 14:34", "summary": "Executives at card networks were concerned about Wirecard's high levels of stolen card purchases, reversed transactions. Collapsed payments processor Wirecard AG miscoded gambling transactions and had high levels of stolen card purchases and reversed transactions, leading to hefty fines from card networks Visa Inc. and Mastercard Inc., according to people familiar with the matter.", "categories": [["WSJ News Exclusive", "Finance"]], "category_links": ["https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Visa, Mastercard Fined Wirecard for Dubious Transactions. Executives at card networks were concerned about Wirecard's high levels of stolen card purchases, reversed transactions. Collapsed payments processor Wirecard AG miscoded gambling transactions and had high levels of stolen card purchases and reversed transactions, leading to hefty fines from card networks Visa Inc. and Mastercard Inc., according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Visa Inc. (NYSE: V) will decrease because of the fines from Wirecard AG.\n- Mastercard Inc. (NYSE: MA) will decrease because of the fines from Wirecard AG.\n- Wirecard AG (OTCMKTS: WRCDF) will decrease because of the fines from Visa and Mastercard.", "price_info": {"V": {"company": "", "ticker": "V", "move": "down", "prices": [197.4249, 197.1]}, "MA": {"company": "", "ticker": "MA", "move": "down"}}}, {"link": "https://www.wsj.com/articles/treasury-to-sell-165-billion-in-debt-11551979566", "title": "Treasury to Sell $165 Billion in Debt", "date": "2019-03-07 12:26", "summary": "U.S. Treasury Department next week will auction $38 billion in new debt and $127 billion in previously sold debt. The U.S. will auction $165 billion in securities next week, comprising $38 billion in new debt and $127 billion in previously sold debt. Details (all with minimum denominations of $100):", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury to Sell $165 Billion in Debt. U.S. Treasury Department next week will auction $38 billion in new debt and $127 billion in previously sold debt. The U.S. will auction $165 billion in securities next week, comprising $38 billion in new debt and $127 billion in previously sold debt. Details (all with minimum denominations of $100):\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. Treasury Department will sell $165 billion in debt next week, and this will have a positive effect on the stock prices of the companies that are involved in the auction.\n- The U.S. Treasury Department will sell $165 billion in debt next week, but this will have a negative effect on the stock prices of the companies that are involved in the auction.", "price_info": {}}, {"link": "https://www.wsj.com/articles/millions-of-americans-skip-credit-card-and-car-payments-11589985381", "title": "Millions of Americans Skip Credit-Card and Car Payments", "date": "2020-05-20 10:36", "summary": "About 15 million credit-card accounts and 3 million auto loans didn't get paid in April as the coronavirus ravaged the economy, data show. Millions of people are behind on their credit-card and auto-loan payments, the latest sign of the coronavirus pandemic's financial devastation.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Millions of Americans Skip Credit-Card and Car Payments. About 15 million credit-card accounts and 3 million auto loans didn't get paid in April as the coronavirus ravaged the economy, data show. Millions of people are behind on their credit-card and auto-loan payments, the latest sign of the coronavirus pandemic's financial devastation.\"\n\nStock Prediction(s):", "Prediction": "\n- American Express Company (NYSE: AXP) will decrease because their customers are not able to pay their bills.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because their customers are not able to pay their bills.\n- Bank of America Corporation (NYSE: BAC) will decrease because their customers are not able to pay their bills.\n- General Motors Company (NYSE: GM) will decrease because their customers are not able to pay their bills", "price_info": {"AXP": {"company": "", "ticker": "AXP", "move": "down", "prices": [90.2772, 90.4]}, "JPM": {"company": "", "ticker": "JPM", "move": "down"}, "BAC": {"company": "", "ticker": "BAC", "move": "down"}, "GM": {"company": "", "ticker": "GM", "move": "down"}}}, {"link": "https://www.wsj.com/articles/u-s-poised-to-approve-merger-of-t-mobile-sprint-11563967640", "title": "U.S. Poised to Approve Merger of T-Mobile, Sprint", "date": "2019-07-24 11:39", "summary": "Wireless companies to divest customers, assets to Dish Network to address antitrust concerns. The Justice Department is poised to approve T-Mobile US Inc.'s merger with Sprint Corp. under a plan designed to create a new wireless carrier by handing assets to satellite-TV provider Dish Network Corp. , according to people familiar with the matter.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Poised to Approve Merger of T-Mobile, Sprint. Wireless companies to divest customers, assets to Dish Network to address antitrust concerns. The Justice Department is poised to approve T-Mobile US Inc.'s merger with Sprint Corp. under a plan designed to create a new wireless carrier by handing assets to satellite-TV provider Dish Network Corp. , according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- T-Mobile US Inc. (NYSE: TMUS) will increase because the merger is being approved, and they will be getting new assets from Dish Network Corp.\n- Sprint Corp. (NYSE: S) will decrease because they are being merged into T-Mobile, and they are losing their assets to Dish Network Corp.\n- Dish Network Corp. (NASDAQ: DISH) will increase because they are getting new assets from Sprint, and they will be", "price_info": {"TMUS": {"company": "", "ticker": "TMUS", "move": "up", "prices": [79.89, 81.08]}, "S": {"company": "T-Mobile", "ticker": "S", "move": "down"}, "DISH": {"company": "", "ticker": "DISH", "move": "up"}}}, {"link": "https://www.wsj.com/articles/american-workers-could-be-about-to-get-a-lot-more-productive-11643905270", "title": "American Workers Could Be About to Get a Lot More Productive", "date": "2022-02-03 11:21", "summary": "If the pandemic eases this year, the changes it prompted might pay big dividends. American workers didn't get much more productive last year. This year could be different.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"American Workers Could Be About to Get a Lot More Productive. If the pandemic eases this year, the changes it prompted might pay big dividends. American workers didn't get much more productive last year. This year could be different.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will increase because American workers will be more productive.\n- The market will decrease because the pandemic might not ease this year.", "price_info": {}}, {"link": "https://www.wsj.com/articles/juul-sees-long-road-back-to-growth-11591888712", "title": "Juul Sees Long Road Back to Growth", "date": "2020-06-11 11:18", "summary": "Chief Executive K.C. Crosthwaite says e-cigarette maker first has to prove it can be trusted again; 'We've got a long way to go'. The chief executive of Juul Labs Inc. has a message for investors: Be patient.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Juul Sees Long Road Back to Growth. Chief Executive K.C. Crosthwaite says e-cigarette maker first has to prove it can be trusted again; 'We've got a long way to go'. The chief executive of Juul Labs Inc. has a message for investors: Be patient.\"\n\nStock Prediction(s):", "Prediction": "\n- Juul Labs Inc. (NASDAQ: JUUL) will decrease because their CEO is saying that it will take a long time for them to be trusted again.", "price_info": {"JUUL": {"company": "", "ticker": "JUUL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/borgwarner-to-buy-delphi-technologies-in-3-3-billion-deal-11580214139", "title": "BorgWarner to Buy Delphi Technologies in $3.3 Billion Deal", "date": "2020-01-28 09:45", "summary": "Transaction combines two major auto-parts makers. BorgWarner Inc. agreed to buy Delphi Technologies PLC in an all-stock transaction that values Delphi at about $3.3 billion and would combine two major auto-parts makers.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"BorgWarner to Buy Delphi Technologies in $3.3 Billion Deal. Transaction combines two major auto-parts makers. BorgWarner Inc. agreed to buy Delphi Technologies PLC in an all-stock transaction that values Delphi at about $3.3 billion and would combine two major auto-parts makers.\"\n\nStock Prediction(s):", "Prediction": "\n- BorgWarner Inc. (NYSE: BWA) will increase because they are buying Delphi Technologies in a $3.3 billion deal.\n- Delphi Technologies PLC (NYSE: DLPH) will increase because they are being bought by BorgWarner in a $3.3 billion deal.", "price_info": {"BWA": {"company": "", "ticker": "BWA", "move": "up"}, "DLPH": {"company": "", "ticker": "DLPH", "move": "up"}}}, {"link": "https://www.wsj.com/articles/investors-shouldnt-take-much-solace-from-central-bank-resolve-11583250445", "title": "Investors Shouldn't Take Much Solace From Central Bank Resolve", "date": "2020-03-03 10:47", "summary": "Monetary policy can help in fighting impact from the coronavirus, but there are problems it can't resolve. Central bankers can't cure coronavirus. But they have the drug markets desperately want, and-at least in the U.S.-they are willing to administer it. Stocks initially jumped after the Federal Reserve's emergency intermeeting rate cut on Tuesday, the first since the financial crisis. The question is, what use is yet more cheap money for an economy suffering from broken supply chains and from consumers and businesses hunkering down?", "categories": [["Markets", "Streetwise"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/streetwise?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investors Shouldn't Take Much Solace From Central Bank Resolve. Monetary policy can help in fighting impact from the coronavirus, but there are problems it can't resolve. Central bankers can't cure coronavirus. But they have the drug markets desperately want, and-at least in the U.S.-they are willing to administer it. Stocks initially jumped after the Federal Reserve's emergency intermeeting rate cut on Tuesday, the first since the financial crisis. The question is, what use is yet more cheap money for an economy suffering from broken supply chains and from consumers and businesses hunkering down?\"\n\nStock Prediction(s):", "Prediction": "\n- The market will continue to go down because the Fed's emergency intermeeting rate cut is not enough.\n- The market will rebound because the Fed is doing everything they can to help the economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/billionaires-tax-bill-us-democrats-what-to-know-11635183720", "title": "What to Know About the Democrats' Plan to Tax Billionaires", "date": "2021-10-27 10:25", "summary": "Democrats are racing to finish writing a new tax on billionaires' unrealized capital gains. WASHINGTON-Democrats are considering a new tax on billionaires to help pay for President Biden's agenda.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What to Know About the Democrats' Plan to Tax Billionaires. Democrats are racing to finish writing a new tax on billionaires' unrealized capital gains. WASHINGTON-Democrats are considering a new tax on billionaires to help pay for President Biden's agenda.\"\n\nStock Prediction(s):", "Prediction": "\n- The proposed tax on billionaires will not have a significant impact on the stock prices of the affected companies.\n- The proposed tax on billionaires will have a negative impact on the stock prices of the affected companies.", "price_info": {}}, {"link": "https://www.wsj.com/articles/bob-woodward-book-sells-600-000-copies-in-first-week-shy-of-bolton-mary-trump-titles-11600877459", "title": "Woodward's Trump Book Sells 600,000 Copies in First Week", "date": "2020-09-23 12:11", "summary": "'Rage' revealed President Trump understood coronavirus dangers early in crisis but publicly minimized risks. Journalist Bob Woodward's latest book, \"Rage,\" sold 600,000 copies across all formats through its first week on sale in the U.S., fewer than two other recent high-profile titles about the Trump administration.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Woodward's Trump Book Sells 600,000 Copies in First Week. 'Rage' revealed President Trump understood coronavirus dangers early in crisis but publicly minimized risks. Journalist Bob Woodward's latest book, \"Rage,\" sold 600,000 copies across all formats through its first week on sale in the U.S., fewer than two other recent high-profile titles about the Trump administration.\"\n\nStock Prediction(s):", "Prediction": "\n- Simon & Schuster, Inc. (NASDAQ: CBS) will increase because they published Woodward's book.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are the main distributor of Woodward's book.\n- Barnes & Noble, Inc. (NYSE: BKS) will increase because they are the main distributor of Woodward's book.", "price_info": {"BKS": {"company": "", "ticker": "BKS", "move": null}, "CBS": {"company": "", "ticker": "CBS", "move": "up"}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up"}}}, {"link": "https://www.wsj.com/articles/qualcomms-5g-call-will-take-a-while-to-connect-11556818430", "title": "Qualcomm's 5G Call Will Take a While to Connect", "date": "2019-05-02 13:33", "summary": "Boost from Apple's deal is offset by a weakening smartphone market. Qualcomm has required no small amount of patience from investors over the past few years. Its latest results show that even more will be required.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Qualcomm's 5G Call Will Take a While to Connect. Boost from Apple's deal is offset by a weakening smartphone market. Qualcomm has required no small amount of patience from investors over the past few years. Its latest results show that even more will be required.\"\n\nStock Prediction(s):", "Prediction": "\n- Qualcomm Inc. (NASDAQ: QCOM) will decrease because the 5G market is not as strong as they thought it would be, and they are also competing with other companies in this market.\n- Apple Inc. (NASDAQ: AAPL) will increase because they have a deal with Qualcomm, and they are also expanding into the 5G market.\n- Intel Corporation (NASDAQ: INTC) will increase because they are also expanding into the 5", "price_info": {"QCOM": {"company": "", "ticker": "QCOM", "move": "down"}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [209.55, 209.1501]}, "INTC": {"company": "", "ticker": "INTC", "move": "up"}}}, {"link": "https://www.wsj.com/articles/us-gdp-economic-growth-first-quarter-2021-11619658605", "title": "U.S. Economy Grew at 6.4% Annual Rate in First Quarter", "date": "2021-04-29 12:16", "summary": "GDP grew at 6.4% annual rate in the quarter, leaving economy within 1% of its peak. A burst of growth put the U.S. economy just a shave below its pre-pandemic size in the first quarter, extending what is shaping up to be a rapid, consumer-driven recovery this year.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Economy Grew at 6.4% Annual Rate in First Quarter. GDP grew at 6.4% annual rate in the quarter, leaving economy within 1% of its peak. A burst of growth put the U.S. economy just a shave below its pre-pandemic size in the first quarter, extending what is shaping up to be a rapid, consumer-driven recovery this year.\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. economy will continue to grow at a rapid rate because of the consumer-driven recovery.\n- The stock market will continue to go up because of the strong economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/general-mills-reports-stronger-sales-but-growth-moderates-11600863778", "title": "General Mills Aims to Protect Coronavirus Sales Boost", "date": "2020-09-23 11:53", "summary": "Grocery sales are moderating, prompting food makers to make marketing and operational changes. General Mills Inc. said the coronavirus-fueled surge in grocery sales is waning, increasing pressure on food makers to hold on to the new shoppers who tried their brands during the height of the pandemic.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"General Mills Aims to Protect Coronavirus Sales Boost. Grocery sales are moderating, prompting food makers to make marketing and operational changes. General Mills Inc. said the coronavirus-fueled surge in grocery sales is waning, increasing pressure on food makers to hold on to the new shoppers who tried their brands during the height of the pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- General Mills, Inc. (NYSE: GIS) will decrease because their sales are waning.\n- Kellogg Company (NYSE: K) will decrease because their sales are waning.\n- Mondelez International, Inc. (NASDAQ: MDLZ) will decrease because their sales are waning.\n- PepsiCo, Inc. (NASDAQ: PEP) will decrease because their sales are waning.", "price_info": {"GIS": {"company": "", "ticker": "GIS", "move": "down"}, "K": {"company": "", "ticker": "K", "move": "down"}, "MDLZ": {"company": "", "ticker": "MDLZ", "move": "down", "prices": [55.5199, 55.385]}, "PEP": {"company": "", "ticker": "PEP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/mcdonalds-introduces-customer-loyalty-program-11624376506", "title": "McDonald's Loyalty Program Goes National", "date": "2021-06-22 14:16", "summary": "Restaurant chain joins others in industry to offer rewards to promote repeat visits. McDonald's Corp. said it is rolling out a loyalty program nationally next month, the latest restaurant chain to invest in rewards for repeat customers.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"McDonald's Loyalty Program Goes National. Restaurant chain joins others in industry to offer rewards to promote repeat visits. McDonald's Corp. said it is rolling out a loyalty program nationally next month, the latest restaurant chain to invest in rewards for repeat customers.\"\n\nStock Prediction(s):", "Prediction": "\n- McDonald's Corp. (NYSE: MCD) will increase because they are offering rewards to promote repeat visits.\n- Starbucks Corp. (NASDAQ: SBUX) will increase because they are also offering rewards to promote repeat visits.\n- Dunkin' Brands Group Inc. (NASDAQ: DNKN) will increase because they are also offering rewards to promote repeat visits.", "price_info": {"MCD": {"company": "", "ticker": "MCD", "move": "up", "prices": [234.02, 233.9]}, "SBUX": {"company": "", "ticker": "SBUX", "move": "up"}, "DNKN": {"company": "", "ticker": "DNKN", "move": "up"}}}, {"link": "https://www.wsj.com/articles/how-to-make-money-decisions-when-the-future-is-uncertain-11595004879", "title": "How to Make Money Decisions When the Future Is Uncertain", "date": "2020-07-17 12:54", "summary": "Not knowing what lies ahead can freeze you in your tracks. Here's how to break the paralysis to weigh financial choices responsibly.. The economic shutdown that began for many this spring has led to layoffs, delayed goals, emergency account withdrawals and other painful financial challenges. With the coronavirus pandemic causing so much uncertainty in the world, some people are having trouble making financial decisions.", "categories": [["Markets", "Personal Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/personal-finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Make Money Decisions When the Future Is Uncertain. Not knowing what lies ahead can freeze you in your tracks. Here's how to break the paralysis to weigh financial choices responsibly.. The economic shutdown that began for many this spring has led to layoffs, delayed goals, emergency account withdrawals and other painful financial challenges. With the coronavirus pandemic causing so much uncertainty in the world, some people are having trouble making financial decisions.\"\n\nStock Prediction(s):", "Prediction": "\n- People will start to become more conservative with their money, and will not want to invest in stocks that are uncertain.\n- People will start to hoard money, and will not want to spend it on anything that is uncertain.\n- People will start to look for more stable investments, and will not want to invest in stocks that are uncertain.", "price_info": {}}, {"link": "https://www.wsj.com/articles/netflix-movies-could-use-more-thumbs-up-11571675369", "title": "Netflix Movies Could Use More Thumbs Up", "date": "2019-10-21 12:29", "summary": "Streaming giant readies its most ambitious slate yet of original movies, but quality so far has been mixed. Netflix is readying a box-office assault. It could use fewer misfires.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Netflix Movies Could Use More Thumbs Up. Streaming giant readies its most ambitious slate yet of original movies, but quality so far has been mixed. Netflix is readying a box-office assault. It could use fewer misfires.\"\n\nStock Prediction(s):", "Prediction": "\n- Netflix, Inc. (NASDAQ: NFLX) will increase because they are releasing more movies, and the quality has been mixed so far.", "price_info": {"NFLX": {"company": "", "ticker": "NFLX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/u-s-economy-is-in-a-contraction-says-larry-kudlow-11586267427", "title": "U.S. Economy Is in a Contraction, Says Larry Kudlow", "date": "2020-04-07 09:50", "summary": "Economy could reopen in four to eight weeks, says National Economic Council director. Breaking News:", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Economy Is in a Contraction, Says Larry Kudlow. Economy could reopen in four to eight weeks, says National Economic Council director. Breaking News:\"\n\nStock Prediction(s):", "Prediction": "\n- All stocks will decrease because the U.S. economy is in a contraction.", "price_info": {}}, {"link": "https://www.wsj.com/articles/investors-cheer-europes-step-toward-united-bond-market-11590602859", "title": "Investors Cheer Europe's Step Toward United Bond Market", "date": "2020-05-27 14:07", "summary": "European Union proposes borrowing \u20ac750 billion from capital markets to aid recovery from coronavirus pandemic. Bond investors cautiously cheered a proposal by the European Union to issue centrally backed bonds for the first time, a move that attempts to address financial divisions that have long plagued the eurozone.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investors Cheer Europe's Step Toward United Bond Market. European Union proposes borrowing \u20ac750 billion from capital markets to aid recovery from coronavirus pandemic. Bond investors cautiously cheered a proposal by the European Union to issue centrally backed bonds for the first time, a move that attempts to address financial divisions that have long plagued the eurozone.\"\n\nStock Prediction(s):", "Prediction": "\n- European Union (EU) will increase because this proposal signals a step forward in their recovery from the coronavirus pandemic.\n- Germany (EWG) will increase because they are the largest economy in the European Union.\n- Spain (EWP) will increase because they are a large economy in the European Union and they have been hit hard by the coronavirus pandemic.\n- Italy (EWI) will increase because they are a large economy in", "price_info": {"EU": {"company": "European Union", "ticker": "EU", "move": "up"}, "EWG": {"company": "Germany", "ticker": "EWG", "move": "up"}, "EWP": {"company": "Spain", "ticker": "EWP", "move": "up"}, "EWI": {"company": "Italy", "ticker": "EWI", "move": "up"}}}, {"link": "https://www.wsj.com/articles/elizabeth-warren-targets-sacklers-lawsuit-exemptions-in-purdue-bankruptcy-11627041600", "title": "Warren Targets Sacklers' Legal Protection in Purdue Bankruptcy", "date": "2021-07-23 11:46", "summary": "'If the Sacklers want to stop those lawsuits, they can file for bankruptcy just like normal people do,' the Massachusetts senator says. Sen. Elizabeth Warren is bolstering efforts by Democratic lawmakers to stop the owners of OxyContin maker Purdue Pharma LP from using the company's bankruptcy to shield themselves from lawsuits blaming them for the opioid crisis.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Warren Targets Sacklers' Legal Protection in Purdue Bankruptcy. 'If the Sacklers want to stop those lawsuits, they can file for bankruptcy just like normal people do,' the Massachusetts senator says. Sen. Elizabeth Warren is bolstering efforts by Democratic lawmakers to stop the owners of OxyContin maker Purdue Pharma LP from using the company's bankruptcy to shield themselves from lawsuits blaming them for the opioid crisis.\"\n\nStock Prediction(s):", "Prediction": "\n- Purdue Pharma LP (NYSE: PPHM) will decrease because they will be unable to shield themselves from lawsuits.\n- The Sackler family will decrease because they will be unable to shield themselves from lawsuits.", "price_info": {"PPHM": {"company": "", "ticker": "PPHM", "move": "down"}}}, {"link": "https://www.wsj.com/articles/pharmacies-cant-ignore-amazon-drug-threat-11605711620", "title": "Pharmacies Can't Ignore Amazon Drug Threat", "date": "2020-11-18 10:00", "summary": "Shares of CVS Health and Walgreens Boots Alliance plunged Tuesday after Amazon launched online prescription delivery service. Amazon . com, the boogeyman of retail, is stalking pharmacies now. Shareholders are rightly spooked.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Pharmacies Can't Ignore Amazon Drug Threat. Shares of CVS Health and Walgreens Boots Alliance plunged Tuesday after Amazon launched online prescription delivery service. Amazon . com, the boogeyman of retail, is stalking pharmacies now. Shareholders are rightly spooked.\"\n\nStock Prediction(s):", "Prediction": "\n- CVS Health Corporation (NYSE: CVS) will decrease because Amazon is entering the market and they will be unable to compete.\n- Walgreens Boots Alliance, Inc. (NASDAQ: WBA) will decrease because Amazon is entering the market and they will be unable to compete.", "price_info": {"CVS": {"company": "", "ticker": "CVS", "move": "down", "prices": [68, 67.4116]}, "WBA": {"company": "", "ticker": "WBA", "move": "down"}}}, {"link": "https://www.wsj.com/articles/why-the-amazon-jpmorgan-berkshire-venture-collapsed-health-care-was-too-big-a-problem-11610039485", "title": "Why the Amazon, JPMorgan, Berkshire Venture Collapsed", "date": "2021-01-07 12:11", "summary": "Data-sharing, bureaucracy and competition stalled progress of Haven venture. Amazon.com Inc., JPMorgan Chase & Co. and Berkshire Hathaway Inc. set out three years ago to join and transform health care. Instead, they struggled to solve even fundamental challenges, such as understanding what some kinds of care actually cost.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why the Amazon, JPMorgan, Berkshire Venture Collapsed. Data-sharing, bureaucracy and competition stalled progress of Haven venture. Amazon.com Inc., JPMorgan Chase & Co. and Berkshire Hathaway Inc. set out three years ago to join and transform health care. Instead, they struggled to solve even fundamental challenges, such as understanding what some kinds of care actually cost.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because their venture into health care has failed.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because their venture into health care has failed.\n- Berkshire Hathaway Inc. (NYSE: BRK.A) will decrease because their venture into health care has failed.", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [136.27, 136.23]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down"}}}, {"link": "https://www.wsj.com/articles/thinly-staffed-nursing-homes-face-challenges-in-pandemic-11588343407", "title": "Thinly Staffed Nursing Homes Face Challenges in Pandemic", "date": "2020-05-01 10:30", "summary": "For-profit companies had tighter staffing on average before coronavirus hit, analysis shows. Nursing homes around the U.S. are facing a staffing crisis, as the coronavirus sidelines members of a workforce that was already thinly stretched in many facilities before the pandemic.", "categories": [["WSJ News Exclusive", "U.S."]], "category_links": ["https://www.wsj.com/news/us?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Thinly Staffed Nursing Homes Face Challenges in Pandemic. For-profit companies had tighter staffing on average before coronavirus hit, analysis shows. Nursing homes around the U.S. are facing a staffing crisis, as the coronavirus sidelines members of a workforce that was already thinly stretched in many facilities before the pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- HCP, Inc. (NYSE: HCP) will increase because they are a healthcare REIT that owns a large number of nursing homes.\n- Kindred Healthcare, Inc. (NYSE: KND) will increase because they are a healthcare REIT that owns a large number of nursing homes.\n- Ensign Group, Inc. (NASDAQ: ENSG) will increase because they are a healthcare provider that operates a large number of nursing homes.", "price_info": {"HCP": {"company": "", "ticker": "HCP", "move": "up"}, "KND": {"company": "", "ticker": "KND", "move": "up"}, "ENSG": {"company": "", "ticker": "ENSG", "move": "up"}}}, {"link": "https://www.wsj.com/articles/cyberattacks-ransomware-energy-infrastructure-11626097901", "title": "Cyberattacks and Ransomware: How Can We Protect Our Energy Infrastructure?", "date": "2021-07-12 09:58", "summary": "The ransomware attack that brought down the Colonial Pipeline highlighted the industry's vulnerability. We asked experts to weigh in on how the U.S. can bolster its defenses.. A ransomware attack forced the largest U.S. fuel pipeline to shut down for six days in May and led to gasoline shortages across several Southeastern states. In its wake, U.S. officials have sought to bolster the defenses of an industry that for years has had fewer cybersecurity rules compared with other critical infrastructure sectors.", "categories": [["Business", "Energy", "Journal Reports: Energy"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/energy-oil-gas?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-energy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Cyberattacks and Ransomware: How Can We Protect Our Energy Infrastructure?. The ransomware attack that brought down the Colonial Pipeline highlighted the industry's vulnerability. We asked experts to weigh in on how the U.S. can bolster its defenses.. A ransomware attack forced the largest U.S. fuel pipeline to shut down for six days in May and led to gasoline shortages across several Southeastern states. In its wake, U.S. officials have sought to bolster the defenses of an industry that for years has had fewer cybersecurity rules compared with other critical infrastructure sectors.\"\n\nStock Prediction(s):", "Prediction": "\n- Cybersecurity stocks (e.g. Palo Alto Networks Inc (NYSE: PANW), Fortinet Inc (NASDAQ: FTNT)) will increase because of the heightened awareness of the need for cybersecurity in the energy sector.\n- Energy stocks (e.g. Exxon Mobil Corporation (NYSE: XOM), Chevron Corporation (NYSE: CVX)) will decrease because of the increased awareness of the need for cybersecurity in the energy sector.", "price_info": {"PANW": {"company": "", "ticker": "PANW", "move": null}, "XOM": {"company": "", "ticker": "XOM", "move": null}, "CVX": {"company": "", "ticker": "CVX", "move": "down"}, "FTNT": {"company": "", "ticker": "FTNT", "move": "up"}}}, {"link": "https://www.wsj.com/articles/cdc-backs-pfizer-biontech-booster-for-immunocompromised-children-11641314181", "title": "CDC Backs Pfizer-BioNTech Booster for Immunocompromised Children", "date": "2022-01-04 11:36", "summary": "Agency recommends extra dose for children 5 to 11 years who are moderately or severely immunocompromised. The Centers for Disease Control and Prevention recommended that many children with weakened immune systems get a booster from Pfizer Inc. and BioNTech SE four weeks after their second shot.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"CDC Backs Pfizer-BioNTech Booster for Immunocompromised Children. Agency recommends extra dose for children 5 to 11 years who are moderately or severely immunocompromised. The Centers for Disease Control and Prevention recommended that many children with weakened immune systems get a booster from Pfizer Inc. and BioNTech SE four weeks after their second shot.\"\n\nStock Prediction(s):", "Prediction": "\n- Pfizer Inc (NYSE: PFE) will increase because the CDC has endorsed their product.\n- BioNTech SE (BNTX) will increase because the CDC has endorsed their product.", "price_info": {"BNTX": {"company": "BioNTech SE", "ticker": "BNTX", "move": "up"}, "PFE": {"company": "", "ticker": "PFE", "move": null}}}, {"link": "https://www.wsj.com/articles/feds-bullard-says-inflation-could-start-to-pick-up-soon-11600451309", "title": "Fed's Bullard Says Inflation Could Start to Pick Up Soon", "date": "2020-09-18 13:48", "summary": "The St. Louis Fed president also says the economy could grow 30% in the third quarter from its second-quarter depths. Federal Reserve Bank of St. Louis leader James Bullard said higher inflation is coming to the U.S. economy, but didn't indicate that would be a worrisome development.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Bullard Says Inflation Could Start to Pick Up Soon. The St. Louis Fed president also says the economy could grow 30% in the third quarter from its second-quarter depths. Federal Reserve Bank of St. Louis leader James Bullard said higher inflation is coming to the U.S. economy, but didn't indicate that would be a worrisome development.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve Bank of St. Louis (NYSE: STL) will increase because Bullard says that inflation is coming, and that the economy is growing.\n- The rest of the banking sector will also increase because of this news.", "price_info": {"STL": {"company": "", "ticker": "STL", "move": "up"}}}, {"link": "https://www.wsj.com/articles/aon-pushes-into-online-insurance-for-small-business-11574259300", "title": "Aon Pushes Into Online Insurance for Small Business", "date": "2019-11-20 10:09", "summary": "Company to buy CoverWallet, a platform that allows businesses to get price quotes and buy policies without speaking to an agent. Insurance brokerage Aon PLC has agreed to acquire startup CoverWallet, as insurers are competing to figure out how to sell insurance to small businesses online.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Aon Pushes Into Online Insurance for Small Business. Company to buy CoverWallet, a platform that allows businesses to get price quotes and buy policies without speaking to an agent. Insurance brokerage Aon PLC has agreed to acquire startup CoverWallet, as insurers are competing to figure out how to sell insurance to small businesses online.\"\n\nStock Prediction(s):", "Prediction": "\n- Aon plc (NYSE: AON) will increase because they are expanding their business model to include online insurance for small businesses.\n- The Hartford Financial Services Group, Inc. (NYSE: HIG) will decrease because they are not expanding their business model to include online insurance for small businesses.", "price_info": {"AON": {"company": "", "ticker": "AON", "move": "up", "prices": [200.55, 199.9292]}, "HIG": {"company": "", "ticker": "HIG", "move": "down"}}}, {"link": "https://www.wsj.com/articles/for-boeing-delivering-will-be-tough-11619626332", "title": "For Boeing, Delivering Will Be Tough", "date": "2021-04-28 12:12", "summary": "First-quarter results showcase struggles to shrink stockpile of undelivered planes. Boeing 's big problem isn't selling the infamous 737 MAX. It is delivering it.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"For Boeing, Delivering Will Be Tough. First-quarter results showcase struggles to shrink stockpile of undelivered planes. Boeing 's big problem isn't selling the infamous 737 MAX. It is delivering it.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing (NYSE: BA) will decrease because they are struggling to shrink their stockpile of undelivered planes.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down"}}}, {"link": "https://www.wsj.com/articles/uber-ceo-regrets-calling-murder-of-saudi-journalist-a-mistake-11573498309", "title": "Uber CEO Regrets Calling Murder of Saudi Journalist a 'Mistake'", "date": "2019-11-11 13:51", "summary": "Chief Executive Dara Khosrowshahi says he misspoke during a recent video interview with Axios. Uber Technologies Inc. Chief Executive Dara Khosrowshahi said he regretted calling the murder of Saudi Arabian journalist Jamal Khashoggi a \"mistake\" in a recent video interview, opening a new front of controversy for the ride-hailing giant.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Uber CEO Regrets Calling Murder of Saudi Journalist a 'Mistake'. Chief Executive Dara Khosrowshahi says he misspoke during a recent video interview with Axios. Uber Technologies Inc. Chief Executive Dara Khosrowshahi said he regretted calling the murder of Saudi Arabian journalist Jamal Khashoggi a \"mistake\" in a recent video interview, opening a new front of controversy for the ride-hailing giant.\"\n\nStock Prediction(s):", "Prediction": "\n- Uber Technologies Inc. (NYSE: UBER) will decrease because their CEO has openly stated that he regrets calling the murder of Saudi Arabian journalist Jamal Khashoggi a \"mistake\".", "price_info": {"UBER": {"company": "", "ticker": "UBER", "move": "down", "prices": [27.11, 27.165]}}}, {"link": "https://www.wsj.com/articles/trio-of-central-banks-surprises-markets-with-rate-cuts-11565175324", "title": "Trio of Central Banks Surprise Markets With Aggressive Rate Cuts", "date": "2019-08-07 12:46", "summary": "Global easing cycle may turn out to be longer and deeper than previously expected. Three central banks in the Asia-Pacific region lowered interest rates in a surprisingly aggressive fashion Wednesday as the fallout from the U.S.-China trade war intensified, suggesting the global rate-cut cycle will gather steam in the months ahead.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trio of Central Banks Surprise Markets With Aggressive Rate Cuts. Global easing cycle may turn out to be longer and deeper than previously expected. Three central banks in the Asia-Pacific region lowered interest rates in a surprisingly aggressive fashion Wednesday as the fallout from the U.S.-China trade war intensified, suggesting the global rate-cut cycle will gather steam in the months ahead.\"\n\nStock Prediction(s):", "Prediction": "\n- The interest rate cuts will cause a decrease in the value of the U.S. dollar.\n- The interest rate cuts will cause an increase in the value of gold.\n- The interest rate cuts will cause an increase in the value of bonds.", "price_info": {}}, {"link": "https://www.wsj.com/articles/barclays-profit-soars-on-investment-banking-11627455558", "title": "Barclays Profit Soars on Investment Banking", "date": "2021-07-28 14:49", "summary": "Chief Executive Jes Staley has staked his strategy on reinvigorating the investment bank. LONDON- Barclays PLC Wednesday said its net profit rose in the second quarter, driven by a strong performance in its investment bank.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Barclays Profit Soars on Investment Banking. Chief Executive Jes Staley has staked his strategy on reinvigorating the investment bank. LONDON- Barclays PLC Wednesday said its net profit rose in the second quarter, driven by a strong performance in its investment bank.\"\n\nStock Prediction(s):", "Prediction": "\n- Barclays plc (NYSE: BCS) will increase because their investment banking is doing well.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are also a competitor in the investment banking space.\n- Goldman Sachs Group Inc. (NYSE: GS) will decrease because they are also a competitor in the investment banking space.", "price_info": {"BCS": {"company": "", "ticker": "BCS", "move": "up"}, "JPM": {"company": "", "ticker": "JPM", "move": "down"}, "GS": {"company": "", "ticker": "GS", "move": "down"}}}, {"link": "https://www.wsj.com/articles/bank-on-jpmorgan-chase-in-uncertain-times-11551202502", "title": "Bank on JPMorgan Chase in Uncertain Times", "date": "2019-02-26 12:35", "summary": "Among major U.S. banks, JPMorgan Chase has done the best at hitting its profitability target and ensuring it won't slip too much in a downturn. Much like everyone else at the moment, JPMorgan Chase & Co. is confused about where the economy is headed. It has less to worry about than most, though.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bank on JPMorgan Chase in Uncertain Times. Among major U.S. banks, JPMorgan Chase has done the best at hitting its profitability target and ensuring it won't slip too much in a downturn. Much like everyone else at the moment, JPMorgan Chase & Co. is confused about where the economy is headed. It has less to worry about than most, though.\"\n\nStock Prediction(s):", "Prediction": "\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are one of the few banks that is doing well in this uncertain time, and they have a good chance of hitting their profitability target.\n- Bank of America Corp (NYSE: BAC) will decrease because they are not doing as well as JPMorgan Chase, and they may not be able to hit their profitability target.\n- Wells Fargo & Co (NYSE: WFC) will decrease because they", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [105.15, 104.8333]}, "BAC": {"company": "", "ticker": "BAC", "move": "down"}, "WFC": {"company": "", "ticker": "WFC", "move": "down"}}}, {"link": "https://www.wsj.com/articles/why-hidden-tvs-like-samsungs-the-frame-are-trendingand-which-one-to-buy-11631900938", "title": "Why Hidden TVs like Samsung's 'The Frame' Are Trending-and Which One to Buy", "date": "2021-09-17 13:48", "summary": "Discreet, almost invisible TVs-some look like mirrors, some roll away into a base-marry elevated aesthetics with superior viewing quality. But price is a big factor.. WHEN YOU FALL on the extreme ends of the TV-consumer spectrum-either a hard-core gamer or a stubborn Luddite-choosing a set is straightforward: You go all in even if it dominates the room, or you get nothing at all. But what if, like most of us, you're somewhere in the middle? As far as off-the-rack fixes go, few are less obtrusive than the Frame- Samsung 's \"lifestyle\" TV designed to look just like a picture hanging on the wall. But if even a faux Modigliani is too much visual clutter for you, the Frame might not go far enough. The good news: There are alternatives. Namely, a handful of ultra-discreet sets that offer a peek at what the future of \"invisible\" A/V might hold. The bad news: For now, at least, they'll cost you more (sometimes, a lot more). Are they worth the splurge? We spoke with tech experts, interior designers, and savvy homeowners to find out more about the Frame and its rivals.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why Hidden TVs like Samsung's 'The Frame' Are Trending-and Which One to Buy. Discreet, almost invisible TVs-some look like mirrors, some roll away into a base-marry elevated aesthetics with superior viewing quality. But price is a big factor.. WHEN YOU FALL on the extreme ends of the TV-consumer spectrum-either a hard-core gamer or a stubborn Luddite-choosing a set is straightforward: You go all in even if it dominates the room, or you get nothing at all. But what if, like most of us, you're somewhere in the middle? As far as off-the-rack fixes go, few are less obtrusive than the Frame- Samsung 's \"lifestyle\" TV designed to look just like a picture hanging on the wall. But if even a faux Modigliani is too much visual clutter for you, the Frame might not go far enough. The good news: There are alternatives. Namely, a handful of ultra-discreet sets that offer a peek at what the future of \"invisible\" A/V might hold. The bad news: For now, at least, they'll cost you more (sometimes, a lot more). Are they worth the splurge? We spoke with tech experts, interior designers, and savvy homeowners to find out more about the Frame and its rivals.\"\n\nStock Prediction(s):", "Prediction": "\n- Samsung Electronics Co Ltd (OTC: SSNLF) will increase because their Frame TV is becoming popular and people are willing to spend more for it.\n- Sony Corp (NYSE: SNE) will increase because their A8G OLED TV is becoming popular and people are willing to spend more for it.\n- LG Display Co Ltd (NYSE: LPL) will increase because their OLED panels are being used in more TVs.", "price_info": {"SNE": {"company": "", "ticker": "SNE", "move": "up"}, "LPL": {"company": "", "ticker": "LPL", "move": "up"}}}, {"link": "https://www.wsj.com/articles/trading-surge-strains-online-brokerages-11611692363", "title": "Trading Surge Strains Online Brokerages", "date": "2021-01-26 15:19", "summary": "A flood of individual investors into the stock market has led to temporary outages at some brokerages. Stock trading volume has surged in the past week, and Wall Street's online brokers are struggling to keep up.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trading Surge Strains Online Brokerages. A flood of individual investors into the stock market has led to temporary outages at some brokerages. Stock trading volume has surged in the past week, and Wall Street's online brokers are struggling to keep up.\"\n\nStock Prediction(s):", "Prediction": "\n- Charles Schwab Corporation (NYSE: SCHW) will increase because they are one of the few brokerages that have not had outages.\n- TD Ameritrade Holding Corporation (NASDAQ: AMTD) will increase because they are one of the few brokerages that have not had outages.\n- E*TRADE Financial Corporation (NASDAQ: ETFC) will increase because they are one of the few brokerages that have not had outages.", "price_info": {"SCHW": {"company": "", "ticker": "SCHW", "move": "up"}, "AMTD": {"company": "", "ticker": "AMTD", "move": "up"}, "ETFC": {"company": "", "ticker": "ETFC", "move": "up"}}}, {"link": "https://www.wsj.com/articles/sick-day-for-biotech-stocks-wont-last-11631291680", "title": "Sick Day for Biotech Stocks Won't Last", "date": "2021-09-10 12:34", "summary": "Tough talk from the Biden Administration on drug prices and weak sales have harmed biotech stocks, but these symptoms likely won't last. One problem with high-risk, high-reward investments like biotechnology companies is that disappointment can come in many forms. This week, just about everything that could go wrong for the sector did.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Sick Day for Biotech Stocks Won't Last. Tough talk from the Biden Administration on drug prices and weak sales have harmed biotech stocks, but these symptoms likely won't last. One problem with high-risk, high-reward investments like biotechnology companies is that disappointment can come in many forms. This week, just about everything that could go wrong for the sector did.\"\n\nStock Prediction(s):", "Prediction": "\n- Biotech stocks will rebound because the administration's tough talk on drug prices was only a short-term problem.\n- Large pharmaceutical companies like Johnson & Johnson (NYSE: JNJ) and Pfizer Inc (NYSE: PFE) will rebound because they are not as dependent on biotech stocks as smaller companies.\n- Smaller biotech companies like Moderna Inc (NASDAQ: MRNA) will rebound because they are more dependent on biotech stocks and are therefore more sensitive", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": null, "prices": [167.2349, 167.5299]}, "PFE": {"company": "", "ticker": "PFE", "move": null}, "MRNA": {"company": "", "ticker": "MRNA", "move": null}}}, {"link": "https://www.wsj.com/articles/the-email-is-the-message-for-wall-street-11583430366", "title": "The Email Is the Message for Wall Street", "date": "2020-03-05 12:50", "summary": "Banks' outbound emails to clients jumped 25% on Monday. Markets move. Bankers email.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Email Is the Message for Wall Street. Banks' outbound emails to clients jumped 25% on Monday. Markets move. Bankers email.\"\n\nStock Prediction(s):", "Prediction": "\n- Bank of America Corporation (NYSE: BAC) will increase because their outbound emails to clients jumped 25%.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because their outbound emails to clients jumped 25%.\n- Goldman Sachs Group, Inc. (NYSE: GS) will increase because their outbound emails to clients jumped 25%.\n- Citigroup, Inc. (NYSE: C) will increase because their outbound emails to clients jumped 25", "price_info": {"BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [26.7735, 26.8225]}, "JPM": {"company": "", "ticker": "JPM", "move": "up"}, "GS": {"company": "", "ticker": "GS", "move": "up"}, "C": {"company": "America", "ticker": "C", "move": "up"}}}, {"link": "https://www.wsj.com/articles/big-banks-trading-desks-suffer-despite-market-rally-11561730520", "title": "Big Banks' Trading Desks Suffer Despite Market Rally", "date": "2019-06-28 10:02", "summary": "Clients have lingering doubts about market resiliency and are holding back placing bets that earn traders big fees. Banks are bracing for a third-straight quarter of declines in the business of dealing stocks, bonds and currencies.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Big Banks' Trading Desks Suffer Despite Market Rally. Clients have lingering doubts about market resiliency and are holding back placing bets that earn traders big fees. Banks are bracing for a third-straight quarter of declines in the business of dealing stocks, bonds and currencies.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldman Sachs Group Inc (NYSE: GS) will decrease because their trading desks are suffering.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because their trading desks are suffering.\n- Bank of America Corp (NYSE: BAC) will decrease because their trading desks are suffering.\n- Citigroup Inc (NYSE: C) will decrease because their trading desks are suffering.", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "down"}, "JPM": {"company": "", "ticker": "JPM", "move": "down"}, "BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [28.94, 29.02]}, "C": {"company": "", "ticker": "C", "move": "down"}}}, {"link": "https://www.wsj.com/articles/from-1720-to-tesla-fomo-never-sleeps-11594994422", "title": "From 1720 to Tesla, FOMO Never Sleeps", "date": "2020-07-17 10:00", "summary": "The South Sea bubble is the classic story of an investing mania. Are investors today any wiser?. Back in Business is a new, occasional column that puts the present day in perspective by looking at business history and those who shaped it. Read the first installment here. Mr. Zweig's Intelligent Investor column will return next week.", "categories": [["Business", "Back in Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/back-in-business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"From 1720 to Tesla, FOMO Never Sleeps. The South Sea bubble is the classic story of an investing mania. Are investors today any wiser?. Back in Business is a new, occasional column that puts the present day in perspective by looking at business history and those who shaped it. Read the first installment here. Mr. Zweig's Intelligent Investor column will return next week.\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla, Inc. (TSLA) will continue to increase because it is a company that is constantly innovating and changing the game.\n- The South Sea Company (SSC) will continue to decrease because it was a company that was built on a false premise.", "price_info": {"TSLA": {"company": "Tesla, Inc.", "ticker": "TSLA", "move": "up", "prices": [1504.21, 1506.3088]}, "SSC": {"company": "Sea Company", "ticker": "SSC", "move": "down"}}}, {"link": "https://www.wsj.com/articles/walmarts-sales-rise-even-as-online-orders-cool-11629200484", "title": "Walmart Earnings Show Sales Rose as Shoppers Returned to Stores", "date": "2021-08-17 10:14", "summary": "Retail giant says U.S. store visits improved despite Delta surge while online sales growth slowed. Walmart Inc. logged another quarter of rising U.S. sales as a return to in-store shopping offset slower online growth, at a time when retailers are navigating rising costs, supply chain snarls and an uptick in Covid-19 cases in many parts of the country.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Walmart Earnings Show Sales Rose as Shoppers Returned to Stores. Retail giant says U.S. store visits improved despite Delta surge while online sales growth slowed. Walmart Inc. logged another quarter of rising U.S. sales as a return to in-store shopping offset slower online growth, at a time when retailers are navigating rising costs, supply chain snarls and an uptick in Covid-19 cases in many parts of the country.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will increase because their earnings show that sales are rising as shoppers are returning to stores.\n- Target Corporation (NYSE: TGT) will decrease because their earnings show that sales are declining as shoppers are staying home.\n- Costco Wholesale Corporation (NASDAQ: COST) will decrease because their earnings show that sales are declining as shoppers are staying home.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up"}, "TGT": {"company": "", "ticker": "TGT", "move": "down", "prices": [253.755, 252.524918]}, "COST": {"company": "", "ticker": "COST", "move": "down"}}}, {"link": "https://www.wsj.com/articles/hospitals-use-telemedicine-to-minimize-contact-with-virus-patients-11583337283", "title": "Hospitals Use Telemedicine to Minimize Contact With Virus Patients", "date": "2020-03-04 10:54", "summary": "Caregivers make use of phone, interactive video and secure messaging. Hospitals and doctors have a message for patients who want to come in because of fears they might be infected by the novel coronavirus: Try the phone first.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hospitals Use Telemedicine to Minimize Contact With Virus Patients. Caregivers make use of phone, interactive video and secure messaging. Hospitals and doctors have a message for patients who want to come in because of fears they might be infected by the novel coronavirus: Try the phone first.\"\n\nStock Prediction(s):", "Prediction": "\n- Cerner Corporation (NASDAQ: CERN) will increase because they provide technology that is being used for telemedicine.\n- Teladoc Health Inc (NYSE: TDOC) will increase because they provide telemedicine services.\n- American Well Corporation (NASDAQ: AWC) will increase because they provide telemedicine services.\n- Athenahealth, Inc. (NASDAQ: ATHN) will increase because they provide tele", "price_info": {"TDOC": {"company": "", "ticker": "TDOC", "move": "up"}, "CERN": {"company": "", "ticker": "CERN", "move": "up"}, "AWC": {"company": "", "ticker": "AWC", "move": "up"}, "ATHN": {"company": "", "ticker": "ATHN", "move": "up"}}}, {"link": "https://www.wsj.com/articles/3m-to-buy-acelity-for-enterprise-value-of-6-7-billion-11556795031", "title": "3M to Buy Wound-Care Company Acelity", "date": "2019-05-02 10:46", "summary": "Deal for Acelity has a total enterprise value of about $6.7 billion. 3M Co. on Thursday said it agreed to buy wound-care company Acelity Inc. from an investor group for about $4.3 billion as the manufacturing and technology conglomerate continues to build its health-care business.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"3M to Buy Wound-Care Company Acelity. Deal for Acelity has a total enterprise value of about $6.7 billion. 3M Co. on Thursday said it agreed to buy wound-care company Acelity Inc. from an investor group for about $4.3 billion as the manufacturing and technology conglomerate continues to build its health-care business.\"\n\nStock Prediction(s):", "Prediction": "\n- 3M Co. (NYSE: MMM) will increase because they are expanding their health-care business.\n- Acelity Inc. (NYSE: ACLY) will increase because they are being bought by 3M Co.", "price_info": {"MMM": {"company": "", "ticker": "MMM", "move": "up"}, "ACLY": {"company": "", "ticker": "ACLY", "move": "up"}}}, {"link": "https://www.wsj.com/articles/chinese-huawei-executive-is-charged-with-espionage-in-poland-11547201100", "title": "Huawei Executive Is Charged With Espionage in Poland", "date": "2019-01-11 14:24", "summary": "Detention follows a U.S. push to dissuade allies around the world from using Huawei gear. Polish authorities arrested a sales director of Huawei Technologies Co. and charged him with conducting espionage on behalf of China, raising the stakes over Western allegations the global company is a spying tool for Beijing.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Huawei Executive Is Charged With Espionage in Poland. Detention follows a U.S. push to dissuade allies around the world from using Huawei gear. Polish authorities arrested a sales director of Huawei Technologies Co. and charged him with conducting espionage on behalf of China, raising the stakes over Western allegations the global company is a spying tool for Beijing.\"\n\nStock Prediction(s):", "Prediction": "\n- Huawei Technologies Co. (SHE: 002502) will decrease because of the recent news of an executive being arrested and charged with espionage.\n- Apple Inc. (NASDAQ: AAPL) will increase because of the recent news of an executive being arrested and charged with espionage.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up"}}}, {"link": "https://www.wsj.com/articles/madison-square-garden-entertainment-to-acquire-msg-networks-11616769167", "title": "Madison Square Garden Entertainment to Acquire MSG Networks", "date": "2021-03-26 10:32", "summary": "Deal valued at more than $900 million and aims to tap into rise of sports gambling. Madison Square Garden Entertainment Corp. has agreed to acquire media operator MSG Networks Inc. for more than $900 million in a deal that reunites the two companies and is aimed at tapping into the rise of sports gambling.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Madison Square Garden Entertainment to Acquire MSG Networks. Deal valued at more than $900 million and aims to tap into rise of sports gambling. Madison Square Garden Entertainment Corp. has agreed to acquire media operator MSG Networks Inc. for more than $900 million in a deal that reunites the two companies and is aimed at tapping into the rise of sports gambling.\"\n\nStock Prediction(s):", "Prediction": "\n- Madison Square Garden Entertainment Corp. (NYSE: MSG) will increase because they are acquiring MSG Networks Inc. for more than $900 million.\n- MSG Networks Inc. (NYSE: MSGN) will increase because they are being acquired by Madison Square Garden Entertainment Corp. for more than $900 million.", "price_info": {"MSG": {"company": "", "ticker": "MSG", "move": null}, "MSGN": {"company": "", "ticker": "MSGN", "move": "up"}}}, {"link": "https://www.wsj.com/articles/employment-picture-darkening-even-more-than-jobs-figures-suggest-11607101266", "title": "Employment Picture Darkening, Even More than Jobs Figures Suggest", "date": "2020-12-04 12:01", "summary": "Situation has already gotten worse since the November jobs report was compiled. The job market is in danger of stalling. With the Covid epidemic worsening across the country, that should hardly count as a surprise, but perhaps it will stir both Congress and the Federal Reserve to move faster than they otherwise might have.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Employment Picture Darkening, Even More than Jobs Figures Suggest. Situation has already gotten worse since the November jobs report was compiled. The job market is in danger of stalling. With the Covid epidemic worsening across the country, that should hardly count as a surprise, but perhaps it will stir both Congress and the Federal Reserve to move faster than they otherwise might have.\"\n\nStock Prediction(s):", "Prediction": "\n- The employment picture will continue to worsen, and this will cause stocks like Walmart Inc. (NYSE: WMT) and Target Corporation (NYSE: TGT) to decrease.\n- The employment picture will start to improve, and this will cause stocks like Amazon.com, Inc. (NASDAQ: AMZN) and Facebook, Inc. (NASDAQ: FB) to increase.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": null}, "TGT": {"company": "", "ticker": "TGT", "move": null, "prices": [173.76, 173.9]}, "AMZN": {"company": "", "ticker": "AMZN", "move": null}, "FB": {"company": "", "ticker": "FB", "move": null}}}, {"link": "https://www.wsj.com/articles/gamestop-under-renewed-pressure-from-unhappy-investor-group-11583990600", "title": "GameStop Under Renewed Pressure from Unhappy Investor Group", "date": "2020-03-12 09:32", "summary": "The group sends a letter seeking a stockholder representative on the board. GameStop Corp. is facing a renewed threat from a group of shareholders upset with the videogame retailer's performance.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GameStop Under Renewed Pressure from Unhappy Investor Group. The group sends a letter seeking a stockholder representative on the board. GameStop Corp. is facing a renewed threat from a group of shareholders upset with the videogame retailer's performance.\"\n\nStock Prediction(s):", "Prediction": "\n- GameStop Corp. (NYSE: GME) will decrease because they are being pressured by unhappy investors.", "price_info": {"GME": {"company": "", "ticker": "GME", "move": "down"}}}, {"link": "https://www.wsj.com/articles/count-goldmans-millionaire-clients-as-big-winners-on-uber-11557333739", "title": "Count Goldman's Millionaire Clients as Big Winners on Uber", "date": "2019-05-08 12:42", "summary": "Private-wealth clients bought debt in 2015 that would convert into stock at a discount to the eventual IPO price. The discount now stands at 40%.. Wealthy clients of Goldman Sachs Group Inc. will emerge with deeply discounted stakes in Uber Technologies Inc. when it goes public this week, placing them among the biggest winners in a deal full of them.", "categories": [["Markets", "Stocks", "IPOs"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/markets/stocks?mod=breadcrumb", "https://www.wsj.com/news/types/ipos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Count Goldman's Millionaire Clients as Big Winners on Uber. Private-wealth clients bought debt in 2015 that would convert into stock at a discount to the eventual IPO price. The discount now stands at 40%.. Wealthy clients of Goldman Sachs Group Inc. will emerge with deeply discounted stakes in Uber Technologies Inc. when it goes public this week, placing them among the biggest winners in a deal full of them.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldman Sachs Group Inc. (NYSE: GS) will increase because their clients are the biggest winners in the Uber IPO.\n- Uber Technologies Inc. (NYSE: UBER) will increase because they are going public this week.", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "up", "prices": [201.95, 201.74]}, "UBER": {"company": "", "ticker": "UBER", "move": "up"}}}, {"link": "https://www.wsj.com/articles/regulator-fines-pwc-for-audit-shortfalls-related-to-british-service-provider-11560435259", "title": "Regulator Fines PwC for Audit Shortfalls Related to British Service Provider", "date": "2019-06-13 10:14", "summary": "Action follows closer regulatory monitoring of practices of 'Big Four' audit firms. A U.K. regulator fined and reprimanded PricewaterhouseCoopers LLP and two of its partners for shortfalls in its audits of a British service provider, following increased scrutiny over the practices of the country's biggest audit firms.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Regulator Fines PwC for Audit Shortfalls Related to British Service Provider. Action follows closer regulatory monitoring of practices of 'Big Four' audit firms. A U.K. regulator fined and reprimanded PricewaterhouseCoopers LLP and two of its partners for shortfalls in its audits of a British service provider, following increased scrutiny over the practices of the country's biggest audit firms.\"\n\nStock Prediction(s):", "Prediction": "\n- PwC will decrease because of the regulator's fine.\n- Deloitte will decrease because of the regulator's fine.\n- Ernst & Young will decrease because of the regulator's fine.\n- KPMG will decrease because of the regulator's fine.", "price_info": {}}, {"link": "https://www.wsj.com/articles/cfos-gain-valuable-skills-in-bankruptcys-school-of-hard-knocks-11596475325", "title": "CFOs Gain Valuable Skills in Bankruptcy's School of Hard Knocks", "date": "2020-08-03 13:22", "summary": "Finance chiefs that steer companies through the restructuring process get a crash course on how to manage liquidity-and stress-when times get tough. Steering a company through bankruptcy can be an unexpected bright spot on a chief financial officer's r\u00e9sum\u00e9.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"CFOs Gain Valuable Skills in Bankruptcy's School of Hard Knocks. Finance chiefs that steer companies through the restructuring process get a crash course on how to manage liquidity-and stress-when times get tough. Steering a company through bankruptcy can be an unexpected bright spot on a chief financial officer's r\u00e9sum\u00e9.\"\n\nStock Prediction(s):", "Prediction": "\n- The CFOs of companies that have gone through bankruptcy will be in high demand because they have experience managing liquidity and stress.\n- The CFOs of companies that have not gone through bankruptcy will be in high demand because they have not been through a tough restructuring process and will have more experience.", "price_info": {}}, {"link": "https://www.wsj.com/articles/helicopter-merger-is-industrys-response-to-offshore-slowdown-11579887131", "title": "Helicopter Merger Is Industry's Response to Offshore Slowdown", "date": "2020-01-24 14:44", "summary": "Bristow Group and Era Group to combine to create the world's largest operator of commercial helicopters. The planned merger of helicopter operators Bristow Group Inc. and Era Group Inc. marks the troubled industry's latest response to slumping demand for offshore choppers by oil-and-gas drillers after a string of bankruptcy filings.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Helicopter Merger Is Industry's Response to Offshore Slowdown. Bristow Group and Era Group to combine to create the world's largest operator of commercial helicopters. The planned merger of helicopter operators Bristow Group Inc. and Era Group Inc. marks the troubled industry's latest response to slumping demand for offshore choppers by oil-and-gas drillers after a string of bankruptcy filings.\"\n\nStock Prediction(s):", "Prediction": "\n- Bristow Group Inc. (NYSE: BRS) will increase because they are the largest helicopter operator in the world, and this will give them a competitive edge.\n- Era Group Inc. (NYSE: ERA) will increase because they are being acquired by Bristow Group, and this will give them a competitive edge.\n- Textron Inc. (NYSE: TXT) will decrease because they are a direct competitor of Bristow Group and Era Group.", "price_info": {"BRS": {"company": "", "ticker": "BRS", "move": "up"}, "ERA": {"company": "", "ticker": "ERA", "move": "up"}, "TXT": {"company": "", "ticker": "TXT", "move": "down", "prices": [44.28, 44.625]}}}, {"link": "https://www.wsj.com/articles/americas-spending-wave-is-yet-to-hit-11631804016", "title": "America's Spending Wave Is Yet to Hit", "date": "2021-09-16 10:53", "summary": "Retail sales were strong last month despite the Delta variant. What happens if the Delta threat fades?. The Delta variant of Covid-19 might have met its match in the American consumer.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"America's Spending Wave Is Yet to Hit. Retail sales were strong last month despite the Delta variant. What happens if the Delta threat fades?. The Delta variant of Covid-19 might have met its match in the American consumer.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will increase because retail sales were strong last month, and the Delta variant of Covid-19 seems to have faded.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because retail sales were strong last month, and the Delta variant of Covid-19 seems to have faded.\n- Nike, Inc. (NYSE: NKE) will increase because retail sales were strong last month", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [144.121, 144.44]}, "NKE": {"company": "", "ticker": "NKE", "move": "up", "prices": [158.1, 157.81]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3458.45, 3475]}}}, {"link": "https://www.wsj.com/articles/broadcom-ordered-by-eu-to-halt-allegedly-anticompetitive-contract-practices-11571221103", "title": "Broadcom Ordered by EU to Halt Allegedly Anticompetitive Practices", "date": "2019-10-16 10:24", "summary": "Move marks the first time European Union regulators have used 'interim measures' since 2001. BRUSSELS-The European Union ordered semiconductor maker Broadcom Inc. to stop requiring contract terms with customers that the bloc alleges are anticompetitive, even as a probe into the practices continues-the first time regulators have used such an injunction in 18 years.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Broadcom Ordered by EU to Halt Allegedly Anticompetitive Practices. Move marks the first time European Union regulators have used 'interim measures' since 2001. BRUSSELS-The European Union ordered semiconductor maker Broadcom Inc. to stop requiring contract terms with customers that the bloc alleges are anticompetitive, even as a probe into the practices continues-the first time regulators have used such an injunction in 18 years.\"\n\nStock Prediction(s):", "Prediction": "\n- Broadcom Inc. (NASDAQ: AVGO) will decrease because they are being ordered to halt anticompetitive practices.\n- Qualcomm Inc. (NASDAQ: QCOM) will increase because they are not being ordered to halt anticompetitive practices.", "price_info": {"AVGO": {"company": "", "ticker": "AVGO", "move": "down", "prices": [289.98, 288.06]}, "QCOM": {"company": "", "ticker": "QCOM", "move": "up", "prices": [77.84, 77.59]}}}, {"link": "https://www.wsj.com/articles/u-k-balks-at-wholesale-airlines-bailout-clouding-global-recovery-efforts-11585076488", "title": "U.K. Balks at Wholesale Airlines Bailout, Clouding Global Recovery Efforts", "date": "2020-03-24 15:01", "summary": "As Washington finalizes its own industry response amid the coronavirus crisis, other governments face stark choice amid global meltdown. LONDON-The U.K. is balking at a full-scale bailout of its airlines, telling British carriers to seek out private-sector remedies first and making clear the uneven hurdles the global aviation industry faces in finding ways to survive the fallout of the new coronavirus outbreak.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.K. Balks at Wholesale Airlines Bailout, Clouding Global Recovery Efforts. As Washington finalizes its own industry response amid the coronavirus crisis, other governments face stark choice amid global meltdown. LONDON-The U.K. is balking at a full-scale bailout of its airlines, telling British carriers to seek out private-sector remedies first and making clear the uneven hurdles the global aviation industry faces in finding ways to survive the fallout of the new coronavirus outbreak.\"\n\nStock Prediction(s):", "Prediction": "\n- International Airlines Group SA (NYSE: IAG) will decrease because the U.K. is balking at a bailout and they are a direct competitor.\n- American Airlines Group Inc (NASDAQ: AAL) will decrease because the U.K. is balking at a bailout and they are a direct competitor.\n- Delta Air Lines, Inc. (NYSE: DAL) will decrease because the U.K. is balking at a bailout and", "price_info": {"IAG": {"company": "", "ticker": "IAG", "move": "down", "prices": [2.33, 2.34]}, "DAL": {"company": "", "ticker": "DAL", "move": null, "prices": [27, 27.82]}, "AAL": {"company": "", "ticker": "AAL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/bed-bath-beyond-names-four-independent-directors-11559126990", "title": "Bed Bath & Beyond Names Four Independent Directors", "date": "2019-05-29 14:57", "summary": "Pressure revolved around the chain's efforts to address new consumer behavior. Bed Bath & Beyond Inc. named four new independent directors to its board and reached a settlement with activist investors who had been pressing the company to make leadership changes.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bed Bath & Beyond Names Four Independent Directors. Pressure revolved around the chain's efforts to address new consumer behavior. Bed Bath & Beyond Inc. named four new independent directors to its board and reached a settlement with activist investors who had been pressing the company to make leadership changes.\"\n\nStock Prediction(s):", "Prediction": "\n- Bed Bath & Beyond Inc. (NASDAQ: BBBY) will increase because they addressed the concerns of their activist investors and are making changes to their board.\n- Target Corporation (NYSE: TGT) will increase because they are also making changes to their board and are addressing the concerns of their activist investors.", "price_info": {"TGT": {"company": "", "ticker": "TGT", "move": "up", "prices": [79.54, 79.63]}, "BBBY": {"company": "", "ticker": "BBBY", "move": "up"}}}, {"link": "https://www.wsj.com/articles/u-s-factory-activity-slowed-in-may-11559571899", "title": "U.S. Factory Activity Cooled in May", "date": "2019-06-03 15:22", "summary": "ISM's manufacturing index fell to lowest reading since October 2016. U.S. factory-sector growth slowed in May as manufacturers confronted renewed trade tensions, and manufacturing activity in other major economies deteriorated.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Factory Activity Cooled in May. ISM's manufacturing index fell to lowest reading since October 2016. U.S. factory-sector growth slowed in May as manufacturers confronted renewed trade tensions, and manufacturing activity in other major economies deteriorated.\"\n\nStock Prediction(s):", "Prediction": "\n- The Dow Jones Industrial Average (NYSE: DJIA) will decrease because of the news about the U.S. factory activity.\n- The S&P 500 (NYSE: SPX) will decrease because of the news about the U.S. factory activity.\n- The Nasdaq Composite (NASDAQ: COMP) will decrease because of the news about the U.S. factory activity.", "price_info": {"DJIA": {"company": "", "ticker": "DJIA", "move": "down"}, "SPX": {"company": "", "ticker": "SPX", "move": "down"}, "COMP": {"company": "", "ticker": "COMP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/greek-police-are-rounding-up-asylum-seekers-and-forcing-them-into-turkey-migrants-say-11589989139", "title": "Greece Forcing Asylum Seekers Into Turkey, Migrants Say", "date": "2020-05-20 11:39", "summary": "Greece denies extrajudicial deportations after human-rights activists accuse authorities of using pandemic as cover for abuses. Greek police, escalating their tough measures against migration, have been rounding up asylum seekers living in the country and forcibly expelling them to Turkey, according to accounts by migrants who have experienced this, lawyers and human-rights activists.", "categories": [["WSJ News Exclusive", "Europe"]], "category_links": ["https://www.wsj.com/news/types/europe-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Greece Forcing Asylum Seekers Into Turkey, Migrants Say. Greece denies extrajudicial deportations after human-rights activists accuse authorities of using pandemic as cover for abuses. Greek police, escalating their tough measures against migration, have been rounding up asylum seekers living in the country and forcibly expelling them to Turkey, according to accounts by migrants who have experienced this, lawyers and human-rights activists.\"\n\nStock Prediction(s):", "Prediction": "\n- The stock prices of companies that provide services to asylum seekers will decrease because of this news.\n- The stock prices of companies that provide services to refugees will decrease because of this news.\n- The stock prices of companies that provide services to immigrants will decrease because of this news.", "price_info": {}}, {"link": "https://www.wsj.com/articles/apples-guidance-on-its-services-revenue-left-analysts-with-more-questions-11547665611", "title": "Apple's Guidance on Its Services Revenue Left Analysts With More Questions", "date": "2019-01-16 14:06", "summary": "The iPhone maker's services business got a boost from new accounting rules, but some analysts and investors didn't catch the change. Apple Inc. this month sparked confusion and frustration among analysts and investors trying to decipher the performance of the company's services business, fanning lingering concerns about transparency at one of the world's most closely watched companies.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple's Guidance on Its Services Revenue Left Analysts With More Questions. The iPhone maker's services business got a boost from new accounting rules, but some analysts and investors didn't catch the change. Apple Inc. this month sparked confusion and frustration among analysts and investors trying to decipher the performance of the company's services business, fanning lingering concerns about transparency at one of the world's most closely watched companies.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will decrease because of the confusion around their services business.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are a more transparent company and their services business is doing well.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down"}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up"}}}, {"link": "https://www.wsj.com/articles/china-2020-trade-risks-become-debt-risks-11577463948", "title": "China 2020: Trade Risks Become Debt Risks", "date": "2019-12-27 11:25", "summary": "With trade risks receding, keeping China's rickety financial system on the rails will dominate 2020. China's terrible, no good, very bad year is finally drawing to a close. Next year is set to start off better, but there are some nasty icebergs lurking beneath apparently calmer waters.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"China 2020: Trade Risks Become Debt Risks. With trade risks receding, keeping China's rickety financial system on the rails will dominate 2020. China's terrible, no good, very bad year is finally drawing to a close. Next year is set to start off better, but there are some nasty icebergs lurking beneath apparently calmer waters.\"\n\nStock Prediction(s):", "Prediction": "\n- The Chinese yuan (CNY) will appreciate because the trade war is over and the Chinese government is focusing on keeping the financial system stable.\n- The Chinese stock market (SHCOMP) will appreciate because the trade war is over and the Chinese government is focusing on keeping the financial system stable.\n- The American stock market (S&P 500) will depreciate because the trade war is not over and the American government is not focusing on keeping the financial", "price_info": {"CNY": {"company": "", "ticker": "CNY", "move": null}}}, {"link": "https://www.wsj.com/articles/ships-turn-into-floating-storage-units-for-oil-and-gas-as-chinese-buyers-back-out-11583339047", "title": "Ships Turn Into Floating Storage Units for Oil, Gas as Chinese Buyers Back Out", "date": "2020-03-04 14:41", "summary": "As the coronavirus outbreak spreads, shippers are warehousing an increasing amount of fuel on the high seas. ", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ships Turn Into Floating Storage Units for Oil, Gas as Chinese Buyers Back Out. As the coronavirus outbreak spreads, shippers are warehousing an increasing amount of fuel on the high seas. \"\n\nStock Prediction(s):", "Prediction": "\n- Shipping companies will increase because the need for storage will increase.\n- Oil and gas companies will decrease because the need for their product will decrease.", "price_info": {}}, {"link": "https://www.wsj.com/articles/omicrons-impact-on-oil-demand-weaker-than-expected-in-late-2021-11642507605", "title": "Omicron's Impact on Oil Demand Weaker Than Expected in Late 2021", "date": "2022-01-18 15:51", "summary": "Uncertainties remain over new variants of the virus and renewed mobility restrictions, cartel says. Demand for oil was stronger than expected in the final three months of 2021, as rising Covid-19 cases failed to diminish global appetite for crude or result in significant mobility restrictions, the Organization of the Petroleum Exporting Countries said Tuesday.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Omicron's Impact on Oil Demand Weaker Than Expected in Late 2021. Uncertainties remain over new variants of the virus and renewed mobility restrictions, cartel says. Demand for oil was stronger than expected in the final three months of 2021, as rising Covid-19 cases failed to diminish global appetite for crude or result in significant mobility restrictions, the Organization of the Petroleum Exporting Countries said Tuesday.\"\n\nStock Prediction(s):", "Prediction": "\n- Omicron Petroleum Ltd. (NYSE: OML) will increase because their impact on oil demand was weaker than expected.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because their impact on oil demand was weaker than expected.\n- Chevron Corporation (NYSE: CVX) will increase because their impact on oil demand was weaker than expected.\n- BP plc (NYSE: BP) will increase because their impact on oil demand was weaker than expected", "price_info": {"OML": {"company": "", "ticker": "OML", "move": null}, "XOM": {"company": "", "ticker": "XOM", "move": "up"}, "CVX": {"company": "", "ticker": "CVX", "move": "up"}, "BP": {"company": "", "ticker": "BP", "move": "up"}}}, {"link": "https://www.wsj.com/articles/consumer-stocks-take-an-early-victory-lap-11559741889", "title": "Consumer Stocks Take an Early Victory Lap", "date": "2019-06-05 09:38", "summary": "Shares in Nestl\u00e9, P&G and Unilever are trading near record highs even though they continue to lose share to smaller competitors. Investors have decided that the worst is over for the world's top consumer companies, but the bout of optimism is probably premature.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Consumer Stocks Take an Early Victory Lap. Shares in Nestl\u00e9, P&G and Unilever are trading near record highs even though they continue to lose share to smaller competitors. Investors have decided that the worst is over for the world's top consumer companies, but the bout of optimism is probably premature.\"\n\nStock Prediction(s):", "Prediction": "\n- Nestl\u00e9 SA (OTCMKTS: NSRGY) will continue to increase because they are a top consumer company and the worst is over for them.\n- Procter & Gamble Co (NYSE: PG) will continue to increase because they are a top consumer company and the worst is over for them.\n- Unilever NV (NYSE: UL) will continue to increase because they are a top consumer company and the worst is over for them.", "price_info": {"PG": {"company": "", "ticker": "PG", "move": "up", "prices": [106.15, 106.18]}, "UL": {"company": "", "ticker": "UL", "move": "up"}}}, {"link": "https://www.wsj.com/articles/citigroup-names-new-consumer-banking-head-11604343215", "title": "Citigroup Names New Consumer Banking Head", "date": "2020-11-02 13:53", "summary": "Incoming CEO Jane Fraser is tapping one of her top lieutenants, Anand Selva, to replace her as head of consumer bank. Citigroup Inc. on Monday named a new leader for its global consumer bank and said its chief risk officer will leave, two changes that highlight how the incoming chief executive, Jane Fraser, can start making her mark on the bank.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Citigroup Names New Consumer Banking Head. Incoming CEO Jane Fraser is tapping one of her top lieutenants, Anand Selva, to replace her as head of consumer bank. Citigroup Inc. on Monday named a new leader for its global consumer bank and said its chief risk officer will leave, two changes that highlight how the incoming chief executive, Jane Fraser, can start making her mark on the bank.\"\n\nStock Prediction(s):", "Prediction": "\n- Citigroup Inc. (NYSE: C) will increase because they have a new head of consumer banking.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they have a new head of consumer banking.\n- Wells Fargo & Co. (NYSE: WFC) will increase because they have a new head of consumer banking.\n- Bank of America Corp (NYSE: BAC) will increase because they have a new head of consumer banking.", "price_info": {"C": {"company": "", "ticker": "C", "move": "up"}, "JPM": {"company": "", "ticker": "JPM", "move": "up"}, "WFC": {"company": "", "ticker": "WFC", "move": "up", "prices": [21.7, 21.945]}, "BAC": {"company": "", "ticker": "BAC", "move": "up"}}}, {"link": "https://www.wsj.com/articles/oil-gains-on-geopolitics-rising-u-s-equities-11557937070", "title": "Oil Gains on Geopolitics, Rising U.S. Equities", "date": "2019-05-15 15:15", "summary": "Crude prices rose despite data showing U.S. inventories at 20-month high. \u2022 Oil prices rose Wednesday as geopolitical tensions and higher stock prices on Wall Street offset bearish data showing U.S. oil inventories are at a 20-month high.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Gains on Geopolitics, Rising U.S. Equities. Crude prices rose despite data showing U.S. inventories at 20-month high. \u2022 Oil prices rose Wednesday as geopolitical tensions and higher stock prices on Wall Street offset bearish data showing U.S. oil inventories are at a 20-month high.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because oil prices are rising, and they are a big player in the oil industry.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because oil prices are rising, and they are a big player in the oil industry.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because oil prices are rising, and they are a big player in the oil industry.\n- BP", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up"}, "XOM": {"company": "", "ticker": "XOM", "move": "up"}}}, {"link": "https://www.wsj.com/articles/microsofts-new-normal-will-need-to-stick-11635361488", "title": "Microsoft's New Normal Will Need to Stick", "date": "2021-10-27 15:04", "summary": "Strong streak of growth and operating profit gains hasn't been seen in nearly two decades, but the stock's valuation sets a new high bar. It is hard to imagine what could go wrong with Microsoft these days. With current expectations where they are, not much would need to.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Microsoft's New Normal Will Need to Stick. Strong streak of growth and operating profit gains hasn't been seen in nearly two decades, but the stock's valuation sets a new high bar. It is hard to imagine what could go wrong with Microsoft these days. With current expectations where they are, not much would need to.\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will continue to grow because they have been seeing strong growth and profits.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they have been seeing a slowdown in sales and profits.", "price_info": {"MSFT": {"company": "", "ticker": "MSFT", "move": "up"}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/rising-demand-for-delivery-is-remaking-chinas-grocery-landscape-11561381366", "title": "After Struggling to Deliver in China, Carrefour Packs Its Bags", "date": "2019-06-24 11:25", "summary": "French company is pulling back as local upstarts seize on the trend toward delivering items directly to customers' homes. BEIJING- Carrefour SA, one of Europe's largest grocery retailers, is unloading most of its operations in China, where big-box retailers are struggling to keep up with nimble delivery providers that are winning over shoppers.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"After Struggling to Deliver in China, Carrefour Packs Its Bags. French company is pulling back as local upstarts seize on the trend toward delivering items directly to customers' homes. BEIJING- Carrefour SA, one of Europe's largest grocery retailers, is unloading most of its operations in China, where big-box retailers are struggling to keep up with nimble delivery providers that are winning over shoppers.\"\n\nStock Prediction(s):", "Prediction": "\n- Carrefour SA (EPA: CA) will decrease because they are pulling out of China, and the Chinese market is only growing.\n- Alibaba Group Holding Ltd. (NYSE: BABA) will increase because they are a direct competitor of Carrefour, and they are doing well in China.\n- JD.com, Inc. (NASDAQ: JD) will increase because they are a direct competitor of Carrefour, and they are doing well in", "price_info": {"BABA": {"company": "", "ticker": "BABA", "move": "up"}, "JD": {"company": "", "ticker": "JD", "move": "up"}}}, {"link": "https://www.wsj.com/articles/feds-brainard-tells-yahoo-finance-lower-rates-possible-amid-trade-risks-11559744865", "title": "Fed's Brainard Says Lower Rates Possible Amid Trade Risks", "date": "2019-06-05 10:27", "summary": "Fed governor says she will watch data carefully to determine central bank's next step. Federal Reserve Governor Lael Brainard signaled an openness to lowering interest rates but she didn't indicate such action was imminent.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Brainard Says Lower Rates Possible Amid Trade Risks. Fed governor says she will watch data carefully to determine central bank's next step. Federal Reserve Governor Lael Brainard signaled an openness to lowering interest rates but she didn't indicate such action was imminent.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed will lower interest rates because of the trade risks.\n- The market will react positively to this news because it will make it easier for people and businesses to borrow money.\n- Bank of America (NYSE: BAC) will increase because they are a major lender, and they will benefit from the lower interest rates.\n- JPMorgan Chase (NYSE: JPM) will increase because they are a major lender, and they will benefit from the lower interest rates.", "price_info": {"BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [27.7253, 27.9354]}, "JPM": {"company": "", "ticker": "JPM", "move": "up"}}}, {"link": "https://www.wsj.com/articles/softbank-invests-940-million-in-nuro-for-driverless-deliveries-11549893721", "title": "SoftBank Invests $940 Million in Nuro for Driverless Deliveries", "date": "2019-02-11 14:17", "summary": "Startup is building robotic vehicles to deliver groceries and other items from the street. SoftBank Group Corp.'s giant tech fund is investing almost $1 billion in a robotic-delivery vehicle startup, a hefty injection of capital that could help accelerate the race to put driverless vehicles on the road.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SoftBank Invests $940 Million in Nuro for Driverless Deliveries. Startup is building robotic vehicles to deliver groceries and other items from the street. SoftBank Group Corp.'s giant tech fund is investing almost $1 billion in a robotic-delivery vehicle startup, a hefty injection of capital that could help accelerate the race to put driverless vehicles on the road.\"\n\nStock Prediction(s):", "Prediction": "\n- Nuro Inc (NASDAQ: NURO) will increase because they have a new investor in SoftBank, and they are getting closer to deploying their driverless vehicles.\n- Ford Motor Company (NYSE: F) will decrease because they are also working on a driverless vehicle, but they are a direct competitor of Nuro.", "price_info": {"F": {"company": "", "ticker": "F", "move": "down"}, "NURO": {"company": "", "ticker": "NURO", "move": "up"}}}, {"link": "https://www.wsj.com/articles/texas-freeze-heats-up-some-refiners-11613592128", "title": "Texas Freeze Heats Up Some Refiners", "date": "2021-02-17 15:02", "summary": "Unusually cold Texas weather is both good and bad for oil refiners as margins get a boost, but some are unable to capitalize. The massive oil-and-gas complex along the U.S. Gulf Coast is built with extreme weather in mind-just not this kind. Bitter cold and resulting blackouts have shut in more production and refining capacity than any recent hurricane, delivering a windfall for some companies with the right assets in the right place.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Texas Freeze Heats Up Some Refiners. Unusually cold Texas weather is both good and bad for oil refiners as margins get a boost, but some are unable to capitalize. The massive oil-and-gas complex along the U.S. Gulf Coast is built with extreme weather in mind-just not this kind. Bitter cold and resulting blackouts have shut in more production and refining capacity than any recent hurricane, delivering a windfall for some companies with the right assets in the right place.\"\n\nStock Prediction(s):", "Prediction": "\n- Marathon Petroleum Corporation (NYSE: MPC) will increase because their refinery in Texas is well-equipped to handle the cold weather and is taking advantage of the situation.\n- Valero Energy Corporation (NYSE: VLO) will increase because their refinery in Texas is well-equipped to handle the cold weather and is taking advantage of the situation.\n- Phillips 66 (NYSE: PSX) will increase because their refinery in Texas is well-equipped to handle the cold", "price_info": {"MPC": {"company": "", "ticker": "MPC", "move": "up"}, "VLO": {"company": "", "ticker": "VLO", "move": "up"}, "PSX": {"company": "", "ticker": "PSX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/kkr-reports-second-quarter-profit-amid-financial-market-recovery-11596542070", "title": "KKR Reports Second-Quarter Profit Amid Financial-Market Recovery", "date": "2020-08-04 13:39", "summary": "The result marked a rebound for the asset-management company after it logged a large first-quarter loss. KKR & Co. on Tuesday said its second-quarter profit rose year over year, marking a recovery for the private-equity firm after it logged a large first-quarter loss amid the market turmoil sparked by the coronavirus pandemic.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"KKR Reports Second-Quarter Profit Amid Financial-Market Recovery. The result marked a rebound for the asset-management company after it logged a large first-quarter loss. KKR & Co. on Tuesday said its second-quarter profit rose year over year, marking a recovery for the private-equity firm after it logged a large first-quarter loss amid the market turmoil sparked by the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- KKR & Co. (NYSE: KKR) will increase because they have rebounded from their large first-quarter loss.\n- Blackstone Group LP (NYSE: BX) will increase because they have rebounded from their large first-quarter loss.\n- Carlyle Group LP (NASDAQ: CG) will increase because they have rebounded from their large first-quarter loss.", "price_info": {"KKR": {"company": "", "ticker": "KKR", "move": "up"}, "BX": {"company": "", "ticker": "BX", "move": "up", "prices": [51.87, 52.19]}, "CG": {"company": "", "ticker": "CG", "move": "up"}}}, {"link": "https://www.wsj.com/articles/boeing-plans-new-staff-buyouts-11597757758", "title": "Boeing Plans New Staff Buyouts", "date": "2020-08-18 10:37", "summary": "Travel slump leaves aerospace giant looking to cut more jobs than previously planned. Boeing Co. plans more job cuts in response to a pandemic-driven drop in jetliner demand it expects to continue for at least three years.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Boeing Plans New Staff Buyouts. Travel slump leaves aerospace giant looking to cut more jobs than previously planned. Boeing Co. plans more job cuts in response to a pandemic-driven drop in jetliner demand it expects to continue for at least three years.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co. (NYSE: BA) will decrease because they are expecting a three-year slump in jetliner demand.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down"}}}, {"link": "https://www.wsj.com/articles/manufacturings-737-max-problem-11576601673", "title": "Manufacturing's 737 MAX Problem", "date": "2019-12-17 11:54", "summary": "A rebound in industrial production may be cut short by Boeing's troubles. The good news is that manufacturing picked up last month. The bad news is that is it is probably due for yet another round of weakness.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Manufacturing's 737 MAX Problem. A rebound in industrial production may be cut short by Boeing's troubles. The good news is that manufacturing picked up last month. The bad news is that is it is probably due for yet another round of weakness.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing (NYSE: BA) will decrease because of their 737 MAX problem.\n- General Electric (NYSE: GE) will decrease because of their GE Capital problem.\n- Honeywell (NYSE: HON) will decrease because of their Honeywell Aerospace problem.\n- 3M (NYSE: MMM) will decrease because of their health and safety problem.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down"}, "GE": {"company": "", "ticker": "GE", "move": "down"}, "HON": {"company": "", "ticker": "HON", "move": "down"}, "MMM": {"company": "", "ticker": "MMM", "move": "down"}}}, {"link": "https://www.wsj.com/articles/why-merck-is-playing-catch-up-in-the-coronavirus-vaccine-chase-11603470832", "title": "Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase", "date": "2020-10-23 12:33", "summary": "Initial hesitation by senior executives about joining the global effort puts the company in an unusual spot: behind. As the new coronavirus spread in mid-February, Merck & Co.'s executives and scientists took sides in a high-stakes debate.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase. Initial hesitation by senior executives about joining the global effort puts the company in an unusual spot: behind. As the new coronavirus spread in mid-February, Merck & Co.'s executives and scientists took sides in a high-stakes debate.\"\n\nStock Prediction(s):", "Prediction": "\n- Merck & Co. (NYSE: MRK) will increase because they have now decided to join the global effort to develop a vaccine.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are a direct competitor of Merck.\n- AstraZeneca plc (NYSE: AZN) will decrease because they are also working on a vaccine, but they are a direct competitor of Merck.\n- Pfizer Inc (NYSE:", "price_info": {"MRK": {"company": "", "ticker": "MRK", "move": "up"}, "JNJ": {"company": "", "ticker": "JNJ", "move": "down"}, "AZN": {"company": "", "ticker": "AZN", "move": "down", "prices": [52.04, 52.2484]}}}, {"link": "https://www.wsj.com/articles/feds-mester-makes-plea-for-more-fiscal-aid-in-television-interview-11605801565", "title": "Two Fed Officials Voice Concern on Economy as Virus Cases Surge", "date": "2020-11-19 15:22", "summary": "Cleveland Fed leader says it isn't clear how much more support the Fed could give the economy. Two Federal Reserve officials at the heart of central bank decision making this year sent warnings Thursday about what lies ahead for the economy as coronavirus cases spiral higher.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Two Fed Officials Voice Concern on Economy as Virus Cases Surge. Cleveland Fed leader says it isn't clear how much more support the Fed could give the economy. Two Federal Reserve officials at the heart of central bank decision making this year sent warnings Thursday about what lies ahead for the economy as coronavirus cases spiral higher.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will go down because two Fed officials are worried about the economy.\n- The market will go down because two Fed officials are worried about the economy, and this is adding to the overall market volatility.", "price_info": {}}, {"link": "https://www.wsj.com/articles/bank-of-america-tech-executives-see-promise-in-5g-3-d-printing-11620153528", "title": "Bank of America Tech Executives See Promise in 5G, 3-D Printing", "date": "2021-05-04 14:38", "summary": "The bank plans to spend $3.5 billion this year on new tech initiatives. Bank of America Corp.'s technology executives are interested in championing new initiatives over the next few years using data analytics, fifth-generation wireless networks and possibly 3-D printing, as demand for the bank's digital services has skyrocketed during the pandemic.", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/cio-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bank of America Tech Executives See Promise in 5G, 3-D Printing. The bank plans to spend $3.5 billion this year on new tech initiatives. Bank of America Corp.'s technology executives are interested in championing new initiatives over the next few years using data analytics, fifth-generation wireless networks and possibly 3-D printing, as demand for the bank's digital services has skyrocketed during the pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Bank of America Corp. (NYSE: BAC) will increase because they are investing in new technologies that will be beneficial in the long run.\n- IBM (NYSE: IBM) will increase because they are a direct competitor of Bank of America and they are also investing in new technologies.\n- Microsoft (NASDAQ: MSFT) will increase because they are a direct competitor of Bank of America and they are also investing in new technologies.", "price_info": {"BAC": {"company": "", "ticker": "BAC", "move": "up"}, "IBM": {"company": "", "ticker": "IBM", "move": "up"}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [247.1139, 247.595]}}}, {"link": "https://www.wsj.com/articles/credit-suisse-faces-possible-charges-on-greensill-loan-11615884514", "title": "Credit Suisse Faces Possible Loss Over Greensill Collapse", "date": "2021-03-16 13:56", "summary": "Swiss bank says it received $50 million back so far from $140 million owed by the firm. Credit Suisse Group AG warned that the bank and investors in some of its funds face potential losses from the collapse of U.K. financial firm Greensill Capital earlier this month.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Credit Suisse Faces Possible Loss Over Greensill Collapse. Swiss bank says it received $50 million back so far from $140 million owed by the firm. Credit Suisse Group AG warned that the bank and investors in some of its funds face potential losses from the collapse of U.K. financial firm Greensill Capital earlier this month.\"\n\nStock Prediction(s):", "Prediction": "\n- Credit Suisse Group AG (NYSE: CS) will decrease because of the potential losses from the collapse of Greensill Capital.", "price_info": {"CS": {"company": "", "ticker": "CS", "move": "down"}}}, {"link": "https://www.wsj.com/articles/u-k-starts-national-security-probe-of-nvidia-s-40-billion-deal-to-buy-arm-11618837683", "title": "Nvidia's $40 Billion Deal to Buy Arm Faces U.K. National-Security Probe", "date": "2021-04-19 13:54", "summary": "Proposed acquisition of chip designer from SoftBank is already undergoing antitrust review. LONDON-The U.K. government is starting a national-security review of Nvidia Corp.'s $40 billion deal to buy British chip designer Arm from SoftBank Group Corp. , raising a new hurdle for an industry-reshaping proposal facing significant regulatory scrutiny around the world.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Nvidia's $40 Billion Deal to Buy Arm Faces U.K. National-Security Probe. Proposed acquisition of chip designer from SoftBank is already undergoing antitrust review. LONDON-The U.K. government is starting a national-security review of Nvidia Corp.'s $40 billion deal to buy British chip designer Arm from SoftBank Group Corp. , raising a new hurdle for an industry-reshaping proposal facing significant regulatory scrutiny around the world.\"\n\nStock Prediction(s):", "Prediction": "\n- Nvidia Corporation (NASDAQ: NVDA) will decrease because their acquisition is being investigated by the U.K. government.\n- Arm Holdings plc (LON: ARM) will increase because they are being acquired by Nvidia for $40 billion.", "price_info": {"NVDA": {"company": "", "ticker": "NVDA", "move": "up", "prices": [613.98, 614.75]}}}, {"link": "https://www.wsj.com/articles/shrinking-u-s-crude-discount-threatens-exports-11566315495", "title": "Shrinking U.S. Crude Discount Threatens Exports", "date": "2019-08-20 14:55", "summary": "Gap between U.S. crude benchmark and global Brent price has fallen to lowest level since July 2018. U.S. oil prices are trading at the smallest discount to global prices in more than a year-a reversal that is crimping domestic exports and could lead to a buildup of crude.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Shrinking U.S. Crude Discount Threatens Exports. Gap between U.S. crude benchmark and global Brent price has fallen to lowest level since July 2018. U.S. oil prices are trading at the smallest discount to global prices in more than a year-a reversal that is crimping domestic exports and could lead to a buildup of crude.\"\n\nStock Prediction(s):", "Prediction": "\n- Enterprise Products Partners L.P. (NYSE: EPD) will increase because they are a direct beneficiary of the shrinking U.S. crude discount.\n- Phillips 66 (NYSE: PSX) will increase because they are a direct beneficiary of the shrinking U.S. crude discount.\n- Marathon Petroleum Corporation (NYSE: MPC) will increase because they are a direct beneficiary of the shrinking U.S. crude discount.\n- Valero Energy Corporation", "price_info": {"EPD": {"company": "", "ticker": "EPD", "move": "up"}, "PSX": {"company": "", "ticker": "PSX", "move": "up"}, "MPC": {"company": "", "ticker": "MPC", "move": "up"}}}, {"link": "https://www.wsj.com/articles/ford-skids-again-but-might-yet-pass-gm-11580927211", "title": "Ford Skids Again but Might Yet Pass GM", "date": "2020-02-05 13:26", "summary": "For all its operational excellence, General Motors seems incapable of exciting investors in rapidly changing industry. The fourth quarter was anything but normal for Detroit, with the longest strike in decades at General Motors and a mangled vehicle launch at Ford Motor . But fourth-quarter reports still followed what has become the usual pattern: GM steered a smooth course while Ford skidded.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ford Skids Again but Might Yet Pass GM. For all its operational excellence, General Motors seems incapable of exciting investors in rapidly changing industry. The fourth quarter was anything but normal for Detroit, with the longest strike in decades at General Motors and a mangled vehicle launch at Ford Motor . But fourth-quarter reports still followed what has become the usual pattern: GM steered a smooth course while Ford skidded.\"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Company (NYSE: F) will continue to skid because of their vehicle launch, while General Motors (NYSE: GM) will remain stable because of their operational excellence.", "price_info": {"F": {"company": "", "ticker": "F", "move": null}, "GM": {"company": "", "ticker": "GM", "move": null}}}, {"link": "https://www.wsj.com/articles/palladium-prices-hit-record-despite-chinese-auto-disruption-11582043654", "title": "Palladium Prices Hit Record Despite Chinese Auto Disruption", "date": "2020-02-18 15:47", "summary": "Demand for the precious metal has surged as auto regulators tighten emissions regulations in China and Europe. Palladium prices soared Tuesday despite shutdowns and delays at car plants in China, the world's biggest consumer of the precious metal, highlighting an extended spell of volatility in the commodity's market.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Palladium Prices Hit Record Despite Chinese Auto Disruption. Demand for the precious metal has surged as auto regulators tighten emissions regulations in China and Europe. Palladium prices soared Tuesday despite shutdowns and delays at car plants in China, the world's biggest consumer of the precious metal, highlighting an extended spell of volatility in the commodity's market.\"\n\nStock Prediction(s):", "Prediction": "\n- Impala Platinum Holdings Ltd. (OTCMKTS: IMPUY) will increase because palladium prices are hitting record highs, and they are a major producer of palladium.\n- Northam Platinum Ltd. (OTCMKTS: NHMYY) will increase because palladium prices are hitting record highs, and they are a major producer of palladium.\n- Lonmin Plc (OTCMKTS: LNMIY) will increase", "price_info": {}}, {"link": "https://www.wsj.com/articles/volvo-cars-needs-investors-to-value-brain-over-brawn-11627051135", "title": "Volvo Cars Needs Investors to Value Brain Over Brawn", "date": "2021-07-23 10:38", "summary": "As the Swedish car maker gears up for an initial public offering, a hyperactive first half showcases both its strategic flexibility and financial limitations. The mooted initial public offering of Volvo Cars is a must-watch test case of investor appetite for smaller car manufacturers as the industry's technological transition accelerates.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Volvo Cars Needs Investors to Value Brain Over Brawn. As the Swedish car maker gears up for an initial public offering, a hyperactive first half showcases both its strategic flexibility and financial limitations. The mooted initial public offering of Volvo Cars is a must-watch test case of investor appetite for smaller car manufacturers as the industry's technological transition accelerates.\"\n\nStock Prediction(s):", "Prediction": "\n- Volvo Cars AB (OTC: VLVLY) will increase because they are a smaller car manufacturer that is transitioning to electric, and they are gearing up for an IPO.\n- Geely Automobile Holdings Ltd. (OTC: GELYY) will increase because they are a larger car manufacturer that owns Volvo, and they are also transitioning to electric.\n- Tesla, Inc. (NASDAQ: TSLA) will decrease because they are a direct", "price_info": {"TSLA": {"company": "", "ticker": "TSLA", "move": "down", "prices": [641.5348, 638.09]}}}, {"link": "https://www.wsj.com/articles/u-s-scores-guilty-plea-in-mozambique-corruption-case-11563894033", "title": "U.S. Scores Guilty Plea in Mozambique Corruption Case", "date": "2019-07-23 11:00", "summary": "Credit Suisse banker also implicates Lebanese businessman Iskandar Safa. The U.S. Department of Justice has gained a key advantage in its prosecution of an alleged global corruption ring involving $2 billion of Mozambican government-debt deals.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Scores Guilty Plea in Mozambique Corruption Case. Credit Suisse banker also implicates Lebanese businessman Iskandar Safa. The U.S. Department of Justice has gained a key advantage in its prosecution of an alleged global corruption ring involving $2 billion of Mozambican government-debt deals.\"\n\nStock Prediction(s):", "Prediction": "\n- Credit Suisse Group AG (NYSE: CS) will increase because they have a banker that has plead guilty, and this will give them a leg up in the investigation.\n- Iskandar Safa will decrease because he has been implicated in the corruption case.", "price_info": {"CS": {"company": "", "ticker": "CS", "move": "down"}}}, {"link": "https://www.wsj.com/articles/ecb-official-defends-private-calls-to-investors-and-banks-after-policy-meetings-11606937738", "title": "ECB Official Defends Private Calls to Investors and Banks", "date": "2020-12-02 14:35", "summary": "Philip Lane says private calls to the likes of BlackRock, Goldman aimed to address questions on policy decisions and seek feedback. FRANKFURT-The European Central Bank's chief economist plans to place private calls to banks and investors after the ECB's policy meeting next week, he said Wednesday, continuing an unusual communications practice that has raised eyebrows among financiers and central-bank officials.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"ECB Official Defends Private Calls to Investors and Banks. Philip Lane says private calls to the likes of BlackRock, Goldman aimed to address questions on policy decisions and seek feedback. FRANKFURT-The European Central Bank's chief economist plans to place private calls to banks and investors after the ECB's policy meeting next week, he said Wednesday, continuing an unusual communications practice that has raised eyebrows among financiers and central-bank officials.\"\n\nStock Prediction(s):", "Prediction": "\n- The ECB will continue to defend their private calls to investors and banks, and this will continue to cause some backlash.\n- The ECB will eventually stop making these calls, and this will cause the stock prices of banks and investors to decrease.", "price_info": {}}, {"link": "https://www.wsj.com/articles/what-investors-learned-from-the-first-peek-inside-youtubes-financials-11580836322", "title": "What Investors Saw Inside YouTube's Financials", "date": "2020-02-04 12:12", "summary": "Google reveals YouTube is smaller than outsiders thought-but still a juggernaut. If YouTube were a stand-alone company, it would be among the biggest advertising players in the world. Yet the online video service isn't as large as many outsiders expected.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What Investors Saw Inside YouTube's Financials. Google reveals YouTube is smaller than outsiders thought-but still a juggernaut. If YouTube were a stand-alone company, it would be among the biggest advertising players in the world. Yet the online video service isn't as large as many outsiders expected.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will decrease because YouTube is not as large as people thought, and this could be a sign that their other businesses are also not as strong as people thought.\n- Facebook, Inc. (NASDAQ: FB) will increase because they are the only other major social media company, and this could be a sign that they are continuing to dominate the market.", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "down"}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [208.8379, 209.13]}}}, {"link": "https://www.wsj.com/articles/novavax-starts-late-stage-trial-of-covid-19-vaccine-in-u-s-mexico-11609171205", "title": "Novavax Starts Late-Stage Trial of Covid-19 Vaccine", "date": "2020-12-28 12:24", "summary": "Latest shot will become the fifth to enter final-stage testing in the U.S., and if results are positive it could receive authorization sometime during 2021. Novavax Inc. said Monday it is starting a new clinical trial of up to 30,000 people in the U.S. and Mexico to test whether its experimental Covid-19 vaccine safely protects people from the disease.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Novavax Starts Late-Stage Trial of Covid-19 Vaccine. Latest shot will become the fifth to enter final-stage testing in the U.S., and if results are positive it could receive authorization sometime during 2021. Novavax Inc. said Monday it is starting a new clinical trial of up to 30,000 people in the U.S. and Mexico to test whether its experimental Covid-19 vaccine safely protects people from the disease.\"\n\nStock Prediction(s):", "Prediction": "\n- Novavax, Inc. (NASDAQ: NVAX) will increase because they are starting a late-stage trial for their Covid-19 vaccine.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of Novavax.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "down"}, "PFE": {"company": "", "ticker": "PFE", "move": "down"}, "NVAX": {"company": "", "ticker": "NVAX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/brian-robbins-expected-to-take-over-leadership-of-paramount-movie-studio-11631281748", "title": "Brian Robbins Expected to Take Over Leadership of Paramount Movie Studio", "date": "2021-09-10 12:19", "summary": "Mr. Robbins, head of Nickelodeon, will replace Jim Gianopulos, as ViacomCBS aims to beef up original content on Paramount+. Brian Robbins, the head of ViacomCBS Inc.'s Nickelodeon kids TV empire, is expected to take over as chairman and chief executive of the company's Paramount Pictures movie studio, according to people familiar with the matter.", "categories": [["WSJ News Exclusive", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Brian Robbins Expected to Take Over Leadership of Paramount Movie Studio. Mr. Robbins, head of Nickelodeon, will replace Jim Gianopulos, as ViacomCBS aims to beef up original content on Paramount+. Brian Robbins, the head of ViacomCBS Inc.'s Nickelodeon kids TV empire, is expected to take over as chairman and chief executive of the company's Paramount Pictures movie studio, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- ViacomCBS Inc. (NASDAQ: VIAC) will increase because they are beefing up their original content with a new CEO.\n- Paramount Pictures (NYSE: VIA) will increase because they have a new leader who is expected to increase the amount of original content.", "price_info": {"VIA": {"company": "", "ticker": "VIA", "move": null, "prices": [10.45, 10.5]}, "VIAC": {"company": "", "ticker": "VIAC", "move": "up"}}}, {"link": "https://www.wsj.com/articles/women-founders-of-ai-startups-take-aim-at-gender-bias-11601388625", "title": "Women Founders of AI Startups Take Aim at Gender Bias", "date": "2020-09-29 10:10", "summary": "They see gender diversity in their companies as crucial in making sure the technology doesn't penalize the underrepresented. When Rana el Kaliouby was pitching investors in 2009 on her artificial-intelligence startup, Affectiva, she and her co-founder tried to steer clear of what she calls the \"e-word\"-emotion.", "categories": [["Business", "Journal Reports: Leadership"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-leadership?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Women Founders of AI Startups Take Aim at Gender Bias. They see gender diversity in their companies as crucial in making sure the technology doesn't penalize the underrepresented. When Rana el Kaliouby was pitching investors in 2009 on her artificial-intelligence startup, Affectiva, she and her co-founder tried to steer clear of what she calls the \"e-word\"-emotion.\"\n\nStock Prediction(s):", "Prediction": "\n- Affectiva Inc (NASDAQ: AFFX) will increase because they are working on a technology that is trying to avoid gender bias.\n- Google Inc (NASDAQ: GOOGL) will increase because they are also working on a technology that is trying to avoid gender bias.", "price_info": {"AFFX": {"company": "", "ticker": "AFFX", "move": "up"}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up"}}}, {"link": "https://www.wsj.com/articles/why-ge-is-doing-a-reverse-stock-split-and-what-it-means-for-you-11615391261", "title": "Why GE Is Doing a Reverse Stock Split and What It Means for You", "date": "2021-03-10 11:51", "summary": "Companies can increase perceived value by reducing shares outstanding, raising share price. General Electric Co. 's plan to pursue a reverse stock split would make it one of the few blue-chip companies in recent years to use a strategy that has been more common among firms struggling to stay listed on stock exchanges.", "categories": [["Markets", "Stocks"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/markets/stocks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why GE Is Doing a Reverse Stock Split and What It Means for You. Companies can increase perceived value by reducing shares outstanding, raising share price. General Electric Co. 's plan to pursue a reverse stock split would make it one of the few blue-chip companies in recent years to use a strategy that has been more common among firms struggling to stay listed on stock exchanges.\"\n\nStock Prediction(s):", "Prediction": "\n- GE will increase because they are doing a reverse stock split, which will make their stock more valuable.\n- Other companies will decrease because this will make GE more valuable in comparison.", "price_info": {}}, {"link": "https://www.wsj.com/articles/ford-to-create-3-000-factory-jobs-in-michigan-as-part-of-new-uaw-contract-11576612129", "title": "Ford to Create 3,000 Factory Jobs in Michigan as Part of New UAW Contract", "date": "2019-12-17 14:48", "summary": "The auto maker will invest nearly $1.5 billion in two Michigan assembly plants. Ford Motor Co. will invest nearly $1.5 billion in two Michigan assembly plants, creating about 3,000 factory jobs in a politically pivotal state.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ford to Create 3,000 Factory Jobs in Michigan as Part of New UAW Contract. The auto maker will invest nearly $1.5 billion in two Michigan assembly plants. Ford Motor Co. will invest nearly $1.5 billion in two Michigan assembly plants, creating about 3,000 factory jobs in a politically pivotal state.\"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Co. (NYSE: F) will increase because they are creating jobs and investing in their factories.\n- General Motors Co. (NYSE: GM) will decrease because they are not creating jobs and are not investing in their factories.", "price_info": {"F": {"company": "", "ticker": "F", "move": "up", "prices": [9.38, 9.36]}, "GM": {"company": "", "ticker": "GM", "move": "down"}}}, {"link": "https://www.wsj.com/articles/senators-warn-trump-saudi-chinese-uranium-plant-risks-spread-of-nuclear-weapons-11597860000", "title": "Senators Warn Trump Saudi-Chinese Uranium Plant Risks Spread of Nuclear Weapons", "date": "2020-08-19 14:00", "summary": "Group of Democratic and Republican lawmakers request briefings on the matter, in letter to the president. WASHINGTON-A bipartisan group of U.S. senators warned President Trump on Wednesday that Saudi Arabia's undeclared nuclear and missile programs pose a serious threat to efforts to stop the spread of nuclear weapons in the region and requested briefings on the subject.", "categories": [["WSJ News Exclusive", "National Security"]], "category_links": ["https://www.wsj.com/news/types/national-security?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Senators Warn Trump Saudi-Chinese Uranium Plant Risks Spread of Nuclear Weapons. Group of Democratic and Republican lawmakers request briefings on the matter, in letter to the president. WASHINGTON-A bipartisan group of U.S. senators warned President Trump on Wednesday that Saudi Arabia's undeclared nuclear and missile programs pose a serious threat to efforts to stop the spread of nuclear weapons in the region and requested briefings on the subject.\"\n\nStock Prediction(s):", "Prediction": "\n- Lockheed Martin Corporation (NYSE: LMT) will increase because they are a major defense contractor and they have a lot of experience in the nuclear industry.\n- Boeing Company (NYSE: BA) will increase because they are a major defense contractor and they have a lot of experience in the nuclear industry.\n- General Electric Company (NYSE: GE) will decrease because they are a major defense contractor, but they are not as involved in the nuclear industry as Lockheed Martin and", "price_info": {"LMT": {"company": "", "ticker": "LMT", "move": "up"}, "BA": {"company": "", "ticker": "BA", "move": "up"}, "GE": {"company": "", "ticker": "GE", "move": "down", "prices": [6.386, 6.37]}}}, {"link": "https://www.wsj.com/articles/coca-cola-posts-higher-quarterly-revenue-amid-pandemic-pressure-11618835394", "title": "Coca-Cola Sales Rebound as Vaccine Rollout Expands", "date": "2021-04-19 09:50", "summary": "Sales volume in March matched levels from two years ago as vaccine rollout boosted return to restaurants, bars. Coca-Cola Co. said its sales volume in March returned to pre-pandemic levels as the rollout of Covid-19 vaccines allows more people to eat out again.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coca-Cola Sales Rebound as Vaccine Rollout Expands. Sales volume in March matched levels from two years ago as vaccine rollout boosted return to restaurants, bars. Coca-Cola Co. said its sales volume in March returned to pre-pandemic levels as the rollout of Covid-19 vaccines allows more people to eat out again.\"\n\nStock Prediction(s):", "Prediction": "\n- Coca-Cola Co. (NYSE: KO) will increase because their sales volume is back to pre-pandemic levels.\n- PepsiCo, Inc. (NYSE: PEP) will decrease because their sales volume is not back to pre-pandemic levels.", "price_info": {"KO": {"company": "", "ticker": "KO", "move": "up"}, "PEP": {"company": "", "ticker": "PEP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/a-super-wednesday-for-insurers-but-a-big-risklooms-11583341080", "title": "A Super Wednesday for Insurers, but a Big Risk Looms", "date": "2020-03-04 11:58", "summary": "Coronavirus could be as risky to the sector as a Bernie Sanders presidency. A big Super Tuesday for Joe Biden meant a super victory lap for health-insurance shareholders on Wednesday. Investors shouldn't assume their troubles are behind them altogether, though.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"A Super Wednesday for Insurers, but a Big Risk Looms. Coronavirus could be as risky to the sector as a Bernie Sanders presidency. A big Super Tuesday for Joe Biden meant a super victory lap for health-insurance shareholders on Wednesday. Investors shouldn't assume their troubles are behind them altogether, though.\"\n\nStock Prediction(s):", "Prediction": "\n- UnitedHealth Group Inc (NYSE: UNH) will increase because they are one of the largest health insurers in the United States, and they have already seen a positive reaction from the market.\n- Anthem Inc (NYSE: ANTM) will increase because they are one of the largest health insurers in the United States, and they have already seen a positive reaction from the market.\n- Aetna Inc (NYSE: AET) will increase because they are one", "price_info": {"UNH": {"company": "", "ticker": "UNH", "move": "up"}, "ANTM": {"company": "", "ticker": "ANTM", "move": "up"}, "AET": {"company": "", "ticker": "AET", "move": "up"}}}, {"link": "https://www.wsj.com/articles/nielsen-names-ceo-for-consumer-data-spinoff-11579027329", "title": "Nielsen Names CEO For Consumer-Data Spinoff", "date": "2020-01-14 13:42", "summary": "The company hired an online-sales executive to head its spinoff focused on shopping and retail data. Nielsen Holdings PLC hired an online-sales executive to head its spinoff focused on shopping and retail data, amid heightened competition to supply clients with granular information about consumer habits.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Nielsen Names CEO For Consumer-Data Spinoff. The company hired an online-sales executive to head its spinoff focused on shopping and retail data. Nielsen Holdings PLC hired an online-sales executive to head its spinoff focused on shopping and retail data, amid heightened competition to supply clients with granular information about consumer habits.\"\n\nStock Prediction(s):", "Prediction": "\n- Nielsen Holdings PLC (NYSE: NLSN) will increase because they are focusing on their new spinoff, which will be focused on shopping and retail data.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are a direct competitor of Nielsen, and they will be looking to increase their market share in this space.\n- Facebook, Inc. (NASDAQ: FB) will increase because they are a direct competitor", "price_info": {"NLSN": {"company": "", "ticker": "NLSN", "move": "up", "prices": [20.24, 20.38]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up"}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [219.865, 219.52]}}}, {"link": "https://www.wsj.com/articles/the-economy-is-limping-but-wall-street-is-booming-11599158494", "title": "Economy Is Limping, but Revenue Is Soaring at Wall Street's Banks", "date": "2020-09-03 14:41", "summary": "Panicky investors, pandemic-hit companies turned to banks in the first half, driving fees to an eight-year high. Investment-banking and trading revenues hit an eight-year high in the first half of 2020, a counterintuitive boom that shows the heavy hand of the Federal Reserve and a growing gulf between financial markets and the real economy.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Economy Is Limping, but Revenue Is Soaring at Wall Street's Banks. Panicky investors, pandemic-hit companies turned to banks in the first half, driving fees to an eight-year high. Investment-banking and trading revenues hit an eight-year high in the first half of 2020, a counterintuitive boom that shows the heavy hand of the Federal Reserve and a growing gulf between financial markets and the real economy.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldman Sachs Group Inc (NYSE: GS) will increase because they are one of the few banks that are doing well in this market.\n- JPMorgan Chase & Co (NYSE: JPM) will increase because they are one of the few banks that are doing well in this market.\n- Bank of America Corp (NYSE: BAC) will increase because they are one of the few banks that are doing well in this market.\n- Citigroup Inc (NYSE:", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "up"}, "JPM": {"company": "", "ticker": "JPM", "move": "up"}, "BAC": {"company": "", "ticker": "BAC", "move": "up"}}}, {"link": "https://www.wsj.com/articles/canadian-pacific-stretches-its-pocketbook-and-logic-11628607960", "title": "Canadian Pacific Stretches Its Pocketbook, and Logic", "date": "2021-08-10 12:52", "summary": "Kansas City Southern shareholders are being asked to switch suitors when they have little to gain. Two Canadian railroads' bids to snag U.S. carrier Kansas City Southern is, appropriately enough, resembling a hockey game with the action whizzing between each team's goal.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Canadian Pacific Stretches Its Pocketbook, and Logic. Kansas City Southern shareholders are being asked to switch suitors when they have little to gain. Two Canadian railroads' bids to snag U.S. carrier Kansas City Southern is, appropriately enough, resembling a hockey game with the action whizzing between each team's goal.\"\n\nStock Prediction(s):", "Prediction": "\n- Kansas City Southern (NYSE: KSU) will stay the same because they are being bid on by two Canadian railroads, and it is up to the shareholders to decide who they want to go with.\n- Canadian Pacific Railway Limited (NYSE: CP) will increase because they are the first railroad to make a bid, and they are willing to spend more money than the competition.\n- Canadian National Railway Company (NYSE: CNI) will increase because they are", "price_info": {"KSU": {"company": "", "ticker": "KSU", "move": "up", "prices": [289.6, 289.3787]}, "CP": {"company": "", "ticker": "CP", "move": "up"}, "CNI": {"company": "", "ticker": "CNI", "move": "up"}}}, {"link": "https://www.wsj.com/articles/u-s-government-bonds-decline-as-treasury-auctions-new-debt-11568133890", "title": "U.S. Government Bonds Decline as Treasury Auctions New Debt", "date": "2019-09-10 15:39", "summary": "Auction and crowded slate of corporate issuers added to supply of fresh debt. U.S. government-bond prices fell anew Tuesday, with the Treasury Department and a crowded slate of corporate issuers adding to the supply of fresh debt.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Government Bonds Decline as Treasury Auctions New Debt. Auction and crowded slate of corporate issuers added to supply of fresh debt. U.S. government-bond prices fell anew Tuesday, with the Treasury Department and a crowded slate of corporate issuers adding to the supply of fresh debt.\"\n\nStock Prediction(s):", "Prediction": "\n- The entire market will decrease because of the added supply of debt.\n- Treasury bonds will decrease because of the added supply of debt.\n- Corporate bonds will decrease because of the added supply of debt.", "price_info": {}}, {"link": "https://www.wsj.com/articles/u-s-regulator-to-move-on-low-income-lending-overhaul-without-fed-11579724385", "title": "Regulator to Move on Low-Income Lending Overhaul Without Fed", "date": "2020-01-22 15:19", "summary": "Rift between agencies means banks may have to comply with different sets of rules. WASHINGTON-A top U.S. banking regulator said Wednesday he plans to push ahead with a proposal to overhaul rules governing billions of dollars of lending in low-income neighborhoods despite objections from the Federal Reserve.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Regulator to Move on Low-Income Lending Overhaul Without Fed. Rift between agencies means banks may have to comply with different sets of rules. WASHINGTON-A top U.S. banking regulator said Wednesday he plans to push ahead with a proposal to overhaul rules governing billions of dollars of lending in low-income neighborhoods despite objections from the Federal Reserve.\"\n\nStock Prediction(s):", "Prediction": "\n- The banking sector will decrease because of the rift between agencies, and the different sets of rules that will have to be complied with.\n- Wells Fargo & Co (NYSE: WFC) will decrease because they are a direct competitor of other banks.\n- Bank of America Corp (NYSE: BAC) will decrease because they are a direct competitor of other banks.\n- JPMorgan Chase & Co (NYSE: JPM) will decrease because they are a direct competitor of", "price_info": {"WFC": {"company": "", "ticker": "WFC", "move": "down"}, "BAC": {"company": "", "ticker": "BAC", "move": "down"}, "JPM": {"company": "", "ticker": "JPM", "move": "down"}}}, {"link": "https://www.wsj.com/articles/bitcoin-bulls-under-pressure-after-cryptocurrencys-selloff-11625238740", "title": "Bitcoin Bulls Under Pressure After Cryptocurrency Selloff", "date": "2021-07-02 11:12", "summary": "The digital asset fell 41% in the second quarter, the worst selloff since 2018. Bitcoin's second-quarter selloff left a crater in the bull case for the highly speculative cryptocurrency.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bitcoin Bulls Under Pressure After Cryptocurrency Selloff. The digital asset fell 41% in the second quarter, the worst selloff since 2018. Bitcoin's second-quarter selloff left a crater in the bull case for the highly speculative cryptocurrency.\"\n\nStock Prediction(s):", "Prediction": "\n- Bitcoin (BTC) will continue to decrease because the selloff was significant and it doesn't look like it will recover soon.\n- Ethereum (ETH) will continue to increase because it is a more stable cryptocurrency and it doesn't seem to be affected by the selloff as much.\n- XRP will continue to increase because it is a more stable cryptocurrency and it doesn't seem to be affected by the selloff as much.", "price_info": {"BTC": {"company": "Bitcoin", "ticker": "BTC", "move": "up"}, "ETH": {"company": "Ethereum", "ticker": "ETH", "move": null}}}, {"link": "https://www.wsj.com/articles/that-valentines-day-dinner-will-cost-more-this-year-11581676201", "title": "That Valentine's Day Dinner Will Cost More This Year", "date": "2020-02-14 11:45", "summary": "Restaurant prices rose 3.1% in January from a year ago, matching fastest annual increase since 2009. Americans dining out on Valentine's Day will find there is a price on love that keeps moving higher.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"That Valentine's Day Dinner Will Cost More This Year. Restaurant prices rose 3.1% in January from a year ago, matching fastest annual increase since 2009. Americans dining out on Valentine's Day will find there is a price on love that keeps moving higher.\"\n\nStock Prediction(s):", "Prediction": "\n- The price of food will continue to increase, so restaurant stocks such as Darden Restaurants, Inc. (NYSE: DRI) and The Cheesecake Factory Incorporated (NASDAQ: CAKE) will also continue to increase.\n- The price of food will eventually level off, so restaurant stocks such as Darden Restaurants, Inc. (NYSE: DRI) and The Cheesecake Factory Incorporated (NASDAQ: CAKE) will eventually", "price_info": {"DRI": {"company": "", "ticker": "DRI", "move": null, "prices": [121.95, 122.02]}, "CAKE": {"company": "", "ticker": "CAKE", "move": null}}}, {"link": "https://www.wsj.com/articles/why-rising-oil-prices-are-unlikely-to-kill-the-economic-recovery-11625754584", "title": "Why Rising Oil Prices Are Unlikely to Kill the Economic Recovery", "date": "2021-07-08 10:58", "summary": "Crude prices would have to rise higher for longer to significantly brake global growth. The recent bout of higher oil prices is unlikely to make much of a dent in the global recovery, according to economists who say strong growth and flush consumers in advanced economies will help the world absorb much of the blow from costlier crude.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why Rising Oil Prices Are Unlikely to Kill the Economic Recovery. Crude prices would have to rise higher for longer to significantly brake global growth. The recent bout of higher oil prices is unlikely to make much of a dent in the global recovery, according to economists who say strong growth and flush consumers in advanced economies will help the world absorb much of the blow from costlier crude.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because their profits are tied to the price of oil, and the global economy is still growing.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because their profits are tied to the price of oil, and the global economy is still growing.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because their profits are tied to the price of oil, and the global economy is", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up"}, "XOM": {"company": "", "ticker": "XOM", "move": "up"}}}, {"link": "https://www.wsj.com/articles/jes-staley-probe-is-a-distraction-at-barclays-11581612689", "title": "Jes Staley Probe Is a Distraction at Barclays", "date": "2020-02-13 11:51", "summary": "Brexit is a bigger worry for investors than probe into the chief executive's relationship with Jeffrey Epstein. Investors may be overreacting to news of an investigation into relations between Barclays Chief Executive Jes Staley and the disgraced late billionaire Jeffrey Epstein.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Jes Staley Probe Is a Distraction at Barclays. Brexit is a bigger worry for investors than probe into the chief executive's relationship with Jeffrey Epstein. Investors may be overreacting to news of an investigation into relations between Barclays Chief Executive Jes Staley and the disgraced late billionaire Jeffrey Epstein.\"\n\nStock Prediction(s):", "Prediction": "\n- Barclays plc (NYSE: BCS) will decrease because of the distraction of the CEO's relationship with Jeffrey Epstein.\n- Royal Bank of Scotland Group plc (NYSE: RBS) will decrease because of the distraction of the CEO's relationship with Jeffrey Epstein.\n- HSBC Holdings plc (NYSE: HSBC) will decrease because of the distraction of the CEO's relationship with Jeffrey Epstein.", "price_info": {"BCS": {"company": "", "ticker": "BCS", "move": null}, "RBS": {"company": "", "ticker": "RBS", "move": "down"}, "HSBC": {"company": "", "ticker": "HSBC", "move": "down"}}}, {"link": "https://www.wsj.com/articles/rivian-raises-2-5-billion-as-investors-chase-electric-car-buzz-11594391617", "title": "Rivian Raises $2.5 Billion as Investors Chase Electric-Car Buzz", "date": "2020-07-10 10:33", "summary": "Latest round led by T. Rowe Price also includes Soros Fund and Fidelity Investments. Rivian Automotive LLC, an electric pickup-truck startup backed in part by Ford Motor Co. and Amazon.com Inc., said Friday it had secured another $2.5 billion in funding from private investors, providing it with extra cash to help navigate growing economic uncertainty and release new vehicles next year.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Rivian Raises $2.5 Billion as Investors Chase Electric-Car Buzz. Latest round led by T. Rowe Price also includes Soros Fund and Fidelity Investments. Rivian Automotive LLC, an electric pickup-truck startup backed in part by Ford Motor Co. and Amazon.com Inc., said Friday it had secured another $2.5 billion in funding from private investors, providing it with extra cash to help navigate growing economic uncertainty and release new vehicles next year.\"\n\nStock Prediction(s):", "Prediction": "\n- Rivian Automotive LLC (NYSE: RIV) will increase because they have secured more funding, and they are releasing new vehicles next year.\n- Ford Motor Co. (NYSE: F) will increase because they are backing Rivian Automotive LLC.\n- Amazon.com Inc. (NASDAQ: AMZN) will increase because they are backing Rivian Automotive LLC.", "price_info": {"RIV": {"company": "", "ticker": "RIV", "move": "up", "prices": [15.2674, 15.25]}, "F": {"company": "", "ticker": "F", "move": "up"}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3179.0599, 3177.91]}}}, {"link": "https://www.wsj.com/articles/real-bond-yields-help-explain-surprising-market-moves-11600090704", "title": "'Real' Bond Yields Help Explain Market Moves", "date": "2020-09-14 09:39", "summary": "Negative inflation-adjusted yields spur investors to keep taking risks, even after recent tech-led selloff. No single factor can completely explain this summer's surprising market moves. But one can help: so-called real yields.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"'Real' Bond Yields Help Explain Market Moves. Negative inflation-adjusted yields spur investors to keep taking risks, even after recent tech-led selloff. No single factor can completely explain this summer's surprising market moves. But one can help: so-called real yields.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will continue to move up because investors are looking for returns in a low-yield environment.\n- The market will continue to move down because investors are selling riskier assets after the recent tech-led selloff.", "price_info": {}}, {"link": "https://www.wsj.com/articles/apple-schedules-april-20-event-11618341865", "title": "Apple Schedules April 20 Event", "date": "2021-04-13 15:24", "summary": "New iPads are expected to be among product unveilings. Apple Inc. scheduled an April 20 event dubbed \"Spring Loaded,\" the tech giant's latest virtual gathering to unveil new gadgets.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple Schedules April 20 Event. New iPads are expected to be among product unveilings. Apple Inc. scheduled an April 20 event dubbed \"Spring Loaded,\" the tech giant's latest virtual gathering to unveil new gadgets.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they are releasing new iPads.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are releasing new iPads.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are releasing new iPads.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up"}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up"}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up"}}}, {"link": "https://www.wsj.com/articles/facebook-our-ai-tools-failed-to-catch-new-zealand-attack-video-11553156141", "title": "Facebook Left Up Video of New Zealand Shootings for an Hour", "date": "2019-03-21 10:46", "summary": "The 17-minute broadcast started at around 1:33 p.m. A user flagged the post 12 minutes after it ended. Police alerted Facebook to the video at 2:29 p.m. The company took it down minutes later.. Facebook Inc. left a gruesome video of shootings at a New Zealand mosque up on its site for half an hour after a user brought it to the company's attention, a previously unreported delay that highlights the social media giant's difficulty in controlling violent content on its platform.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook Left Up Video of New Zealand Shootings for an Hour. The 17-minute broadcast started at around 1:33 p.m. A user flagged the post 12 minutes after it ended. Police alerted Facebook to the video at 2:29 p.m. The company took it down minutes later.. Facebook Inc. left a gruesome video of shootings at a New Zealand mosque up on its site for half an hour after a user brought it to the company's attention, a previously unreported delay that highlights the social media giant's difficulty in controlling violent content on its platform.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook Inc. (NASDAQ: FB) will decrease because they are not good at controlling their content.\n- YouTube (owned by Google) (NASDAQ: GOOGL) will decrease because they are not good at controlling their content.\n- Twitter (NYSE: TWTR) will decrease because they are not good at controlling their content.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "down"}, "FB": {"company": "", "ticker": "FB", "move": "down"}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/apple-prepares-office-staff-for-hybrid-workweek-11622745636", "title": "Apple Prepares Office Staff for Hybrid Workweek", "date": "2021-06-03 14:40", "summary": "iPhone maker wants staff to come to the office three days a week starting in September. Apple Inc. is telling office staff to prepare to return to the workplace at least most of the time, joining the growing pool of companies adopting hybrid work.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple Prepares Office Staff for Hybrid Workweek. iPhone maker wants staff to come to the office three days a week starting in September. Apple Inc. is telling office staff to prepare to return to the workplace at least most of the time, joining the growing pool of companies adopting hybrid work.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they are preparing their staff for a hybrid workweek.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are preparing their staff for a hybrid workweek.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are preparing their staff for a hybrid workweek.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [123.8475, 123.48]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up"}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up"}}}, {"link": "https://www.wsj.com/articles/sinclair-unit-secures-financing-amid-push-into-streaming-11642084508", "title": "Sinclair Unit Secures Financing Amid Push Into Streaming", "date": "2022-01-13 09:48", "summary": "Diamond Sports, the largest owner of regional sports networks, also renewed its digital-rights agreement with NBA, securing ability to stream games. Sinclair Broadcast Group Inc., the largest owner of regional sports channels, said its sports unit has secured $600 million in debt financing as it develops a streaming service that it aims to launch by the third quarter.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Sinclair Unit Secures Financing Amid Push Into Streaming. Diamond Sports, the largest owner of regional sports networks, also renewed its digital-rights agreement with NBA, securing ability to stream games. Sinclair Broadcast Group Inc., the largest owner of regional sports channels, said its sports unit has secured $600 million in debt financing as it develops a streaming service that it aims to launch by the third quarter.\"\n\nStock Prediction(s):", "Prediction": "\n- Sinclair Broadcast Group Inc (NASDAQ: SBGI) will increase because they are expanding their business into streaming, which is a growing industry.\n- The Walt Disney Company (NYSE: DIS) will decrease because they own ESPN, which is a direct competitor of Sinclair Broadcast Group's streaming service.", "price_info": {"DIS": {"company": "", "ticker": "DIS", "move": "down"}, "SBGI": {"company": "", "ticker": "SBGI", "move": "up"}}}, {"link": "https://www.wsj.com/articles/mild-winter-weather-hammers-natural-gas-in-december-11609259528", "title": "Mild Winter Weather Hammers Natural Gas in December", "date": "2020-12-29 14:53", "summary": "Recent forecasts show warmer temperatures spreading across the U.S. in the next few weeks, driving an unwind of bullish bets. Natural-gas prices are heading for their second consecutive big monthly drop, stung by warmer-than-expected weather forecasts that are denting demand for the heating fuel.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Mild Winter Weather Hammers Natural Gas in December. Recent forecasts show warmer temperatures spreading across the U.S. in the next few weeks, driving an unwind of bullish bets. Natural-gas prices are heading for their second consecutive big monthly drop, stung by warmer-than-expected weather forecasts that are denting demand for the heating fuel.\"\n\nStock Prediction(s):", "Prediction": "\n- Cheniere Energy, Inc. (NYSEAMERICAN: LNG) will decrease because natural gas prices are dropping.\n- Dominion Energy, Inc. (NYSE: D) will decrease because natural gas prices are dropping.\n- EQT Corporation (NYSE: EQT) will decrease because natural gas prices are dropping.\n- Williams Companies, Inc. (NYSE: WMB) will decrease because natural gas prices are dropping.", "price_info": {"D": {"company": "", "ticker": "D", "move": "down"}, "EQT": {"company": "", "ticker": "EQT", "move": "down"}, "WMB": {"company": "", "ticker": "WMB", "move": "down"}}}, {"link": "https://www.wsj.com/articles/turkish-markets-in-turmoil-as-key-elections-loom-11553697848", "title": "Turkish Markets in Turmoil as Key Elections Loom", "date": "2019-03-27 12:29", "summary": "Rates for a type of Turkish lira borrowing used by currency investors jumped to more than 1,000% from just above 20% last week. The turbulence in Turkey's financial system spread Wednesday with stocks falling sharply and borrowing costs rising, as the government denied it had attempted to block foreign investors from betting against the currency.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Turkish Markets in Turmoil as Key Elections Loom. Rates for a type of Turkish lira borrowing used by currency investors jumped to more than 1,000% from just above 20% last week. The turbulence in Turkey's financial system spread Wednesday with stocks falling sharply and borrowing costs rising, as the government denied it had attempted to block foreign investors from betting against the currency.\"\n\nStock Prediction(s):", "Prediction": "\n- Turkish markets will continue to be in turmoil as the key elections loom.\n- The Turkish lira will continue to be unstable as foreign investors bet against it.\n- Stocks in Turkey will continue to fall as the government fails to stabilize the economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/kidpik-biogen-block-ally-financial-what-to-watch-when-the-stock-market-opens-today-11641988019", "title": "Biogen, PayPal, Block, Ally Financial: What to Watch in the Stock Market Today", "date": "2022-01-12 09:45", "summary": "Biogen shares were dropping; Ally Financial got a boost from a dividend hike. Wall Street stock indexes edged up after inflation data showed the largest annual jump in consumer prices in decades. Here's what we're watching in Wednesday's trading:", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Biogen, PayPal, Block, Ally Financial: What to Watch in the Stock Market Today. Biogen shares were dropping; Ally Financial got a boost from a dividend hike. Wall Street stock indexes edged up after inflation data showed the largest annual jump in consumer prices in decades. Here's what we're watching in Wednesday's trading:\"\n\nStock Prediction(s):", "Prediction": "\n- Biogen Inc (NASDAQ: BIIB) will decrease because their stock is dropping.\n- PayPal Holdings, Inc. (NASDAQ: PYPL) will increase because they are partnering with Biogen.\n- The Charles Schwab Corporation (NYSE: SCHW) will increase because they are partnering with Biogen.\n- Ally Financial Inc. (NYSE: ALLY) will increase because they are hiking their dividend.", "price_info": {"SCHW": {"company": "", "ticker": "SCHW", "move": "up", "prices": [93.99, 93.65]}, "ALLY": {"company": "", "ticker": "ALLY", "move": "up", "prices": [52.0641, 52.1583]}, "BIIB": {"company": "", "ticker": "BIIB", "move": "down"}, "PYPL": {"company": "", "ticker": "PYPL", "move": "up"}}}, {"link": "https://www.wsj.com/articles/mcdonalds-u-s-sales-rebound-from-covid-19-pandemic-11619694000", "title": "McDonald's U.S. Sales Rebound From Pandemic", "date": "2021-04-29 10:06", "summary": "Burger chain says global markets remained challenged by shifting coronavirus restrictions. McDonald's Corp. said new menu items helped it beat sales expectations in the U.S., while business abroad remained volatile because of shifting Covid-19 restrictions.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"McDonald's U.S. Sales Rebound From Pandemic. Burger chain says global markets remained challenged by shifting coronavirus restrictions. McDonald's Corp. said new menu items helped it beat sales expectations in the U.S., while business abroad remained volatile because of shifting Covid-19 restrictions.\"\n\nStock Prediction(s):", "Prediction": "\n- McDonald's Corporation (NYSE: MCD) will increase because their U.S. sales are rebounding.\n- Yum! Brands, Inc. (NYSE: YUM) will decrease because their sales are not rebounding as well as McDonald's.", "price_info": {"MCD": {"company": "", "ticker": "MCD", "move": "up", "prices": [233.81, 234.4363]}, "YUM": {"company": "", "ticker": "YUM", "move": "down"}}}, {"link": "https://www.wsj.com/articles/frozen-dinners-are-back-but-may-get-iced-out-11556891625", "title": "Frozen Dinners Are Back, but May Get Iced Out", "date": "2019-05-03 09:53", "summary": "Mosaic is now shipping frozen meals, but consumer appetite for meal kits is spoiling. \"Back to the Future\" meets meal kits.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Frozen Dinners Are Back, but May Get Iced Out. Mosaic is now shipping frozen meals, but consumer appetite for meal kits is spoiling. \"Back to the Future\" meets meal kits.\"\n\nStock Prediction(s):", "Prediction": "\n- Blue Apron Holdings Inc (NYSE: APRN) will increase because they are a direct competitor of Mosaic and they offer a more premium product.\n- HelloFresh SE (OTC: HFLYF) will increase because they are a direct competitor of Mosaic and they offer a more premium product.\n- Plated Holdings LLC (NYSE: PLATED) will increase because they are a direct competitor of Mosaic and they offer a more premium product.", "price_info": {"APRN": {"company": "", "ticker": "APRN", "move": "up", "prices": [1.008, 1]}}}, {"link": "https://www.wsj.com/articles/e-trade-apple-walmart-stocks-that-defined-the-week-11582328954", "title": "E*Trade, Apple, Walmart: Stocks That Defined the Week", "date": "2020-02-24 14:53", "summary": "Here are seven major companies whose stocks moved on the week's news. E*Trade Financial Corp.", "categories": [["Markets", "Stocks"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/markets/stocks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"E*Trade, Apple, Walmart: Stocks That Defined the Week. Here are seven major companies whose stocks moved on the week's news. E*Trade Financial Corp.\"\n\nStock Prediction(s):", "Prediction": "\n- E*Trade Financial Corp (NASDAQ: ETFC) will increase because they had a good week, with their stock prices going up.\n- Apple Inc. (NASDAQ: AAPL) will increase because they had a good week, with their stock prices going up.\n- Walmart Inc. (NYSE: WMT) will increase because they had a good week, with their stock prices going up.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up"}, "ETFC": {"company": "", "ticker": "ETFC", "move": "up", "prices": [50.48, 50.35]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up"}}}, {"link": "https://www.wsj.com/articles/should-parents-try-to-spend-the-same-amount-of-money-on-each-child-11581695678", "title": "Should Parents Try to Spend the Same Amount of Money on Each Child?", "date": "2020-02-14 10:54", "summary": "Sometimes what seems most equitable isn't necessarily the most fair. Most parents would probably say they love all of their children equally and don't play favorites. Keeping the scales balanced when it comes to family finances, however, is more complicated.", "categories": [["Markets", "Journal Reports: Wealth Management"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-wealth-management?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Should Parents Try to Spend the Same Amount of Money on Each Child?. Sometimes what seems most equitable isn't necessarily the most fair. Most parents would probably say they love all of their children equally and don't play favorites. Keeping the scales balanced when it comes to family finances, however, is more complicated.\"\n\nStock Prediction(s):", "Prediction": "\n- No prediction", "price_info": {}}, {"link": "https://www.wsj.com/articles/iphone-12-vs-iphone-11-vs-iphone-xr-vs-iphone-se-comparing-apples-full-lineup-11602626294", "title": "iPhone 12 vs. iPhone 11 vs. iPhone SE vs. iPhone XR: Comparing Apple's Full Lineup", "date": "2020-10-14 11:56", "summary": "Need help deciding which of the current iPhone models to choose? We put the four new iPhone 12 designs side by side with the three older models still on sale.. At a virtual event on Tuesday, Apple executives announced a bajillion new iPhone 12 models. Or at least pretty close to it.", "categories": [["Tech", "Personal Tech", "Personal Technology: Joanna Stern"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"iPhone 12 vs. iPhone 11 vs. iPhone SE vs. iPhone XR: Comparing Apple's Full Lineup. Need help deciding which of the current iPhone models to choose? We put the four new iPhone 12 designs side by side with the three older models still on sale.. At a virtual event on Tuesday, Apple executives announced a bajillion new iPhone 12 models. Or at least pretty close to it.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they have a new lineup of iPhones that are being released.\n- Samsung Electronics Co Ltd (OTC: SSNLF) will decrease because they are a direct competitor of Apple.\n- Huawei Technologies Co Ltd (OTC: HWTUF) will decrease because they are a direct competitor of Apple.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/china-investigates-ericsson-over-licensing-as-5g-competition-heats-up-11555332158", "title": "China Investigates Ericsson Over Licensing Amid 5G Competition", "date": "2019-04-15 12:22", "summary": "Trump, meanwhile, lashed out at Huawei after a former Obama-era official registered as a lobbyist for the firm. Authorities in China are investigating Swedish telecom-equipment giant Ericsson AB while the firm's Chinese rival, Huawei Technologies Co., moves to counter a U.S. campaign to limit its business, the latest signs of global jockeying to shape next-generation 5G information networks.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"China Investigates Ericsson Over Licensing Amid 5G Competition. Trump, meanwhile, lashed out at Huawei after a former Obama-era official registered as a lobbyist for the firm. Authorities in China are investigating Swedish telecom-equipment giant Ericsson AB while the firm's Chinese rival, Huawei Technologies Co., moves to counter a U.S. campaign to limit its business, the latest signs of global jockeying to shape next-generation 5G information networks.\"\n\nStock Prediction(s):", "Prediction": "\n- Ericsson AB (NASDAQ: ERIC) will decrease because they are being investigated by the Chinese government.\n- Huawei Technologies Co. (NYSE: HWT) will increase because they are being targeted by the United States, and they are a direct competitor of Ericsson.", "price_info": {"HWT": {"company": "", "ticker": "HWT", "move": "up"}, "ERIC": {"company": "", "ticker": "ERIC", "move": "down"}}}, {"link": "https://www.wsj.com/articles/as-world-turns-inward-shinzo-abes-japan-has-turned-outward-11599066608", "title": "As World Turns Inward, Shinzo Abe's Japan Has Turned Outward", "date": "2020-09-02 13:10", "summary": "Departing prime minister's legacy is a more globally engaged Japan. You wouldn't have picked Shinzo Abe as globalization's future champion when he became prime minister of Japan in 2012. He was a proud nationalist intent on rekindling Japanese patriotism, loosening the shackles on the country's military, and playing down its past aggression. No free-market ideologue, he criticized his predecessor's negotiations to join the Trans-Pacific Partnership, an ambitious trade pact with the U.S. and 10 other Pacific nations.", "categories": [["Economy", "Capital Account"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/capital-account?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"As World Turns Inward, Shinzo Abe's Japan Has Turned Outward. Departing prime minister's legacy is a more globally engaged Japan. You wouldn't have picked Shinzo Abe as globalization's future champion when he became prime minister of Japan in 2012. He was a proud nationalist intent on rekindling Japanese patriotism, loosening the shackles on the country's military, and playing down its past aggression. No free-market ideologue, he criticized his predecessor's negotiations to join the Trans-Pacific Partnership, an ambitious trade pact with the U.S. and 10 other Pacific nations.\"\n\nStock Prediction(s):", "Prediction": "\n- Shinzo Abe's (Liberal Democratic Party) legacy will be a more globally engaged Japan, which will benefit companies such as Toyota Motor Corporation (NYSE: TM), Panasonic Corporation (OTCMKTS: PCRFY), and Canon Inc. (NYSE: CAJ).\n- The Democratic Party of Japan will take over as the ruling party in Japan, and they will be less supportive of globalization, which will hurt companies such as Toyota, Panasonic, and Canon.", "price_info": {"TM": {"company": "", "ticker": "TM", "move": "up", "prices": [131.88, 132.356]}, "CAJ": {"company": "", "ticker": "CAJ", "move": "up"}}}, {"link": "https://www.wsj.com/articles/honda-to-close-u-s-factories-for-a-week-over-supply-issues-11615954099", "title": "Toyota, Honda Shut U.S. Factories as Supplies Run Short", "date": "2021-03-17 10:53", "summary": "Cold weather and port logjams add to problems obtaining parts, while Samsung warns its business will suffer from chip shortage. Toyota Motor Corp. , Honda Motor Co. and Samsung Electronics Co. said supply-chain problems were complicating their businesses, as freak weather, port blockages and the continued impact of Covid-19 combine to disrupt global supply chains.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Toyota, Honda Shut U.S. Factories as Supplies Run Short. Cold weather and port logjams add to problems obtaining parts, while Samsung warns its business will suffer from chip shortage. Toyota Motor Corp. , Honda Motor Co. and Samsung Electronics Co. said supply-chain problems were complicating their businesses, as freak weather, port blockages and the continued impact of Covid-19 combine to disrupt global supply chains.\"\n\nStock Prediction(s):", "Prediction": "\n- Toyota Motor Corp. (NYSE: TM) will decrease because of the supply-chain problems.\n- Honda Motor Co. (NYSE: HMC) will decrease because of the supply-chain problems.\n- Samsung Electronics Co. (OTC: SSNLF) will decrease because of the supply-chain problems.", "price_info": {"TM": {"company": "", "ticker": "TM", "move": "down"}, "HMC": {"company": "", "ticker": "HMC", "move": "down"}}}, {"link": "https://www.wsj.com/articles/juul-to-stop-selling-mint-e-cigarettes-11573159938", "title": "Juul to Stop Selling Mint E-Cigarettes", "date": "2019-11-07 15:52", "summary": "Company says move is in response to new data showing popularity of the flavor among teens. Juul Labs Inc. said Thursday it was voluntarily stopping the sale of its mint-flavored e-cigarette refill pods, citing new government data on the flavor's popularity among teens.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Juul to Stop Selling Mint E-Cigarettes. Company says move is in response to new data showing popularity of the flavor among teens. Juul Labs Inc. said Thursday it was voluntarily stopping the sale of its mint-flavored e-cigarette refill pods, citing new government data on the flavor's popularity among teens.\"\n\nStock Prediction(s):", "Prediction": "\n- Juul Labs Inc. (NASDAQ: JUUL) will decrease because they are stopping the sale of their mint-flavored e-cigarette refill pods.", "price_info": {"JUUL": {"company": "", "ticker": "JUUL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/kraft-heinz-shares-slide-after-3g-capital-trims-stake-11568734091", "title": "Kraft Heinz Shares Slide After 3G Trims Stake", "date": "2019-09-17 11:28", "summary": "Brazilian private-equity firm sells about 9% of its stake in struggling food maker. The private-equity firm that helped create Kraft Heinz Co. has sold about 9% of its stake in the struggling food maker, a move that weighed on the company's shares Tuesday.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Kraft Heinz Shares Slide After 3G Trims Stake. Brazilian private-equity firm sells about 9% of its stake in struggling food maker. The private-equity firm that helped create Kraft Heinz Co. has sold about 9% of its stake in the struggling food maker, a move that weighed on the company's shares Tuesday.\"\n\nStock Prediction(s):", "Prediction": "\n- Kraft Heinz Co. (NASDAQ: KHC) will continue to slide because 3G is selling its stake.\n- Mondelez International, Inc. (NASDAQ: MDLZ) will increase because they are not affiliated with 3G.", "price_info": {"KHC": {"company": "", "ticker": "KHC", "move": null}, "MDLZ": {"company": "", "ticker": "MDLZ", "move": "up", "prices": [54.685, 54.7]}}}, {"link": "https://www.wsj.com/articles/demand-at-feds-repo-operations-still-strong-especially-for-longer-loans-11583419829", "title": "Demand at Fed's Repo Operations Still Strong, Especially for Longer Loans", "date": "2020-03-05 10:10", "summary": "Major banks' demand for two-week repos exceeds Fed limit. Major banks' demand for short-term cash from the Federal Reserve remained strong on Thursday, although there was some softening in the appetite for overnight loans.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Demand at Fed's Repo Operations Still Strong, Especially for Longer Loans. Major banks' demand for two-week repos exceeds Fed limit. Major banks' demand for short-term cash from the Federal Reserve remained strong on Thursday, although there was some softening in the appetite for overnight loans.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve Bank of New York (NYSE: FRBNY) will increase because the demand for their repo operations is still strong.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because the demand for their repo operations is still strong.\n- Bank of America Corp (NYSE: BAC) will increase because the demand for their repo operations is still strong.\n- Goldman Sachs Group Inc. (NYSE: GS) will increase because the demand", "price_info": {"FRBNY": {"company": "", "ticker": "FRBNY", "move": "up"}, "JPM": {"company": "", "ticker": "JPM", "move": "up"}, "BAC": {"company": "", "ticker": "BAC", "move": "up"}, "GS": {"company": "", "ticker": "GS", "move": "up"}}}, {"link": "https://www.wsj.com/articles/covid-19-makes-fsa-contribution-decisions-trickier-11605193201", "title": "Covid-19 Makes FSA Contribution Decisions Trickier", "date": "2020-11-12 10:00", "summary": "Closed day-care centers, delayed medical care complicate the math for 2021 flexible spending accounts. The pandemic has made it trickier to calculate how much to contribute next year to any flexible spending accounts your employer offers.", "categories": [["Markets", "Personal Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/personal-finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Covid-19 Makes FSA Contribution Decisions Trickier. Closed day-care centers, delayed medical care complicate the math for 2021 flexible spending accounts. The pandemic has made it trickier to calculate how much to contribute next year to any flexible spending accounts your employer offers.\"\n\nStock Prediction(s):", "Prediction": "\n- FSA contributions will increase because people do not want to lose the money that they have already put in.\n- FSA contributions will decrease because people do not want to put more money into a system that might not be there when they need it.", "price_info": {}}, {"link": "https://www.wsj.com/articles/natural-gas-on-track-for-best-week-since-january-11561731177", "title": "Heat Wave Powers Natural Gas to Best Week Since January", "date": "2019-06-28 15:17", "summary": "Prices climb for the week as traders position for continued warm weather. Natural-gas prices edged lower Friday but still closed out their best week since January, a sign some traders are positioning for warm summer weather that could lift demand.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Heat Wave Powers Natural Gas to Best Week Since January. Prices climb for the week as traders position for continued warm weather. Natural-gas prices edged lower Friday but still closed out their best week since January, a sign some traders are positioning for warm summer weather that could lift demand.\"\n\nStock Prediction(s):", "Prediction": "\n- Chesapeake Energy Corporation (NYSE: CHK) will increase because of the heat wave and the increased demand for natural gas.\n- Devon Energy Corporation (NYSE: DVN) will increase because of the heat wave and the increased demand for natural gas.\n- EOG Resources, Inc. (NYSE: EOG) will increase because of the heat wave and the increased demand for natural gas.\n- Southwestern Energy Company (NYSE: SWN) will increase", "price_info": {"CHK": {"company": "", "ticker": "CHK", "move": "up", "prices": [1.95, 1.96]}, "DVN": {"company": "", "ticker": "DVN", "move": "up"}, "EOG": {"company": "", "ticker": "EOG", "move": "up"}, "SWN": {"company": "", "ticker": "SWN", "move": "up"}}}, {"link": "https://www.wsj.com/articles/home-depots-quarterly-profit-rises-11582631034", "title": "Home Depot's Quarterly Profit Rises", "date": "2020-02-25 15:10", "summary": "Retailer's finance chief says the economy is strong and the U.S. consumer is 'healthy'. Home Depot Inc. posted higher profit for its latest quarter, a sign of health for the U.S. economy following lackluster sales reports from other retailers in recent weeks.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Home Depot's Quarterly Profit Rises. Retailer's finance chief says the economy is strong and the U.S. consumer is 'healthy'. Home Depot Inc. posted higher profit for its latest quarter, a sign of health for the U.S. economy following lackluster sales reports from other retailers in recent weeks.\"\n\nStock Prediction(s):", "Prediction": "\n- Home Depot Inc. (NYSE: HD) will increase because their profit rose, and they are a sign of health for the U.S. economy.\n- Lowe's Companies, Inc. (NYSE: LOW) will decrease because their profit declined, and they are not as healthy as Home Depot.", "price_info": {"HD": {"company": "", "ticker": "HD", "move": "up"}, "LOW": {"company": "", "ticker": "LOW", "move": "down"}}}, {"link": "https://www.wsj.com/articles/boeing-swings-to-profit-on-defense-and-jet-sales-11627474051", "title": "Boeing Swings to Profit on Defense and Jet Sales", "date": "2021-07-28 15:11", "summary": "Aircraft orders and defense business underpin improvement, as 10,000 job cuts are shelved amid the airline industry's recovery. Boeing Co. reported its first quarterly profit in nearly two years and said it needs orders from China to participate fully in a stronger-than-expected recovery in air travel.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Boeing Swings to Profit on Defense and Jet Sales. Aircraft orders and defense business underpin improvement, as 10,000 job cuts are shelved amid the airline industry's recovery. Boeing Co. reported its first quarterly profit in nearly two years and said it needs orders from China to participate fully in a stronger-than-expected recovery in air travel.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co. (NYSE: BA) will increase because they have a strong defense and jet sales business, which is improving.\n- Airbus SE (OTCMKTS: EADSY) will decrease because they are Boeing's main competitor in the aircraft market.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down"}}}, {"link": "https://www.wsj.com/articles/european-consumers-despondent-as-coronavirus-lockdowns-spread-11584979772", "title": "European Consumers Despondent as Lockdowns Spread", "date": "2020-03-23 13:46", "summary": "Strict restrictions on movement and interaction will likely push the eurozone into recession. LONDON-Europeans became much gloomier about their economic prospects in early March as governments across the continent announced increasingly stringent restrictions on movement and social interaction, suffering the largest loss of confidence in a single month on record.", "categories": [["Economy", "Europe Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/europe-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"European Consumers Despondent as Lockdowns Spread. Strict restrictions on movement and interaction will likely push the eurozone into recession. LONDON-Europeans became much gloomier about their economic prospects in early March as governments across the continent announced increasingly stringent restrictions on movement and social interaction, suffering the largest loss of confidence in a single month on record.\"\n\nStock Prediction(s):", "Prediction": "\n- European stocks will generally decrease because of the recession that is likely to happen.\n- Luxottica Group SpA (BIT: LUX) will decrease because of the recession that is likely to happen.\n- Ferrari NV (NYSE: RACE) will decrease because of the recession that is likely to happen.\n- Adidas AG (ETR: ADS) will decrease because of the recession that is likely to happen.", "price_info": {"RACE": {"company": "", "ticker": "RACE", "move": "down", "prices": [135.232, 132.29]}}}, {"link": "https://www.wsj.com/articles/wsj-survey-most-economists-say-fed-s-next-move-is-rate-cut-11560434400", "title": "Most Economists Say Fed's Next Move Is Rate Cut, Survey Says", "date": "2019-06-13 10:00", "summary": "Nearly 40% of the 46 economists anticipated the central bank would act in July, while roughly 30% expected a rate cut in September. More than three-quarters of economists surveyed by The Wall Street Journal expect the Federal Reserve's next move will be to lower interest rates, which most expect to happen by the fall.", "categories": [["WSJ News Exclusive", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Most Economists Say Fed's Next Move Is Rate Cut, Survey Says. Nearly 40% of the 46 economists anticipated the central bank would act in July, while roughly 30% expected a rate cut in September. More than three-quarters of economists surveyed by The Wall Street Journal expect the Federal Reserve's next move will be to lower interest rates, which most expect to happen by the fall.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve's next move will be to lower interest rates, which will cause most stocks to go up.\n- The only exception to this rule will be companies that are directly competing with the Federal Reserve, such as Goldman Sachs (NYSE: GS) and JPMorgan Chase (NYSE: JPM).", "price_info": {"GS": {"company": "", "ticker": "GS", "move": null}, "JPM": {"company": "", "ticker": "JPM", "move": null}}}, {"link": "https://www.wsj.com/articles/how-to-prep-your-bike-for-winter-rides-11610050350", "title": "How to Prep Your Bike for Winter Rides", "date": "2021-01-07 15:12", "summary": "Don't let gray days and icy roads leave you trapped inside. Here, a guide to all the gear you need-from tires to fenders to lights-to winterize your bike.. WITH AMERICANS desperate to escape their cramped confines, bike sales have soared along with Covid-19, increasing by 62% between January and October 2020 compared with the same period in 2019, according to market research firm NPD Group. If you're a fair-weather cyclist, however, winter's chill poses a bump in the road-unless you protect your pandemic purchase.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Prep Your Bike for Winter Rides. Don't let gray days and icy roads leave you trapped inside. Here, a guide to all the gear you need-from tires to fenders to lights-to winterize your bike.. WITH AMERICANS desperate to escape their cramped confines, bike sales have soared along with Covid-19, increasing by 62% between January and October 2020 compared with the same period in 2019, according to market research firm NPD Group. If you're a fair-weather cyclist, however, winter's chill poses a bump in the road-unless you protect your pandemic purchase.\"\n\nStock Prediction(s):", "Prediction": "\n- Bike sales will continue to increase because people are looking for ways to get outside and exercise.\n- Shimano Inc (TSE: 7309) will increase because they make bike components, and people will be upgrading their bikes to prepare for winter rides.\n- Specialized Bicycle Components, Inc. (NASDAQ: SPID) will increase because they make bikes, and people will be upgrading their bikes to prepare for winter rides.\n- Trek Bicycle Corporation (NAS", "price_info": {"SPID": {"company": "", "ticker": "SPID", "move": "up"}}}, {"link": "https://www.wsj.com/articles/elon-musk-is-the-worlds-richest-person-he-likes-to-brag-about-it-too-11633976893", "title": "Elon Musk Is the World's Richest Person. He Likes to Brag to Jeff Bezos About It, Too.", "date": "2021-10-11 14:34", "summary": "Mr. Musk replied to Amazon founder on Twitter with a silver medal emoji, an apparent reference to their wealth. Elon Musk is currently the world's richest person. He doesn't want Jeff Bezos to forget it.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Elon Musk Is the World's Richest Person. He Likes to Brag to Jeff Bezos About It, Too.. Mr. Musk replied to Amazon founder on Twitter with a silver medal emoji, an apparent reference to their wealth. Elon Musk is currently the world's richest person. He doesn't want Jeff Bezos to forget it.\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla, Inc. (TSLA) will increase because Elon Musk is the richest person in the world, and he is the CEO of Tesla.\n- Amazon.com, Inc. (AMZN) will decrease because Jeff Bezos is no longer the richest person in the world, and he is the CEO of Amazon.", "price_info": {"TSLA": {"company": "Tesla, Inc.", "ticker": "TSLA", "move": "up"}, "AMZN": {"company": "Amazon.com, Inc.", "ticker": "AMZN", "move": "down"}}}, {"link": "https://www.wsj.com/articles/conagra-ceo-sees-new-consumer-behaviors-lasting-well-into-the-future-11610035005", "title": "Conagra Bets New Consumer Behaviors Will Outlast Pandemic", "date": "2021-01-07 13:07", "summary": "Company ramps up production, advertising to capitalize on past year's shifts toward packaged foods. Conagra Brands Inc. said it is investing in added manufacturing capacity and marketing, aiming to maintain pandemic-driven sales momentum.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Conagra Bets New Consumer Behaviors Will Outlast Pandemic. Company ramps up production, advertising to capitalize on past year's shifts toward packaged foods. Conagra Brands Inc. said it is investing in added manufacturing capacity and marketing, aiming to maintain pandemic-driven sales momentum.\"\n\nStock Prediction(s):", "Prediction": "\n- Conagra Brands Inc. (NYSE: CAG) will increase because they are investing in their production and advertising to capitalize on the pandemic.\n- Kraft Heinz Co (NASDAQ: KHC) will decrease because they are not investing in their production and advertising to capitalize on the pandemic.", "price_info": {"CAG": {"company": "", "ticker": "CAG", "move": "up"}, "KHC": {"company": "", "ticker": "KHC", "move": "down"}}}, {"link": "https://www.wsj.com/articles/chiles-latam-airlines-files-for-u-s-bankruptcy-protection-11590505245", "title": "Chile's Latam Airlines Files for U.S. Bankruptcy Protection", "date": "2020-05-26 11:00", "summary": "Shareholders put up a $900 million bankruptcy loan to keep Latin America's largest airline afloat. Chile's Latam Airlines Group SA, the largest airline in Latin America, has filed for bankruptcy protection in the U.S. after travel restrictions all but emptied the skies in the region, sending air carriers scrambling for ways to cushion the coronavirus impact.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Chile's Latam Airlines Files for U.S. Bankruptcy Protection. Shareholders put up a $900 million bankruptcy loan to keep Latin America's largest airline afloat. Chile's Latam Airlines Group SA, the largest airline in Latin America, has filed for bankruptcy protection in the U.S. after travel restrictions all but emptied the skies in the region, sending air carriers scrambling for ways to cushion the coronavirus impact.\"\n\nStock Prediction(s):", "Prediction": "\n- LATAM Airlines Group SA (NYSE: LTM) will decrease because they have filed for bankruptcy protection.\n- American Airlines Group Inc (NASDAQ: AAL) will decrease because they are a direct competitor of LATAM Airlines.\n- United Airlines Holdings Inc (NASDAQ: UAL) will decrease because they are a direct competitor of LATAM Airlines.", "price_info": {"LTM": {"company": "", "ticker": "LTM", "move": "down"}, "AAL": {"company": "", "ticker": "AAL", "move": null}, "UAL": {"company": "", "ticker": "UAL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/cfpb-chief-kathy-kraninger-sees-role-for-companies-in-preventing-consumer-harm-11551988530", "title": "Consumer-Finance Watchdog: Firms Have Role in Policing Themselves", "date": "2019-03-07 14:55", "summary": "Democrats press new CFPB director on the bureau's direction under Trump-appointed leaders. WASHINGTON-The Trump administration's new consumer-finance chief said she wants to work with businesses to prevent harm to consumers, pledging a collaborative approach to policing financial companies.", "categories": [["Markets", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Consumer-Finance Watchdog: Firms Have Role in Policing Themselves. Democrats press new CFPB director on the bureau's direction under Trump-appointed leaders. WASHINGTON-The Trump administration's new consumer-finance chief said she wants to work with businesses to prevent harm to consumers, pledging a collaborative approach to policing financial companies.\"\n\nStock Prediction(s):", "Prediction": "\n- The stocks of consumer-finance companies will increase because the CFPB is no longer going to be as aggressive in regulating them.\n- The stocks of credit-rating agencies will increase because the CFPB is no longer going to be as aggressive in regulating them.", "price_info": {}}, {"link": "https://www.wsj.com/articles/in-praise-of-ticker-symbols-11585066807", "title": "In Praise of Ticker Symbols", "date": "2020-03-24 12:20", "summary": "Corporate homonyms in the stock market can cause sudden pops and drops for retail investors who aren't cautious. Once upon a time, trainee stock brokers were expected to memorize the ticker symbol of every company in the S&P 500. Also once upon a time, people called actual human brokers to place orders that were then executed by a floor trader.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"In Praise of Ticker Symbols. Corporate homonyms in the stock market can cause sudden pops and drops for retail investors who aren't cautious. Once upon a time, trainee stock brokers were expected to memorize the ticker symbol of every company in the S&P 500. Also once upon a time, people called actual human brokers to place orders that were then executed by a floor trader.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because their ticker symbol is \"GOOGL\" and it is pronounced the same as \"Google.\"\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because their ticker symbol is \"AMZN\" and it is pronounced the same as \"Amazon.\"\n- Apple Inc. (NASDAQ: AAPL) will increase because their ticker symbol is \"", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "up"}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up"}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up"}}}, {"link": "https://www.wsj.com/articles/bankruptcy-pros-want-protections-broadened-to-blunt-coronavirus-impact-11584978603", "title": "Bankruptcy Pros Want Protections Broadened to Blunt Coronavirus Impact", "date": "2020-03-23 11:50", "summary": "The National Bankruptcy Conference urged Congress to loosen restrictions on bankruptcy relief for consumers and businesses, saying current law isn't up to the task. Bankruptcy protections should be broadened for consumers and businesses to help ameliorate the financial damage stemming from the coronavirus, an influential group of bankruptcy professionals said.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bankruptcy Pros Want Protections Broadened to Blunt Coronavirus Impact. The National Bankruptcy Conference urged Congress to loosen restrictions on bankruptcy relief for consumers and businesses, saying current law isn't up to the task. Bankruptcy protections should be broadened for consumers and businesses to help ameliorate the financial damage stemming from the coronavirus, an influential group of bankruptcy professionals said.\"\n\nStock Prediction(s):", "Prediction": "\n- General Motors Company (NYSE: GM) will increase because they are a large company that could go bankrupt if the coronavirus continues to have a large impact.\n- Ford Motor Company (NYSE: F) will increase because they are a large company that could go bankrupt if the coronavirus continues to have a large impact.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because they are a large company that could go bankrupt if the", "price_info": {"GM": {"company": "", "ticker": "GM", "move": "up", "prices": [17.9117, 17.6007]}, "F": {"company": "", "ticker": "F", "move": "up"}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up"}}}, {"link": "https://www.wsj.com/articles/tesla-says-its-car-cameras-arent-activated-in-china-11617804602", "title": "Tesla Says Its In-Car Cameras Aren't Activated in China", "date": "2021-04-12 14:45", "summary": "Company moves to reassure consumers concerned about privacy after Beijing restricted use of the vehicles. Cameras inside Tesla Inc. vehicles aren't activated outside of North America, the company said Wednesday, the latest in the American electric-vehicle maker's efforts to ease privacy concerns about its cars in China.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tesla Says Its In-Car Cameras Aren't Activated in China. Company moves to reassure consumers concerned about privacy after Beijing restricted use of the vehicles. Cameras inside Tesla Inc. vehicles aren't activated outside of North America, the company said Wednesday, the latest in the American electric-vehicle maker's efforts to ease privacy concerns about its cars in China.\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla, Inc. (TSLA) will increase because they have clarified that their in-car cameras are not activated in China.\n- Apple Inc. (AAPL) will decrease because they are a direct competitor of Tesla, and this news could take away some of their market share.", "price_info": {"TSLA": {"company": "Tesla, Inc.", "ticker": "TSLA", "move": "up"}, "AAPL": {"company": "Apple Inc.", "ticker": "AAPL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/comcast-offers-web-connected-tv-service-to-its-internet-customers-11553197471", "title": "Comcast Offers Web-Connected TV Service to Its Internet Customers", "date": "2019-03-21 15:44", "summary": "The 'Xfinity Flex' service, which will cost $5 a month, is being rolled out next week. Comcast Corp. on Thursday unveiled a $5-a-month service for its internet-only customers that will allow access to ad-supported streaming video channels like YouTube and Cheddar, an initiative that could bring in more revenue from people who aren't subscribing to the cable giant's pay-TV service.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Comcast Offers Web-Connected TV Service to Its Internet Customers. The 'Xfinity Flex' service, which will cost $5 a month, is being rolled out next week. Comcast Corp. on Thursday unveiled a $5-a-month service for its internet-only customers that will allow access to ad-supported streaming video channels like YouTube and Cheddar, an initiative that could bring in more revenue from people who aren't subscribing to the cable giant's pay-TV service.\"\n\nStock Prediction(s):", "Prediction": "\n- Comcast Corporation (NASDAQ: CMCSA) will increase because they are expanding their services to include web-connected TV.\n- Roku, Inc. (NASDAQ: ROKU) will increase because they are a direct competitor of Comcast and this will put them at a disadvantage.\n- Apple Inc. (NASDAQ: AAPL) will increase because they are also expanding their services to include web-connected TV.", "price_info": {"CMCSA": {"company": "", "ticker": "CMCSA", "move": "up"}, "ROKU": {"company": "", "ticker": "ROKU", "move": "up"}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up"}}}, {"link": "https://www.wsj.com/articles/consumer-credit-repair-what-to-know-11633014000", "title": "Consumer-Credit Repair: What to Know", "date": "2021-09-30 11:00", "summary": "A mistake on your credit report can make car loans, mortgages and other financial products harder to obtain and more costly. But there are ways to find errors and fix them.. You may have heard horror stories about people whose credit has been permanently ruined by egregious errors on their credit report.", "categories": [["Markets", "Journal Reports: Funds/ETFs"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-funds-etfs?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Consumer-Credit Repair: What to Know. A mistake on your credit report can make car loans, mortgages and other financial products harder to obtain and more costly. But there are ways to find errors and fix them.. You may have heard horror stories about people whose credit has been permanently ruined by egregious errors on their credit report.\"\n\nStock Prediction(s):", "Prediction": "\n- Credit repair companies will increase in value because of the increase in demand for their services.\n- Credit Karma, Inc. (NYSE: COK) will be the biggest beneficiary because they are the most well-known and trusted credit repair company.\n- Other credit repair companies, such as Lexington Law, will also increase in value.", "price_info": {"COK": {"company": "", "ticker": "COK", "move": "up"}}}, {"link": "https://www.wsj.com/articles/airline-makes-real-money-on-fake-flights-11602604097", "title": "Airline Makes Real Money on Fake Flights", "date": "2020-10-13 11:48", "summary": "Industry's new revenue-generating schemes mirror the desperation felt by cooped-up consumers. Nothing brings to mind pleasure quite like the memory of bumping elbows with strangers while trying to carve up \"chicken or beef\" with plastic cutlery.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Airline Makes Real Money on Fake Flights. Industry's new revenue-generating schemes mirror the desperation felt by cooped-up consumers. Nothing brings to mind pleasure quite like the memory of bumping elbows with strangers while trying to carve up \"chicken or beef\" with plastic cutlery.\"\n\nStock Prediction(s):", "Prediction": "\n- Airlines will generally increase because people are desperate to get out and they are finding new ways to make money.\n- Boeing (NYSE: BA) will increase because they are the biggest airplane manufacturer and this will help them sell more planes.\n- Ryanair Holdings plc (NASDAQ: RYAAY) will increase because they are the cheapest airline and people are looking for the best deals.\n- American Airlines Group Inc (NASDAQ: AAL) will", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [163.955, 163.6501]}, "RYAAY": {"company": "", "ticker": "RYAAY", "move": "up"}, "AAL": {"company": "", "ticker": "AAL", "move": "up"}}}, {"link": "https://www.wsj.com/articles/bluestone-resources-sues-greensill-capital-for-fraud-11615907626", "title": "Greensill Capital Is Sued for Fraud", "date": "2021-03-16 13:48", "summary": "Suit by coal-mining company owned by West Virginia governor is tied to $850 million loan. A coal miner owned by the governor of West Virginia has become embroiled in a scandal surrounding a U.K. financing company that declared insolvency last week, suing the lender for alleged fraud.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Greensill Capital Is Sued for Fraud. Suit by coal-mining company owned by West Virginia governor is tied to $850 million loan. A coal miner owned by the governor of West Virginia has become embroiled in a scandal surrounding a U.K. financing company that declared insolvency last week, suing the lender for alleged fraud.\"\n\nStock Prediction(s):", "Prediction": "\n- Greensill Capital Ltd. (OTC: GSC) will decrease because of the lawsuit.\n- Other lenders such as Goldman Sachs Group Inc. (NYSE: GS) and JPMorgan Chase & Co. (NYSE: JPM) will increase because they are not involved in the lawsuit.", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "down"}, "JPM": {"company": "", "ticker": "JPM", "move": "up"}}}, {"link": "https://www.wsj.com/articles/village-roadshow-producer-on-movies-including-joker-and-the-matrix-explores-strategic-options-11642182117", "title": "Village Roadshow, Producer on 'Joker' and 'The Matrix,' Explores Strategic Options", "date": "2022-01-14 12:42", "summary": "Film-and-TV financier has tapped investment bank PJT to explore variety of options and has considered a sale. Village Roadshow Entertainment Group, a film-and-television financier with a deep library of content, is exploring strategic options including taking on a significant investment or selling itself, according to people familiar with the matter.", "categories": [["WSJ News Exclusive", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Village Roadshow, Producer on 'Joker' and 'The Matrix,' Explores Strategic Options. Film-and-TV financier has tapped investment bank PJT to explore variety of options and has considered a sale. Village Roadshow Entertainment Group, a film-and-television financier with a deep library of content, is exploring strategic options including taking on a significant investment or selling itself, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Village Roadshow Entertainment Group Ltd. (ASX: VRL) will increase because they are exploring strategic options and have tapped an investment bank.\n- Warner Bros. Entertainment Inc. (NYSE: TWX) will increase because they are a direct competitor of Village Roadshow and own a majority of the company.\n- 21st Century Fox Inc. (NASDAQ: FOX) will increase because they are a direct competitor of Village Roadshow and own a majority of", "price_info": {"TWX": {"company": "", "ticker": "TWX", "move": "up"}, "FOX": {"company": "", "ticker": "FOX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/ups-names-carol-tome-chief-executive-11584015226", "title": "UPS Replaces CEO David Abney With Board Member", "date": "2020-03-12 11:58", "summary": "Carol Tom\u00e9 will be the first outsider to run the package giant and will take over as CEO on June 1. United Parcel Service Inc. said Chief Executive David Abney is stepping down from the role and will be succeeded by board member Carol Tom\u00e9, the first outsider to run the century-old delivery giant.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"UPS Replaces CEO David Abney With Board Member. Carol Tom\u00e9 will be the first outsider to run the package giant and will take over as CEO on June 1. United Parcel Service Inc. said Chief Executive David Abney is stepping down from the role and will be succeeded by board member Carol Tom\u00e9, the first outsider to run the century-old delivery giant.\"\n\nStock Prediction(s):", "Prediction": "\n- UPS (NYSE: UPS) will increase because they have a new CEO, and she is an outsider with a lot of experience.\n- FedEx Corporation (NYSE: FDX) will decrease because they are a direct competitor of UPS.", "price_info": {"UPS": {"company": "", "ticker": "UPS", "move": "up"}, "FDX": {"company": "", "ticker": "FDX", "move": "down", "prices": [99.2, 99.3299]}}}, {"link": "https://www.wsj.com/articles/g7-finance-ministers-central-bankers-stand-ready-to-cooperate-further-to-address-coronavirus-11583240339", "title": "Mnuchin Ready to Work With Congress on Emergency Funding Package", "date": "2020-03-03 12:26", "summary": "G-7 countries ready to cooperate on actions to guard against economic risks from coronavirus, officials say. WASHINGTON-Treasury Secretary Steven Mnuchin said the administration looked forward to an emergency funding package from Congress to deal with the spreading coronavirus and signaled it is prepared to ask for more as authorities in the U.S. and around the world race to mitigate the economic impact of the epidemic.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Mnuchin Ready to Work With Congress on Emergency Funding Package. G-7 countries ready to cooperate on actions to guard against economic risks from coronavirus, officials say. WASHINGTON-Treasury Secretary Steven Mnuchin said the administration looked forward to an emergency funding package from Congress to deal with the spreading coronavirus and signaled it is prepared to ask for more as authorities in the U.S. and around the world race to mitigate the economic impact of the epidemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldman Sachs Group Inc (NYSE: GS) will increase because they have been predicting that a pandemic would happen, and they will be able to capitalize on the market volatility.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they have been predicting that a pandemic would happen, and they will be able to capitalize on the market volatility.\n- Bank of America Corp (NYSE: BAC) will increase because they have been predicting that a", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "up"}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [117.815, 117.02]}, "BAC": {"company": "", "ticker": "BAC", "move": "up"}}}, {"link": "https://www.wsj.com/articles/wsj-survey-coronavirus-to-trigger-u-s-growth-contraction-in-second-quarter-11583958308", "title": "WSJ Survey: Coronavirus to Trigger U.S. Economic Contraction in Second Quarter", "date": "2020-03-12 10:06", "summary": "Economists polled by The Wall Street Journal see 'significant drag' on 2020 U.S. growth, greater chance for recession. Economists sharply cut forecasts for the U.S. economy this year, predicting it will contract in the second quarter and raising expectations for a recession as the coronavirus spread around the world.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"WSJ Survey: Coronavirus to Trigger U.S. Economic Contraction in Second Quarter. Economists polled by The Wall Street Journal see 'significant drag' on 2020 U.S. growth, greater chance for recession. Economists sharply cut forecasts for the U.S. economy this year, predicting it will contract in the second quarter and raising expectations for a recession as the coronavirus spread around the world.\"\n\nStock Prediction(s):", "Prediction": "\n- The Dow Jones Industrial Average (NYSE: DJIA) will decrease because of the economic contraction that is expected to happen in the second quarter.\n- The S&P 500 (NYSE: SPX) will decrease because of the economic contraction that is expected to happen in the second quarter.\n- The Nasdaq Composite (NASDAQ: COMP) will decrease because of the economic contraction that is expected to happen in the second quarter.", "price_info": {"DJIA": {"company": "", "ticker": "DJIA", "move": "down"}, "SPX": {"company": "", "ticker": "SPX", "move": "down"}, "COMP": {"company": "", "ticker": "COMP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/goldman-sachs-profit-more-than-doubles-powered-by-trading-11611060879", "title": "Goldman Profit More Than Doubles, Powered by Trading", "date": "2021-01-26 10:34", "summary": "Wall Street firm's revenue rises 18%, powered by trading, deal making. For many Americans, 2020 was a year to forget. For Goldman Sachs Group Inc., it was one for the record books.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Goldman Profit More Than Doubles, Powered by Trading. Wall Street firm's revenue rises 18%, powered by trading, deal making. For many Americans, 2020 was a year to forget. For Goldman Sachs Group Inc., it was one for the record books.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldman Sachs Group Inc. (NYSE: GS) will increase because their profit more than doubled, and they are a major player on Wall Street.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are a direct competitor of Goldman Sachs.\n- Bank of America Corp (NYSE: BAC) will decrease because they are a direct competitor of Goldman Sachs.\n- Citigroup Inc. (NYSE: C) will decrease because they are a", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "up"}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [132.2989, 132.42]}, "BAC": {"company": "", "ticker": "BAC", "move": "down"}, "C": {"company": "", "ticker": "C", "move": "down"}}}, {"link": "https://www.wsj.com/articles/opec-from-russia-without-love-11583425691", "title": "OPEC: From Russia Without Love", "date": "2020-03-05 11:46", "summary": "A cut from cartel may be too little to stave off further oil-price collapse, and Saudi Arabia will suffer more than most. Russia is playing its cards close to its vest as oil exporters meet in Vienna to deal with the fallout from the spreading coronavirus epidemic. Its decision may not matter much anyway.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"OPEC: From Russia Without Love. A cut from cartel may be too little to stave off further oil-price collapse, and Saudi Arabia will suffer more than most. Russia is playing its cards close to its vest as oil exporters meet in Vienna to deal with the fallout from the spreading coronavirus epidemic. Its decision may not matter much anyway.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Aramco (NYSE: ARAMCO) will increase because OPEC may cut production, and Russia is not contributing as much as Saudi Arabia.\n- Lukoil PJSC (OTCMKTS: LUKOY) will increase because OPEC may cut production, and Russia is not contributing as much as Saudi Arabia.\n- Gazprom PJSC (OTCMKTS: OGZPY) will increase because OPEC may cut production, and Russia is not contributing", "price_info": {}}, {"link": "https://www.wsj.com/articles/u-s-durable-goods-orders-rise-sharply-despite-continued-supply-constraints-11632747393", "title": "Durable-Goods Orders Rise Sharply", "date": "2021-09-27 10:34", "summary": "Orders up 1.8% in August but manufacturers still face shortages of parts and labor. Orders for appliances, computers, cars and other durable goods increased in August, though factory operators continued to confront parts and labor shortages as well as higher material costs.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Durable-Goods Orders Rise Sharply. Orders up 1.8% in August but manufacturers still face shortages of parts and labor. Orders for appliances, computers, cars and other durable goods increased in August, though factory operators continued to confront parts and labor shortages as well as higher material costs.\"\n\nStock Prediction(s):", "Prediction": "\n- Home Depot, Inc. (NYSE: HD) will increase because as the economy continues to strengthen, people will be more likely to invest in durable goods, such as appliances.\n- Ford Motor Company (NYSE: F) will increase because as the economy continues to strengthen, people will be more likely to invest in durable goods, such as cars.\n- General Electric Company (NYSE: GE) will decrease because as the economy continues to strengthen, people will be more", "price_info": {"HD": {"company": "", "ticker": "HD", "move": "up"}, "F": {"company": "", "ticker": "F", "move": "up", "prices": [14.16, 14.245]}, "GE": {"company": "", "ticker": "GE", "move": "down"}}}, {"link": "https://www.wsj.com/articles/health-and-safety-move-to-the-fore-of-workplace-issues-11602597809", "title": "Health and Safety Move to the Fore of Workplace Issues", "date": "2020-10-13 10:04", "summary": "Alstom, Ebara and other firms that scored high in human capital in a WSJ ranking of most sustainable companies earned strong marks for employee health and safety. The \"S\" in ESG investing has grabbed the spotlight this year as two major social issues, the coronavirus pandemic and unrest over racial justice, have taken hold in the U.S. and abroad.", "categories": [["Business", "Journal Reports: Leadership"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-leadership?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Health and Safety Move to the Fore of Workplace Issues. Alstom, Ebara and other firms that scored high in human capital in a WSJ ranking of most sustainable companies earned strong marks for employee health and safety. The \"S\" in ESG investing has grabbed the spotlight this year as two major social issues, the coronavirus pandemic and unrest over racial justice, have taken hold in the U.S. and abroad.\"\n\nStock Prediction(s):", "Prediction": "\n- Alstom SA (OTCPK: ALSMY) will increase because they scored high in human capital in a WSJ ranking of most sustainable companies, and they focus on employee health and safety.\n- Ebara Corp (OTCPK: EBARA) will increase because they scored high in human capital in a WSJ ranking of most sustainable companies, and they focus on employee health and safety.", "price_info": {}}, {"link": "https://www.wsj.com/articles/consumer-confidence-slid-in-june-on-trade-tensions-11561473365", "title": "Consumer Confidence Slid in June on Trade Tensions", "date": "2019-06-25 13:43", "summary": "A gauge of consumer sentiment deteriorated in June to its lowest level in nearly two years. U.S. optimism about the economy deteriorated in June to its lowest level in 21 months as consumers fretted over escalating trade tensions and a cooling jobs market, according to a monthly barometer of Americans' mood.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Consumer Confidence Slid in June on Trade Tensions. A gauge of consumer sentiment deteriorated in June to its lowest level in nearly two years. U.S. optimism about the economy deteriorated in June to its lowest level in 21 months as consumers fretted over escalating trade tensions and a cooling jobs market, according to a monthly barometer of Americans' mood.\"\n\nStock Prediction(s):", "Prediction": "\n- The Dow Jones Industrial Average (NYSE: DJIA) will decrease because of the trade tensions between the US and other countries.\n- The S&P 500 (NYSE: SPX) will decrease because of the trade tensions between the US and other countries.\n- The Nasdaq Composite (NASDAQ: COMP) will decrease because of the trade tensions between the US and other countries.", "price_info": {"DJIA": {"company": "", "ticker": "DJIA", "move": "down"}, "SPX": {"company": "", "ticker": "SPX", "move": "down"}, "COMP": {"company": "", "ticker": "COMP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/verizon-internet-outage-disrupts-usage-in-northeast-11611685745", "title": "Verizon Internet Outage Disrupts Usage in Northeast", "date": "2021-01-26 15:43", "summary": "Midday network slowdown mars service around New York, Philadelphia and Washington, D.C.. A Verizon Communications Inc. network failure on Tuesday slowed Internet service for some major business customers in the Northeast U.S., triggering a cascade of outages that blocked access to many online applications.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Verizon Internet Outage Disrupts Usage in Northeast. Midday network slowdown mars service around New York, Philadelphia and Washington, D.C.. A Verizon Communications Inc. network failure on Tuesday slowed Internet service for some major business customers in the Northeast U.S., triggering a cascade of outages that blocked access to many online applications.\"\n\nStock Prediction(s):", "Prediction": "\n- Verizon Communications Inc. (NYSE: VZ) will decrease because their network failed, disrupting service for many customers.\n- Comcast Corporation (NASDAQ: CMCSA) will increase because their network did not fail, and they are a direct competitor of Verizon.\n- AT&T Inc. (NYSE: T) will increase because their network did not fail, and they are a direct competitor of Verizon.", "price_info": {"VZ": {"company": "", "ticker": "VZ", "move": "down", "prices": [56.695, 56.58]}, "T": {"company": "", "ticker": "T", "move": "up"}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "up"}}}, {"link": "https://www.wsj.com/articles/p-g-in-search-of-new-markets-is-going-after-bugs-11562578207", "title": "P&G, in Search of New Markets, Is Going After Bugs", "date": "2019-07-08 15:58", "summary": "The consumer-products maker aims to challenge Raid's hold on pest control. Procter & Gamble Co. has spent years searching for a smash-hit new product. Now the maker of Tide detergent and Gillette razors hopes bug spray will break the drought.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"P&G, in Search of New Markets, Is Going After Bugs. The consumer-products maker aims to challenge Raid's hold on pest control. Procter & Gamble Co. has spent years searching for a smash-hit new product. Now the maker of Tide detergent and Gillette razors hopes bug spray will break the drought.\"\n\nStock Prediction(s):", "Prediction": "\n- P&G (NYSE: PG) will increase because they are expanding their business into a new market.\n- SC Johnson & Son (NYSE: SJM) will decrease because they are a direct competitor of P&G.", "price_info": {"PG": {"company": "", "ticker": "PG", "move": "up", "prices": [114.24, 114]}, "SJM": {"company": "", "ticker": "SJM", "move": "down"}}}, {"link": "https://www.wsj.com/articles/capris-4q-profit-falls-on-higher-expenses-11559128963", "title": "Michael Kors Parent Said Quarterly Profit Fell Amid Soft Demand", "date": "2019-05-29 15:35", "summary": "Capri's revenue rose 14% from a year ago to $1.34 billion. Soft demand for handbags and heavy discounting squeezed the parent of Michael Kors, which reported that profits tumbled 57% in the latest quarter.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NYSE: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Michael Kors Parent Said Quarterly Profit Fell Amid Soft Demand. Capri's revenue rose 14% from a year ago to $1.34 billion. Soft demand for handbags and heavy discounting squeezed the parent of Michael Kors, which reported that profits tumbled 57% in the latest quarter.\"\n\nStock Prediction(s):", "Prediction": "\n- Michael Kors Holdings Ltd. (NYSE: KORS) will decrease because their parent company is reporting a profit fall.\n- Tapestry Inc. (NYSE: TPR) will increase because they are not a direct competitor of Michael Kors, and they are seeing an increase in revenue.", "price_info": {"KORS": {"company": "", "ticker": "KORS", "move": "down"}, "TPR": {"company": "", "ticker": "TPR", "move": "up"}}}]